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Abstract 
 
Objective: The main goal of this study is to compare the Quality of Life (QoL) of Chronic 
Obstructive  Pulmonary  Disease  (COPD)  patients  between  three  different  regions:    the 
United Arab Emirates (UAE), the United Kingdom (UK) and Morocco. Another aim of this 
research is to assess the predictive factors correlated to the QoL and study the extent of 
their involvement as well as any possible interaction between them. It is also designed to 
compare the QoL of control group (healthy individuals) among the same countries. 
Methods: A total of 1800 subjects were recruited including stable COPD patients (n=430), 
and a control group (n=1370) from the UK, Morocco and the UAE. St George’s Respiratory 
Questionnaire  (SGRQ)  was  the  instrument  used  to  evaluate  the  QoL,  while  Mahler 
Dyspnoea Index was used to assess the dyspnoea. Lung functions were measured by a 
standardised Vitalograph spirometer, while a hand grip dynamometer was used to measure 
the muscle strength. Data was analysed using ANOVA Post Hoc test to compare the QoL 
between the centres and  linear  regression  analysis used to assess the effect of various 
variables upon the QoL scores components. Extra questions were asked to the patients to 
study their awareness of their condition and its management, which have been tested using 
chi-square statistical method. 
Results: Our results show that differences in the QoL between the countries exist. The UK 
had better overall QoL than Morocco and the UAE, with no significant difference between 
genders. How well total SGRQ scores were predicted by BMI, dyspnoea index, total muscle 
grip and pulmonary function were assessed and the results indicated that age, total muscle 
grip,  FVC%  predicted,  and  dyspnoea  index  are  significantly  associated  with  the  QoL. 
Regarding  the  control  groups,  our  results  indicated  that  there  was  a  highly  significant 
difference in all variables between the three countries. 
Conclusion: Muscle grip, age, dyspnoea and FVC% predicted are good predictors of QoL in 
COPD patients. Patients’ QoL deteriorates with older age and increased dyspnoea. COPD 
patients with poor QoL experience muscle weakness and poor lung function. There was 
clearly a difference between the QoL of COPD patients in the three regions and the reason 
behind this is mainly due to the socio-economic status and the health care system followed 
in each country rather than the demographic location. Comparative Study on the QoL of COPD Patients 
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1.1 Definition 
Currently, Chronic Obstructive Pulmonary Disease (COPD) is defined by the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD, 2009) as a preventable and 
treatable  disease  with  some  extra  pulmonary  effects  that  may  contribute  to  the 
severity in individual patients. It is a disease state characterised by chronic airflow 
limitation that is not fully reversible. The airflow limitation is usually progressive and 
associated with an abnormal inflammatory response of the lung to noxious gases 
including cigarette smoke, biomass fuels and occupational agents. COPD should be 
regarded  as  a  pulmonary  disease,  but  these  co-morbidities  must  be  taken  into 
account in a comprehensive diagnostic assessment of severity and in determining 
appropriate treatment. (GOLD, 2009) 
Previous  definitions  of  COPD  have  emphasised  the  terms  of  bronchitis  and 
emphysema,  which  were  not  included  in  the  last  report  of  the  GOLD  guidelines. 
(GOLD,  2009)  Emphysema  is  defined  anatomically  as  abnormal  permanent 
enlargement  of  the  airspaces  distal  to  the  terminal  bronchioles,  and  subsequent 
destruction of alveolar walls. (American Thoracic Society, 1995) Chronic Bronchitis is 
a chronic productive cough for 3 months in each of 2 consecutive years in a patient 
in whom other causes of productive chronic cough have been excluded. (GOLD, 
2009) 
While greater emphasis is now placed on extra-pulmonary disease, the definition of 
COPD  still  rests  upon  airflow  obstruction.  Airflow  obstruction,  usually  measured 
using  spirometry,  is  a  useful  marker  of  disease  since  testing  is  reasonably 
reproducible and widely available. (Ekaterina, 2010) However, the broad term COPD 
is used to designate a condition that defies more precise classification, the concept Comparative Study on the QoL of COPD Patients 
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of COPD as a diagnostic category continues to evolve and remains controversial. 
(Pride and Vermeire, 1998) 
1.2 Epidemiology 
The slow and intermittent nature of COPD progression, along with the similarity of its 
symptoms to other respiratory diseases, all stand behind the majority of undetected 
affected patients.  Moreover, failure of patients to recognise their condition and seek 
early  help,  particularly  among  the  ―third  world‖  population,  made  epidemiologists‘ 
duty  harder  in  terms  of  achieving  the  most  accurate  reflective  records  about  the 
disease worldwide. (Fletcher, 2010) 
A study presented on the 19
th May 2010 at the American Thoracic Society (ATS) 
Conference  in  New  Orleans  by  the  leading  charity,  Education  for  Health  (EFH), 
shows that the economic toll of COPD is set to soar as the disease heads towards 
being the third biggest cause of death globally by 2020. The international and expert-
led survey is the first of its kind detailing the  impact of COPD on a working-age 
population and highlights an urgent need to keep individuals with COPD active and 
contributing to society for the benefit of all. (ATS, 2010) 
The survey highlights that society faces a double economic impact from the growing 
COPD crisis. Patients are losing an average of USD 1,800 per year in lost income 
due to their COPD, which equates to lifetime losses of nearly USD 20,000. Nearly 1 
in  5  of  45  to  68  years  old  are  forced  to  retire  prematurely  due  to  the  condition, 
thereby  incurring  increased  health  costs  and  reducing  personal  contribution  from 
taxation. (Fletcher, 2010) 
In addition to the global financial impact of COPD, the survey also illustrates the 
personal and Quality of Life (QoL) consequences for individuals, including effects on Comparative Study on the QoL of COPD Patients 
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their household income, certainty for the future and being able to maintain the same 
level of lifestyle prior to diagnosis. This not only affects individuals with the disease 
but other family members, potentially restricting their lifestyle choices and earning 
abilities further compounding the problem. (Fletcher, 2010) 
Approximately 210 million people worldwide are currently known to be living  with 
COPD. (WHO, 2009) Symptoms are often mistakenly attributed to aging or other 
respiratory diseases such as asthma, resulting in COPD being undetected in about 
50% of cases and misdiagnosed in about 23%.  
COPD is a major health problem affecting subjects over 40 years of age, the World 
Health Organisation (WHO, 2009) has published that COPD was the fifth leading 
cause of death in 2002. Total deaths from COPD are projected to increase by more 
than 30% in the next 10 years unless urgent action is taken to reduce the underlying 
risk factors, especially tobacco use.  
It is not easy to quantify the population suffering from COPD because COPD is not 
well recognised among the general public, and among healthcare professionals it is 
still under diagnosed and poorly managed. (Shahab et al, 2006) A systematic review 
of all population based studies of COPD from anywhere in the world and published 
from 1990-2004 estimated that the prevalence of COPD in adults above the age of 
40  years  was  9-10%.  (Halbert,  et  al,  2006)  The  estimated  prevalence  of  COPD 
includes approximately 4-13% of adults in Europe and approximately 7% of adults in 
the United States.  
In Africa, the majority of the prevalence surveys on COPD have been conducted in 
limited and specific population groups: miners, agricultural or industrial workers, civil 
servants  and  hospital  patients.  These  studies  used  the  British  Medical  Research Comparative Study on the QoL of COPD Patients 
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Council questionnaire. The results only gave a reflection of the prevalence of COPD, 
as airway obstruction occurs in only a proportion of chronic bronchitis cases. In 1998 
a  study  was  conducted  on  hospitalised  COPD  patients  and  estimated  that  the 
prevalence of COPD in Morocco is 14 % (Bartal, 1998) 
In the Middle East, there are no statistics about the prevalence of COPD. In 2007, 
Hadi  HA  and  co-workers  carried  out  a  large  cohort  study  in  6  Middle  Eastern 
countries  to  report  the  prevalence  of  clinically  recognised  COPD  during  acute 
coronary  syndrome.  Their  results  show  that  the  prevalence  of  COPD  was  5.3% 
(Hadi, 2010) 
According to recent COPD disease surveillance in the United States there was a 
five-fold increase in female COPD-related mortality between 1971 and 2000 and in 
2000 for the first time, more women died from COPD than men. (Mannino et al 2002) 
COPD was more common in men, but because of increased tobacco use among 
women  in  high-income  countries  and  the  higher  risk  of  exposure  to  indoor  air 
pollution  (such  as  biomass  fuel  used  for  cooking  and  heating)  in  low-income 
countries, the disease now affects men and women almost equally. According to the 
British  Lung  Foundation,  women  are  more  susceptible  to  developing  COPD  than 
men  as  their  lung  function  worsens  with  less  duration  of  smoking  or  intensity  of 
smoking than that of men. (British Lung Foundation, 2005) 
COPD represents an enormous health problem for the communities: patients and 
their families, the workplace, health institutions, and society as a whole are heavily 
affected by the disease. (Minkoff, 2005)  Comparative Study on the QoL of COPD Patients 
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Costs, both economic and human, associated with medical and auxiliary care, loss of 
livelihood, diminished Quality of Life (QoL) and reduced life expectancy cannot be 
estimated. As knowledge of the pathophysiology of COPD expands, as awareness of 
the enormous social and economic impact of COPD grows, and as the success of 
smoking cessation strategies improves, it is realistic to hope that this public health 
epidemic can be controlled. (Jane, 2001) 
In the UK, the Chief Medical Officer has reported COPD accounts for more than 
£800 million in direct health care costs, although the National Institute for Clinical 
Excellence estimated slightly lower costs. (de Marco, 2004) More than half the costs 
are related to hospital care and costs are, as expected, greater for those with more 
severe  disease:  £149  for  a  person  with  mild  COPD,  £307  for  someone  with 
moderate  COPD  and  £1,307  for  someone  with  severe  COPD.  (Healthcare 
commission, 2006) 
Mortality from COPD in England shows a strong urban rural gradient (Hansell A, 
2003) with high mortality rates in the North of England. There are also striking social 
inequalities with men aged 20-64 employed in unskilled manual occupations being 
14  times  more  likely  to  die  from  COPD  than  those  in  professional  occupations. 
(Burney, 2006) 
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1.3 Aetiology 
Cigarette smoking, both active and passive, is believed to be the major etiological 
factor  in  the  development  of  COPD.  Because  only  10-20%  of  smokers  develop 
severe COPD, other factors in addition to those cited, such as socioeconomic status, 
diet and nutrition, climate, and nonspecific airway hyper-responsiveness, may modify 
risk. 
Smoking affects the lung at various places: the bronchi, the bronchioles, and the 
lung parenchyma. The effect of tobacco smoke in the larger airways (i.e. the bronchi) 
alters both the structure and function of the bronchial mucous glands. Exposure to 
smoke  increases  both  the  number  and  size  of  these  mucus-secreting  glands, 
resulting in the production and deposition of excess mucus within the lumen of the 
airway. In response to enlarged, hyperactive mucous glands, as well as to the influx 
of inflammatory cells, airway walls become thickened. 
Occupational  exposure  to  irritating  fumes  and  dusts  may  aggravate  COPD. 
Exposure to certain vegetable dusts, such as cotton fibre, moulds and fungi in grain 
dust, may increase airway resistance and sometimes produce permanent respiratory 
impairment. Repeated bronchopulmonary infections can also intensify the existing 
pathological  changes,  playing  a  role  in  destruction  of  lung  parenchyma  and  the 
progression of COPD. 
Heredity or biological factors can determine the reactions of pulmonary tissue to 
noxious  agents.  The  homozygotes  may  develop  severe  panlobular  emphysema 
(PLE)  early  in  adult  life.  The  heterozygotes  appear  to  be  predisposed  to  the 
development  of  centrilobular  emphysema  related  to  cigarette  smoking.  The  other Comparative Study on the QoL of COPD Patients 
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better-known  cause  of  chronic  lung  disease  is  mucoviscidosis  or  cystic  fibrosis. 
(Varkey, 2004) 
Bacterial  infection  (Haemophilus  influenza)  colonises  the  normally  sterile  lower 
airways of about 30% of patients with COPD. Smoking and airflow obstruction may 
lead to impaired mucus clearance in lower airways, which predisposes to infection. 
Repeated bouts of infection increase the inflammatory burden that hastens disease 
progression. There is no evidence, however, that long-term use of antibiotics slows 
the progression of COPD in susceptible smokers. (Varkey, 2004) 
1.4 Pathophysiology 
Pathological  changes  in  COPD  lead  to  corresponding  physiological  abnormalities 
that usually become evident first on exercise and later also at rest. Physiological 
changes  characteristic  of  the  disease  include  mucus  hypersecretion,  ciliary 
dysfunction, airflow limitation, pulmonary hyperinflation, gas exchange abnormalities, 
pulmonary hypertension, and they usually develop in this order over the course of 
the  disease.  In  turn,  various  physiological  abnormalities  contribute  to  the 
characteristic symptoms of COPD chronic cough sputum production, and dyspnoea. 
(Barnes et al, 2002) 
Chronic inflammation in the central airways is also associated with an increase in the 
number (metaplasia) of epithelial goblet and squamous cells, dysfunction, damage, 
and/or loss of cilia, enlarged submucosal mucus-secreting glands, an increase in the 
amount of smooth muscle and connective tissue in the airway wall, degeneration of 
the airway cartilage, and mucus hypersecretion. (Mullen et al, 1985) Comparative Study on the QoL of COPD Patients 
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The mechanisms of mucus gland hypertrophy and goblet cell metaplasia have not 
yet been identified, but animal studies show that irritants including cigarette smoke
 
can produce these changes. (Rogers and Jeffery, 1986) 
The  various  pathological  changes  in  the  central  airways  are  responsible  for  the 
symptoms of chronic cough and sputum production, which identify people at risk for 
COPD and may continue to be present throughout the course of the disease. 
The early decline in lung function in COPD is correlated with inflammatory changes 
in the peripheral airways, similar to those that occur in the central airways: exudate 
of fluid and cells in the airway wall and lumen, goblet and squamous cell metaplasia 
of the epithelium, edema of the airway mucosa due to inflammation, and excess 
mucus in the airways due to goblet cell metaplasia. (Cosio et al, 1978) Inflammatory 
changes such as airway edema and mucus hypersecretion also contribute to airway 
narrowing in COPD. (Hogg et al, 1968) 
The peripheral airways become the major site of airways obstruction in COPD, and 
direct  measurements  of  peripheral  airways  resistance  show  that  the  structural 
changes in the airway wall are the most important cause of the increase in peripheral 
airways resistance in COPD. 
1.5 Quality of Life (QoL) 
Several definitions of QoL exist, The World Health Organization (WHO) definition of 
health is ―not merely the absence of disease, but complete physical, psychological, 
and social well-being‖. (WHO, 1958) QoL refers to the physical, psychological and 
social domains of health that are unique to each individual. (Testa, 1996) Another 
definition  is  ―QoL  can  be  defined  as  the  functional  effect  of  an  illness  and  its 
consequent therapy upon a patient, as perceived by a patient‖. (Schipper et al, 1996) Comparative Study on the QoL of COPD Patients 
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Since the health care use by COPD patients is more related to an impaired QoL than 
the severity of the disease itself (Molarius et al, 2001), the goal of managing COPD 
is  improving  the  QoL  of  COPD  patients  by  relieving  symptoms  and  enhancing 
functionality. (Perruzza et al 2003, Van Manen et al 2003) 
Over the past decade, interest in QoL has increased and that is mainly because 
patients  are  more  concerned  about  their  symptoms  and  their  physical  function, 
cognitive performance, psychosocial condition, emotional status and adaptation to 
disease, rather than objective measures such as expiratory airflow. (McSweeny et al 
1982, Prigatano et al 1984, Schrier et al 1990, Stavem et al 2000)
 
Even if the severity of disease is an important determinant of COPD patient's health, 
patient perception and adaptation largely defines the overall QoL. (Curtis et al, 1994) 
Peruzza performed a study and suggested that COPD causes severe deterioration 
of  QoL,  physical  activity  and  functional status  in  elderly  populations  and  that  the 
degree  of  this  impairment  mainly  depends  on  the  severity  of  chronic  airway 
obstruction. (Perruzza et al, 2003) other studies showed that there is a significant 
relationship between age and the QoL of COPD patients. (Stahl et al 2005, Ferrer et 
al 2002) 
Pulmonary  rehabilitation  is  a  multidisciplinary  program  of  care  that  is  individually 
tailored  to  optimise  physical  and  social  performance,  (Nice  Guidelines,  2010) 
rehabilitation  at  home  resulted  in  an  improved  QoL  in  COPD  patients,  this 
improvement was not associated with an improvement in lung function or exercise 
tolerance.  (Wijkstra et  al,  1994) The  improvement of  QoL  is probably  due  to the 
comprehensive care of the rehabilitation program and not only to a part of it. (Jones 
et al, 1992)
 Comparative Study on the QoL of COPD Patients 
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To identify and manage the problems mostly important to COPD patients, a great 
attention  has  been  paid  to  develop  and  validate  QoL  questionnaires  for  these 
patients.  (Guyatt  et  al  1987,  Maille  et  al  1997,  Donohue  et  al  2002)  These 
questionnaires were developed and now being used in clinical trials. (Wijkstra et al 
1994, Spencer et al 2001, Jones et al 1992)
 
The relationship between physiological measurements and QoL has been studied 
separately  and  collectively  in  few  studies.  The  physiological  factors  include  lung 
function tests, Body Mass Index and grip strength. Research has been undertaken 
for the last decade to relate them to QoL. 
Garrido suggested that stable COPD patients experience a low QoL. The factors 
determining  the  QoL  include  gender,  FEV1  (Forced  Expiratory  Volume  in  one 
second), use of oxygen therapy, and the number of visits to emergency departments 
and hospital admissions. (Garrido et al, 2006) However, this particular study was 
only limited to stable COPD patients and there was no account of other physiological 
parameters of the disease. 
Quality of Life (QoL) assessment involves a class of measurement fundamental to 
many  aspects  of  health  care  planning  and  outcomes  research.  It  is  relevant  for 
assessing  symptoms,  side  effects  of  treatment,  disease  progression,  satisfaction 
with  care,  quality  of  support  services,  unmet  needs,  and  appraisal  of  health  and 
health care options. (Rapkin and Schwartz, 2004) 
Elderly  patients  affected  with  COPD-related  respiratory  failure  are  frequently 
impaired in their social life, psychic functions and activities of daily living. Therefore, 
it is of crucial importance to establish the relationship between COPD and QoL in 
those people. In developing QoL measures for clinical trials in patients with chronic Comparative Study on the QoL of COPD Patients 
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airflow  limitation,  the  areas  of  physical  and  emotional  dysfunction  that  patients 
experience and feel are important. 
Interest  in  QoL  over  the  past  decade  has  increased  substantially  because  of 
recognition of the following factors: 
-  Individual patients are most concerned about their symptoms (e.g. dyspnoea) 
and their function (e.g. ability to perform physical tasks), rather than objective 
measures such as expiratory airflow.   
-  QoL  is  a  unique  construct  that  is  different  from  physiologic  measures  or 
survival. 
-  The goals of therapy have been expanded to include relief of symptoms and 
improvement in QoL, in addition to the standard physiologic outcomes. 
COPD  is  a  condition  that  involves  multiple  organs
  and  systems.  In  addition  to 
emphysema, airway inflammation
 and remodelling, COPD is associated with various 
local and systemic
 complications including cachexia, weight loss,
 muscle wasting, 
systemic  inflammation  and  depression.  (Pauwels  et  al  2001,  Yvonne  et  al  2003, 
Vestbo et al 2006) 
 
1.5.1 Effect of Muscle Strength on the QoL of COPD Patients 
Skeletal muscle dysfunction and wasting is considered as one of the most important 
manifestations of COPD. (Wouters, 2002) As the disease severity advances, COPD 
patients  lose  muscle  bulk,  especially  in  their  thighs  and  upper  arms.  Over  time, 
patients start losing exercise endurance and complain of fatigue and dyspnoea on 
minimal exertion. (Sin et al, 2004) Comparative Study on the QoL of COPD Patients 
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Skeletal muscle dysfunction contributes to a reduced health status of patients with 
COPD and  substantially  increases  the  risk of mortality,  independent of traditional 
markers  of  COPD  mortality  such  as  baseline  lung  function,  age,  and  cigarette 
smoking. (Sin & Man, 2006) 
The figure  below  was  presented by  Professor Jones  in the ERS  congress  2008, 
representing the disease pathways in COPD. The figure shows that as stated in the 
beginning of this section that muscle wasting in one of the manifestations of COPD 
which leads to exercise limitation and therefore to an impairment in QoL. (Figure1) 
Unknown
Exercise limitation
Health Impairment
Impaired mood
Sleep Disturbance
Cough
Exacerbations
Breathlessness
Muscle wasting
Expiratory Airflow 
limitation       
Over- inflation 
Dynamic  
Hyperinflation 
V/Q mismatch
Cytokines
Fatigue
Lung Disease
Source: Professor Jones, ERS  Congress 2008  
Figure 1: Disease pathways in COPD 
Many studies confirmed that muscle dysfunction is common in patients with COPD 
and that it plays a role in limiting their exercise capacity and their QoL. (Agusti et al, 
2003) Comparative Study on the QoL of COPD Patients 
  Page 25 
 
COPD  patients  usually  experience  low  exercise  tolerance,  and  peripheral muscle 
dysfunction  is  also  seen  especially  in  patients  with  malnutrition.  This  dysfunction 
includes weakness, atrophy, morphologic changes and altered metabolic capacity. 
(Heijdra et al, 2003) 
Whether the mechanisms of skeletal muscle dysfunction are local, systemic, or both 
are still under debate. A predominantly systemic process would result in a widely 
distributed  loss  of  muscle  function,  whereas  chronic  inactivity  as  result  of 
breathlessness  and  subsequent  deconditioning  would  result  in  dysfunction 
predominantly  in  the  locomotor  muscles  such  as  the  quadriceps.  (Bernard  et  al, 
1998)  The  peripheral  muscle  weakness,  the  relationship  between  quadriceps 
strength  and  the  degree  of  airflow  obstruction  suggest  that  chronic
  inactivity  and 
muscle deconditioning are important factors in
 the loss in muscle mass and strength. 
(Coronell et al, 2004) 
Muscle  wasting  in  COPD  is  poorly  understood.  Certainly  inadequate  nutritional 
intake can affect weight loss and loss of muscle mass. Recent studies suggest that 
intake  of  certain  nutrients  such  as  fresh  fruits  and  vegetables  can  decrease  the 
expression of key inflammatory genes and therefore inflammation. (Kornman, 2006) 
A  study  done  by  Coronell  and  colleagues  (Coronell  et  al,  2004)  has  shown  that 
COPD patients have impaired peripheral muscle function when compared to healthy 
control  group,  suggesting  that  there  might  be  other  factors  contributing  to  this 
impairment. These factors include malnutrition, exposure to corticosteroids, tissue 
hypoxia,  heart  disease  history,  tobacco  use,  systemic  inflammation  and  hormone 
alteration. (Mador and Bozkanat, 2001) Comparative Study on the QoL of COPD Patients 
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Hand grip strength and the rate of decline changes as the weight decreases and the 
disease  advances.  Janaudis-Ferreira  et  al  showed  that  there  are  gender-related 
differences regarding muscle strength in COPD patients, female patients seemed to 
experience  decrease  in  thigh  muscle  function  when  compared  to  male  patients. 
(Janaudis-Ferreira et al, 2006) Rantanen et al suggested that in women, hand grip 
strength  may  predict  mortality.  Grip  strength  tests  may  help  identify  patients  at 
increased risk of deterioration of health. (Rantanen et al, 2003) Ansari suggests that 
hand grip was a powerful predictor of QoL in COPD patients. (Ansari et al, 2007) 
Some  studies  suggested  that  exercise  training  has  shown  to  improve  muscle 
function  in  patients  with  COPD,  suggesting  that  deconditioning  is  an  important 
contributor to the skeletal muscle dysfunction. A study conducted by Simpson et al 
has shown that weight training in COPD patients improves the exercise capacity as 
well as the QoL in these patients. (Simpson et al, 1992) 
Vermeeren  and  colleagues  performed  a  study  and  it  has  been  shown  that  the 
prevalence of nutritional depletion is high in COPD patients and mainly in females. 
There  was  an  association  between  peripheral  muscle  weakness  and  nutritional 
depletion while no association was found between the nutritional depletion and the 
low level of FEV1% predicted (Forced Expiratory Volume in one second). Gender 
and  age  were  also  found  as  independent  predictors  of  muscle  weakness. 
(Vermeeren et al, 2006) 
1.5.2 Relationship between BMI and QoL of COPD Patients 
The  mechanisms  of  weight  loss  are  still  unclear  in  COPD  but  the  main  basis  is 
believed to be due to an inadequate food intake in subjects too short of breath to eat. 
(Karakas et al 2005, Friedrich et al 2006, Prescott et al 2002) However, most weight Comparative Study on the QoL of COPD Patients 
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loss  in  COPD  patients  is  due  to  the  increased  metabolic  demand  of  respiratory 
muscles that are overworked because of emphysema damage. (Schols et al 1991, 
Schols  and  Wouters  2000)  Disturbances  in  intermediary  metabolism  caused  by 
altered anabolic and catabolic mediators such as hormones, cytokines, and growth 
factors,  and  resulting  in  disproportionate  muscle  wasting  have  been  described. 
(Wedzicha, 2004) 
A  study  of  the  up  regulation  of  the  nuclear  transcription  factor  NF-kB  in  muscle 
biopsy specimens of patients with COPD carried out by Agusti et al found a 30% 
increase in NF-kB activity in patients of low body weight compared with those of 
normal body weight and up regulation of the inducible form of nitric oxide synthase 
(iNOS) in the skeletal muscle of low body weight COPD patients. The authors also 
suggest that the higher levels of nitric oxide (NO) in the presence of unregulated 
iNOS can contribute to skeletal muscle atrophy either by enhancing skeletal muscle 
apoptosis or stimulating protein nitrotyrosination. (Agusti et al, 2003) 
COPD patients with malnutrition have shown to have an impaired pulmonary status, 
lower  exercise  capacity,  lower  QoL,  and  higher  mortality  rate.  Several  studies 
conducted  comparing  well  nourished  and malnourished  patients  have  shown  that 
malnourished  patients  have  more  respiratory  muscle  weakness  and  reduced 
maximal  exercise  capacity  compared  with  well  nourished  COPD  patients. 
(Vandenbergh et al 1967, Renzett et al 1996, Burg et al 2004, Gray et al 1996) 
The effect of nutritional status on the QoL is still poorly understood. Katsura and co-
workers  performed  a  study  to  assess  deterioration  of  both  generic  and  disease-
specific QoL in groups of normal weight and underweight patients with stable COPD 
and to investigate whether body weight is a determinant of QoL in COPD patients. Comparative Study on the QoL of COPD Patients 
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The study found that patients with low BMI had poor QoL (assessed by St Goerge‘s 
Respiratory Questionnaire and Short Form-36) and also suggested that to improve 
the QoL and dyspnoea in these patients introduction of nutritional intervention might 
be  of  benefit.  (Katsutra  et  al,  2005)  This  can  be  achieved  by  encouraging  and 
helping patients to avoid weight loss and regain weight as dietary habits play an 
important role in the aetiology of COPD. (Smit et al, 1999) 
Another study carried out by Salpeci et al on 65 male COPD patients has shown that 
BMI is closely related to dyspnoea score, respiratory muscle strength and QoL in 
COPD  patients,  and  suggested  that  pulmonary  rehabilitation  programs  including 
nutritional support should be introduced in the management of COPD. (Salpeci et al, 
2007)
 
Weight and fat-free mass loss, and the impaired function of skeletal muscle have 
been  demonstrated  to  play  an  important  role  in  the  clinical  implications  of 
malnutrition in COPD patients. (Shoup et al, 1997) 
The prevalence of nutritional depletion in a COPD population is high, and especially 
in female patients. The  presence of nutritional depletion  was  not  associated  with 
lower  levels  of  FEV1%predicted.  It  was  suggested  that  the  assessment  of  body 
composition  additional  to  body  weight  should  be  looked  at  in  all  COPD patients, 
independent of the stage of disease severity. (Vermeeren et al, 2006) 
Planas  and  co-workers  performed  a  study  on  a  small  number  of  patients  and 
suggested that in some stable depleted COPD patients, a defined oral nutritional 
supplement to reach total daily energy intake without overfeeding could be beneficial 
to improve their QoL. (Planas et al, 2005) Comparative Study on the QoL of COPD Patients 
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1.5.3 Effect of Dyspnoea on the QoL of COPD Patients 
A  number  of  clinical  and  physiological  outcomes,  such  as  dyspnoea,  functional 
status  and  health  status,  are  recognised  as  being  important  for  characterising 
response to treatment. Dyspnoea is the primary reason for patients seeking medical 
care, and is an important determinant of QoL. One of the main goals of treatment is 
reducing the breathlessness in COPD subjects. (Rennard et al 2002, Celli et al 2004) 
A study carried out by Lareau et al showed that patients‘ ratings of dyspnoea were 
not directly linked to changes in lung impairment. (Lareau et al, 1999) Furthermore, 
there  may  be  improvements  in  dyspnoea,  exercise  capacity  and  QoL  with  only 
minimal changes in FEV1. Although measures such as FEV1 reflect direct changes 
in airflow limitation, it is important to measure dyspnoea to reveal the practical effects 
of treatment on a patient‘s everyday life. (Celli and MacNee, 2004) 
Measurements of dyspnoea provide an insight into the practical effects of treatment 
on everyday life, reflecting whether or not patients perceive an improvement in this 
primary symptom of COPD. Dyspnoea limits exercise capacity in COPD patients and 
is  associated  with  central  perception  of  an  overall  increase  in  central  respiratory 
motor output  directed  preferentially  to  the  rib  cage  muscles.  Patients  with  COPD 
frequently  decrease  their  activity  in  order  to  avoid  the  unpleasant  sensation  of 
breathlessness. Functional status measurement reveals the number of activities that 
a patient can perform. (Celli and MacNee 2004, Mahler et al 1995, Stendardi et al 
2007)
 
A  study  carried  out  by  Martinez  et  al  to  indentify  the  determinants  of  baseline 
dyspnoea  and  to  ascertain  how  that  factor  influences  the  health-related  QoL  of 
patients with COPD, found that anxiety was the main determinant of QoL in COPD Comparative Study on the QoL of COPD Patients 
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patients, and it is triggered mainly by baseline dyspnoea and exertional dyspnoea. 
(Martinez  et  al,  2008)  Higher  dyspnoea  symptoms  have  been  related  to  worse 
exercise performance, health status and poor survival in COPD. (Spruit et al 2007, 
Nachimura et al 2002) 
Hajiro et al carried out a cross-sectional study to compare the level of dyspnoea 
with the staging of COPD severity as defined by the American Thoracic Society 
(ATS) using the SGRQ and SF-36 to assess the QoL and the Medical Research 
Council (MRC) to evaluate the severity of dyspnoea. The results suggested that the 
QoL  of  COPD  patients  ranging  from  mild  to  severe  was  clearly  separated  using 
dyspnoea level rather than the staging of the disease severity as defined by the ATS. 
(Hajiro et al, 1999)  
Dyspnoea being an important determinant of QoL, it is weakly correlated to severity 
of obstruction and there is little information available on how it exercises its effect on 
QoL.  
Nordic walking which an exercise is involving walking with specially designed poles 
was  effective  in  alleviation  of  dyspnoea,  increased  QoL  and  functional  exercise 
capacity after three months according to recommendations. (Nici et al, 2006) 
1.5.4 Relationship between Lung Function and QoL of COPD 
Patients 
Spirometry is a method to measure the airflow obstruction in COPD. A diagnosis of 
airflow obstruction can be made if the FEV1/FVC ratio is less than 70% predicted 
and FEV1 less than 80% predicted. (Jones and Bosh, 1997) In addition to clinical 
exams, spirometry improves diagnosis of COPD and it helps to identify subjects who 
 Comparative Study on the QoL of COPD Patients 
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might benefit from medical treatment in order to prevent and improve exacerbations. 
(Wilt et al, 2005) 
Values  for  the  Forced  Expiratory  Volume  in  1  second  (FEV1)  and  forced  vital 
capacity (FVC) must be compared with the predicted normal values which depend 
on the individual's age, height and sex. 
Spirometry has proven a poor predictor of disability and QoL in COPD but helps in 
predicting prognosis and contributes to the assessment of the severity of COPD. 
Spirometry  alone  cannot  separate  asthma  from  COPD.  Although
  FEV1  is  an 
accurate  marker  of
  mortality  in  population  studies  it  has  only  shown  a  weak 
relationship
 with dyspnoea and QoL. 
Stahl et al carried out a study to assess the relationship between QoL and disease 
severity using lung function measures. The study found that COPD patients had an 
impaired QoL as  the disease advances  and  that the  deterioration  is related  to  a 
decrease in FEV1% predicted normal values. (Stahl et al, 2005) Some studies have 
shown that there is a weak relationship between pulmonary function (FEV1) and the 
QoL in COPD patients. (Ferrer et al 1996, Jones et al 1992, Jones et al 1989)
 
Another  study  conducted  by  McGlone  et  al  found  that  there  is  a  significant 
relationship  between  physical  activity,  disease  severity  which  was  assessed  by 
spirometry  and  QoL  of  COPD patients.  (McGlone  et  al,  2006) Ketelaars and  co-
workers  conducted  a  study  to  assess  the  contribution  of  respiratory  impairment 
(measured  by  lung  function  tests),  physical  disability,  coping,  age,  and 
socioeconomic variables on the QoL. They found that FEV1, walking test and coping 
strategies are good predictors of the QoL. (Ketelaars et al, 1997) Comparative Study on the QoL of COPD Patients 
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Recent  studies  have  shown  that  FEV  in  6  seconds  (FEV6)  is  a  good  surrogate 
marker for the FVC. (Vandevoorde 2005, Akpinar 2006, Vandedevoorde, 2006) The 
major benefit of using FEV6 is that it is easier for the patients because the maximal 
end-expiration can be avoided.  Results have proven that FEV1/FEV6 is a sensitive 
and  specific  test  and  can  be  used  as  a  valid  alternative  for  FEV1/FVC  in  the 
diagnosis of airway obstruction. (Jing, 2009) 
1.5.5 Quality of Life (QoL) Measures 
One important reason for measuring QoL in patients with chronic respiratory disease 
is to differentiate between patients who have a better health status and those who 
have a worse health status (a discriminative instrument). 
The  most  widely  used  application  (for  both  clinical  and  research  purposes)  for 
measuring QoL is to detect how much QoL has changed in response to therapy (an 
evaluative  instrument).  Related  to  the  responsiveness  criterion  of  a  QoL 
questionnaire  is  the  threshold  for  a  clinically  meaningful  change.  There  are  two 
approaches to measure the QoL that we will be reviewing below. 
1.5.5.1  General Measures 
A number of generic QoL instruments have been used to characterise COPD. 
Sickness  Impact  Profile  (SIP)  has  been  well  validated  and  demonstrated  to  be 
reliable  and  responsive  among  patients  with  COPD.  (Engstrom  et  al,  2001)  This 
instrument  was  designed  to  both  interviewer  or  self-administered.  It  takes  20-30 
minutes to be completed which is one of its disadvantages.  
Medical Outcome Study (MOS) Short Form-36 (SF-36) has proven to be reliable 
and  responsive  in  COPD.  (Mahler  &  Mackowiak,  1995)  SF-36  consists  of  eight Comparative Study on the QoL of COPD Patients 
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domains:  physical-functioning,  role-physical,  bodily  pain,  general  health,  vitality, 
social-functioning,  role  emotional  and  general  health.  The  SF-36  also  has  two 
summary scores: a physical component scale and a mental component scale that 
were developed with factor analysis. This questionnaire offers significant advantages 
in  that  it  is  self-administered,  completed  in  5  min  and  has  been  translated  and 
validated in several languages. 
Nottingham Health Profile (NHP) uses statements that measure departures from 
―normal‖ functioning by affirming particular statements or items that describe QoL. 
The first part contains 38 items that fall into six domains: physical mobility, energy, 
sleep, pain, social isolation and emotional reactions. The second section contains 
seven items that address areas of daily living affected by a patient‘s health status. 
(Hunt  et  al,  1980)  NHP  has  been  proven  valid  and  reliable  among  patients  with 
COPD, it is self-administered and can be completed in 10-15 min. (van Schayck et 
al, 1995) 
Quality Well Being (QWB) is a questionnaire developed as part of the health status 
index. (Fanshel & Bush, 1970) QWB contains three scales: mobility, physical activity 
and social activity. A single cross-sectional study has been performed demonstrating 
validity among patients with COPD. (Kaplan et al, 1984) This questionnaire can be 
either by interviewer or self-administered and takes 20 min to complete. 
1.5.5.2  COPD-Specific Measures 
Disease-specific measures can be designed to include items that are particular to 
the  condition  being  studied  as  well  as  exclude  items  that  are  not  related  to  the 
condition. Comparative Study on the QoL of COPD Patients 
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A few COPD-specific QoL measures are available; we will be summarising these in 
the following sections. 
Chronic Respiratory Disease Questionnaire (CRDQ) 
Developed in 1987 by Guyatt, it contains 20 questions and covers four dimensions of 
functioning dyspnoea, fatigue, emotional function and mastery or a ―feeling of control 
over the disease‖. (Guyatt et al, 1987) 
The  CRDQ  is  administered  to  the  patient  by  a  trained  interviewer  and  requires 
approximately 20 minutes to be completed. Guyatt found that the instrument was 
reliable and sensitive to the effects of bronchodilator or steroid treatment, as well as 
rehabilitation program. (Guyatt et al, 1987) 
In addition, changes in CRDQ were moderately but significantly related to changes in 
pulmonary function variables, exercise capability and clinician or self-improvement 
ratings. Since this instrument includes physical symptoms related to COPD process, 
it may be useful for periodic clinical evaluations of patients‘ adjustment. (Cottrell, 
1992) 
St. George’s Respiratory Questionnaire (SGRQ)  
St George‘s Respiratory Questionnaire (SGRQ) has become one of the most widely 
used instruments for
 assessing QoL in respiratory patients. The SGRQ has been 
used  extensively  in  descriptive  and  therapeutic  evaluation  studies  (bronchodilator 
agents, oxygen therapy, psychotherapy and respiratory rehabilitation). (Ferrer et al, 
2002) 
St George‘s Respiratory Questionnaire, developed by Professor Paul Jones at St 
George‘s  Hospital  in  London  in  1990,  is  a  standardised  self  questionnaire  for Comparative Study on the QoL of COPD Patients 
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measuring  impaired  health,  daily  life,  and  perceived  well-being  (QoL)  in  airways 
disease. It was developed to be used by patients with fixed and reversible airway 
obstruction and has been designed to allow comparative measurements of health 
between  patient  populations  and  quantify  changes  in  health  following  therapy. 
(Jones et al, 1991) 
St  Georges‘  Respiratory  Questionnaire  is  used  to  assess  the  health  of  specific 
population at a point in time, monitor their health over time, both cross-sectional and 
longitudinally, and evaluate the efficacy of the medical interventions. SGRQ is valid, 
repeatable and sensitive questionnaire. 
SGRQ is a 76-item questionnaire which measures three dimensions: 
1.  Symptoms associated with pulmonary disease (frequency and severity), 
2.  Activities likely to be limited by dyspnoea, 
3.  Impacts on social and psychological functioning resulting from the airway 
obstruction. 
Symptom  section  contains  items  on  five-point  Likert  scale;  Activity  and  Impact 
sections are dichotomous items (yes/no). Scores range from 0 to 100, with higher 
scores indicating poor health. (Jones et al, 1991) 
The questionnaire‘s parent language is UK English and it has been validated and 
translated  into  many  languages  including  American  English,  French,  Arabic, 
Moroccan dialect, Indian, Spanish, Chinese, Danish, Polish, Portuguese, Swedish, 
and other languages with the exception of African. (Jones and Wijkstra, 2005) Comparative Study on the QoL of COPD Patients 
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More recently, a shortened version of the SGRQ has been developed and validated 
for COPD (SGRQ-C). (Meguro et al 2007, Meguro and Jones 2005) 
Seattle Obstructive Lung Disease Questionnaire (SOLQ)  
Developed by Tu SP in 1997, SOLQ is self-administered questionnaire that takes 10-
15  minutes  to  be  completed  and  it  consists  of  29  items  measuring  four  health 
dimensions (Tu et al, 1997): physical
 function, emotional function, coping skills and 
treatment satisfaction. 
Studies have shown that the SOLQ is a reliable,
 valid and responsive measure of 
physical and emotional function, coping
 skills, and treatment satisfaction. Brief, self-
administered, and computer
 scannable, it is useful in monitoring long-term outcomes 
among large groups
 of COPD patients. (Tu et al, 1997) 
Quality of Life Questionnaire for Respiratory Illness  
Developed by Maillé and colleagues, this questionnaire was intended for use with 
asthma as well as with COPD. (Maillé et al, 1994) 
Fifty-five items were chosen for the questionnaire from a pool of 221 accordingly to 
whether  COPD  or  asthma  patients  indicated  that  an  item  applied  to  their  recent 
experience.  The  items  are  grouped  into  seven  subscales:  Breathing  problems, 
physical problems, emotions, situations triggering or enhancing breathing problems, 
daily and domestic activities, social activities, relationship and sexuality and general 
activities. 
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1.6 Management of COPD 
After COPD is being diagnosed, a successful management of the disease should be 
aimed  at  relieving  the  symptoms,  preventing  disease  progression,  improving 
exercise  tolerance,  improving  health  status  and  patients‘  Quality  of  Life  (QoL), 
preventing  and  treating  the  complications  and  exacerbations,  and  reducing  the 
mortality. (Siafakas and Celli, 2006) 
COPD has a long natural history and different stages of severity. In addition to a 
systematic management, a multidisciplinary approach should be adapted according 
to each individual patient. In order to achieve a good management some factors 
should  be  taken  in  considerations:  for  all  stages  of  COPD  smoking  should  be 
stopped,  the  assessment  of  severity  should  be  diagnosed  early  and  properly, 
education and self-management, rehabilitation, early detection of exacerbation and 
end of life issues. (Siafakas and Celli, 2006) 
Before  starting  any  treatment,  a  diagnosis  of  the  condition  should  be  confirmed. 
History of cigarette smoking, complaining of cough, sputum and shortness of breath 
are suggestive of the disease. 
Management of stable COPD includes pharmacological therapy, long term oxygen 
therapy (LTOT), rehabilitation and surgery. The following figure (Figure 2) represents 
the therapy to be induced at each stage of COPD; the scale of severity of COPD 
includes symptoms, signs and spirometry according to Global Initiative for Chronic 
Obstructive Lung Disease. (GOLD, 2009) 
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1.6.1 Pharmacologic Therapy 
The treatments used for COPD reduce the symptoms, increase exercise capacity, 
reduce  exacerbations  and  improve  the  QoL.  Glucocorticoids  and  inhaled 
corticosteroids  have  shown  to  reduce  COPD  exacerbations  and  the  rate  of 
deterioration in health status in patients with severe and very severe COPD, but over 
time it loses the effect on FEV1. 
Combination therapy can also be used to increase the degree of bronchodilation for 
equivalent  or lesser side  effects. The  combination of  short-acting  β-agonists  plus 
anticholinergic  in  one  inhaler  (Fenoterol/Ipratropium,  Salbutamol/Ipratropium) 
produces greater and more sustained improvements in FEV1 than either drug alone 
and does not produce evidence of tachyphylaxis over 90 days of treatment. (Snider, 
Figure 2: Schematic illustration of therapy at each stage of chronic obstructive pulmonary disease 
Stage  I: Mild  II: Moderate  III: Severe  IV: Very severe 
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FEV1/FVC<0.70 
FEV1≥80% 
predicted 
FEV1/FVC<0.70 
50%≤FEV1<80% 
predicted 
FEV1/FVC<0.70 
30%≤FEV1<50% 
predicted 
FEV1/FVC<0.70 
FEV1<30% or 
FEV1<50% Plus chronic 
respiratory failure 
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-Active reduction of risk factor(s), influenza vaccination. 
-Add short-acting bronchodilator (when needed). 
  -Add regular treatment with one or more long-acting bronchodilators 
-Add rehabilitation. 
  -Add inhaled glucocorticoids if repeated 
exacerbation. 
  - Add long-term     oxygen 
if chronic respiratory failure 
- Consider surgical 
treatment 
FEV1: Forced Expiratory Volume in 1 second, FVC: Forced Vital Capacity. 
Source: Adapted from Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). 
Global strategy for diagnosis, management, and prevention of COPD. 2009. Available from http://goldcopd.org. Comparative Study on the QoL of COPD Patients 
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1989) It has been shown that this combination improves lung function and the health 
status. (Guyatt et al, 1987) 
Combination  of  inhaled  glucocorticosteroid/bronchodilator  therapy,  an  inhaled 
glucocortico-steroid combined with a long-acting β- agonist, is more effective than 
the  individual  components  in  reducing  exacerbations  and  improving  lung  function 
and health status. (Szafranski et al, 2003) 
Patients with alpha-1 antitrypsin deficiency and established emphysema can benefit 
from alpha-1 antritrypsin augmentation therapy. (Siafakas and Celli, 2006) 
1.6.2 Long-Term Oxygen Therapy (LTOT) 
Used in severe COPD patients, it is believed that LTOT improves exercise, sleep 
and survival in patients with chronic respiratory failure. The main aim of the oxygen 
therapy is to increase the baseline PaO2 (partial pressure of oxygen in arterial blood) 
to at least 8kPa and/or arterial oxygen saturation SaO2>90% (symbol for percentage 
of  available  hemoglobin  that  is  saturated  with  oxygen)  during  sleep  and  rest. 
(Nocturnal Oxygen Therapy Trial Group, 1980) 
Long-term oxygen therapy prolongs life in patients with COPD. (Medical Research 
Council Working Party 1981, Nocturnal Oxygen Therapy Trial Group 1980)  Survival 
appeared to depend on the daily duration of treatment, with better outcome among 
subjects  who  received  oxygen  for  more  hours  per  day.  LTOT  has  also  been 
associated with improvements in mood, neuro-cognitive function, sleep and Quality 
of Life. (Kim et al, 2008) 
Before starting LTOT, COPD patients should be receiving appropriate treatment for 
their condition (e.g. bronchodilators, corticosteroids and treatment of infections). Gas Comparative Study on the QoL of COPD Patients 
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exchange  can  improve  substantially  following  smoke  cessation;  therefore 
assessment for LTOT should be made at least 1 month after the patient has stopped 
smoking. (McDonald et al, 2009) LTOT is contraindicated in current smoker, as it 
increases fire risk and the probability that the poorer prognosis conferred by smoking 
will offset treatment benefits. (Muehibeberger et al, 1998) 
1.6.3 Pulmonary Rehabilitation 
Pulmonary  rehabilitation  includes  exercise  programs,  nutritional  counselling  and 
patient education. The rehabilitation reduces the symptoms, improves the QoL, and 
improves  patients‘  functional  and  maximum  exercise  capacity  and  emotional 
participation in daily activities. It also reduces the depression, anxiety and the length 
of hospital stay. (Siafakas and Celli 2006 & Nice guidelines, 2006) 
1.6.4 COPD Surgery 
Bullectomy is a surgical procedure to remove a large bulla (large air-filled spaces in 
the lungs that are bigger than 1 centimeter or so in diameter) that does not contribute 
to gas exchange; it can be performed thoracoscopically. Once the bulla is removed, 
the healthy air sacs around it have room to expand, and the muscles used to breathe 
can function better. This procedure improves lung function and reduces dyspnoea. 
(Laros et al, 1986 & Lederer et al, 2007) 
Lung Volume Reduction Surgery (LVRS) is the resection of parts of the lung to 
reduce  hyperinflation;  it  improves  the  mechanical  efficiency  of  the  respiratory 
muscles and the expiratory flow rates by increasing the recoil pressure of the lung. 
(Cooper  et  al,  1995)  This  helps  the  lungs  work  better  and  in  carefully  selected 
patients, LVRS can improve breathing and QoL. (Yim et al, 2004)   Comparative Study on the QoL of COPD Patients 
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Lung  transplantation  is  performed  in  very  advanced  COPD  subjects  where  the 
damaged lung is removed and replaced with a healthy lung from a deceased donor. 
Lung  transplant  improves  lung  function,  exercise  capacity,  symptoms  and  QoL. 
(Trulock 1997, Thabu et al 2008, Janseen et al 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Comparative Study on the QoL of COPD Patients 
  Page 42 
 
1.7 Main Aims and Objectives 
The introduction chapter provided an overview and a summary of the studies carried 
out  to  assess  the  QoL  of  COPD  patients  and  those  that  tested  the  relationship 
between the QoL, muscle strength, Body Mass Index, lung function and dyspnoea. 
The main aims and objectives of this study are to: 
  Compare the QoL of COPD patients between three different countries which 
represent different regions: United Kingdom (UK), Morocco and the United 
Arab Emirates (UAE). 
  Compare the QoL of the control group between the three countries. 
  Assess  the  relationship  between  the  QoL  and  Body  Mass  Index  of  stable 
COPD patients. 
   Assess  the  relationship  between  the  QoL  and  muscle  strength  of  stable 
COPD patients. 
  Assess the relationship between the QoL and lung function of stable COPD 
patients. 
  Assess  the  relationship  between  the  QoL  and  dyspnoea  of  stable  COPD 
patients. 
This is the first study comparing the QoL of COPD patients between three different 
countries and regions, bearing in mind that these countries have different cultural, 
socio-economical  and  environmental  backgrounds.  To  my  knowledge  this  will  be 
also  the  first  study  that  assesses  the  QoL  of  COPD  patients  in  the  UAE  and  in Comparative Study on the QoL of COPD Patients 
  Page 43 
 
Morocco,  also  looking  at  the  possible  relationship  between  the  QoL  and  several 
variables (BMI, muscle strength, and dyspnoea). 
1.8 Hypothesis 
The main hypothesis is that the patients from the United Kingdom will have better 
QoL than patients from Morocco and the United Arab Emirates. This is believed to 
be due to the patient‘s care system and health services provided in the UK and that 
are not found in the other countries, considered as emerging countries. 
The other hypothesis is that COPD patients with low QoL will have low BMI, poor 
muscle strength and severe shortness of breath. 
Our hypothesis will be tested by using different tools as follows: 
1.  St George‘s Respiratory Questionnaire (SGRQ) to assess the QoL of COPD 
patients. 
2.  Hand-held spirometer to measure the lung function. 
3.  Hand-held dynamometer to measure the muscle strength. 
4.  Base line Dyspnoea Index (BDI) to assess the dyspnoea. 
In the following chapter, detailed measurements and research tools will be discussed 
along with an overview of the study subjects recruited, centres involved, inclusion 
and exclusion criteria.   Comparative Study on the QoL of COPD Patients 
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In this chapter a detailed methodology used in the recruitment of COPD patients and 
the control group will be given. The measurements used during this study will also be 
discussed as well as the analysis methods. 
2.1  Selection of Patients with COPD 
For this study, outpatients with COPD were recruited by a cluster sampling method. 
Participants were recruited during the period of November 2004 to January 2007 
from chest clinics in three countries: 
1.  United Kingdom: Royal Victoria Infirmary (RVI) (Newcastle). 
2.  Morocco: Avicenne Hospital (Rabat), Moulay Youssef Hospital (Rabat), and 
20-Août  Hospital  (Casablanca).  We  used  the  three  hospitals  in  Morocco 
because they are all connected and under one healthcare team doing rotation 
during the week. 
3.  United Arab Emirates: Al Maktoum Hospital and Dubai Hospital (Dubai). 
The  study  has  been  approved  by  the  University  of  Sunderland  and  the  NHS 
Newcastle Ethical Committee in the United Kingdom; by the Department of Health 
Dubai in the United Arab Emirates; and by the Ministry of Health in Morocco. 
The  targeted  patients  (males  and  females  aged  40  years  old  and  above)  were 
identified during their attendance to the outpatient chest clinics and were invited to 
take part in the study. 
Comprehensive  information  about  the  nature  of  the  study  was  supplied  to  each 
patient and details about the test that will be performed by the investigator (myself) 
including  the  questionnaire,  spirometry  and  muscle  strength  measurements  were 
also explained to the subjects.  Patients were assured that their responses would be Comparative Study on the QoL of COPD Patients 
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treated confidentially and that their participation in the study would not affect their 
medical treatment. (Appendix 1) 
The diagnosis of COPD was made by the consulting doctors and was based on the 
definition  provided  by  the  Global  Initiative  for  Chronic  Obstructive  Lung  Disease 
(GOLD).  The  COPD  patients  who  were  included  in  the  study  were  either  newly 
diagnosed with COPD or coming to the clinic for a follow-up. 
Subjects who could not participate, either because they refused to take part in the 
study, or those who had exacerbation within two weeks, or were with known co-
morbidities  (hemi-paralysis,  severe  visual  impairment).  These  details  were  taken 
from patients‘ medical files and from the healthcare professional following the case. 
Patients unable to perform spirometry due to shortness of breath were excluded from 
the study. 
2.1.1 Measurements 
2.1.1.1  Patients’ Information 
The  following  personal  information  (Appendix  2)  was  collected  from  the 
patient/patient file: 
  Gender 
  Age 
  Height and weight to calculate the BMI 
  Smoking history 
  Medical history Comparative Study on the QoL of COPD Patients 
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2.1.1.2  Lung Function Characteristics 
The Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC) and 
the  ratio  FEV1/FVC%  were  measured  using  the  same  hand-held  spirometer 
(Vitalograph). The spirometer was provided by the University of Sunderland to use 
during the study in all the centres (Morocco and the United Arab Emirates). In the 
United  Kingdom  I  was  not  able  to  perform  the  spirometry  and  therefore  used 
readings from the patient file as it is a routine to perform spirometry for the patients 
at every visit to the chest clinic and our hand-held spirometer could not be used 
because the patients were not keen to perform the spirometry twice during their visit 
to the physician, this information was told by the physician at the start of the study 
after some patients were asked and refused to do so. 
Before  a  subject  is  tested  it  is  important  to  perform  a  calibration  check  on  the 
spirometer. If a calibration is not performed then it is impossible to know whether the 
results obtained are accurate or not. The calibration mode can be entered by holding 
down the "VIEW" arrow button whilst holding down the "ON" button. The messages 
"zeroing sensor" and "please wait" are displayed. When the instrument is ready to be 
calibrated the display shows ―pump air‖. The calibration syringe (we have used 1-L 
syringe vitalograph - 3 x 1 to give us 3 L calibration) should be attached and one litre 
of air is pumped through the flow head. It usually takes around one second for each 
litre pumped through, the air should not be blasted through the flow head as this will 
not  calibrate.  The  message  "sampling  flow"  appears.  If  the  calibration  does  not 
require modification, the display shows an asterix in the top left hand corner. If it 
does require modification, the display shows "pump air" followed by the measured 
volume in millimetres. The procedure is repeated until calibration is successful; it 
usually requires only one more pump. Comparative Study on the QoL of COPD Patients 
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The airflow obstruction was represented by FEV1/FVC% and FEV1% predicted. The 
European Respiratory Society (ERS) guidelines set up equations for the European 
patients  in  order to  calculate  the  predicted  values  of  FEV1  the equations are  as 
follows: (Quanjer et al, 1993) 
-  Males    FEV1 predicted= 4.30 x height (m) - 0.029 x age (yrs) - 2.49 
FVC predicted= 5.76 x height (m) - 0.026 x age (yrs) – 4.34 
-  Females  FEV1 predicted= 3.95 x height (m) - 0.025 x age (yrs)  - 2.60 
FVC predicted= 4.43 x height (m) - 0.026 x age (yrs) - 2.89 
Then  we  calculated  the  FEV1%  predicted  and  FVC%  predicted  for  the  COPD 
patients using these equations: 
 
 
The  classification  of  COPD  used  in  this  research  is  the  GOLD  guidelines 
classification which is mentioned in the introduction chapter. (Figure 2) 
2.1.1.3  Muscle Strength 
A hand grip dynamometer was provided by the University of Sunderland to measure 
the muscle strength of each patient. Reasons behind performing the test and the 
method how to hold the dynanomometer were explained to the subjects. The hand 
grip strength values of each hand (right and left) was measured and recorded. Comparative Study on the QoL of COPD Patients 
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2.1.1.4  Dyspnoea 
Patients were asked to answer a few questions related to their breathlessness in 
relation to the impaired activities using the Mahler Dyspnoea Index (MDI). MDI was 
developed  by  Mahler  and  colleagues  in  1984  to  assess  the  shortness  of  breath 
experienced by COPD patients and it consists of: (a) Baseline Dyspnoea Index (BDI) 
to measure the severity of dyspnoea at a single point in time as well as the impact of 
dyspnoea on an individual‘s life, and (b) Transition Dyspnoea Index (TDI) to note 
changes from the baseline assessment. (Mahler et al, 1984) Each index rates three 
different  categories: magnitude  of task  needed  to  evoke  dyspnoea, magnitude of 
effort needed to evoke dyspnoea, and functional impairment. Dyspnoea was rated in 
five  grades  from  0  (severe)  to  4  (unimpaired)  for  each  category.  The  score  is 
determined based on the answers of the patient.  
BDI  indices  have  been  validated  in  a  multinational  clinical  trial,  the  BDI  was 
significantly correlated with the Dyspnoea Diary and the symptom and activity scores 
of the SGRQ. (Witeck, 2003) (Baseline Dyspnoea Index: Appendix 6) 
2.1.1.5  Quality of Life (QoL) 
Patient‘s  QoL  was  assessed  using  the  St  Georges‘  Respiratory  Questionnaire 
(SGRQ) with the permission of Professor Paul Jones from St Georges‘ Hospital in 
London. English version (Appendix 3) of the questionnaire is used in all the centres 
and administered by the same investigator (myself) throughout the data collection 
and it was translated directly to the patients into the appropriate dialect in Morocco 
and in the United Arab Emirates. The translation was made by me with the help of 
the physicians and we agreed about the medical and frequently used terms, that Comparative Study on the QoL of COPD Patients 
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patients  would  understand  and  to  employ  in  each  dialect  to  avoid  any  major 
confusion. The Arabic version of SGRQ (Appendix 4) was used for reference. 
As discussed in the introduction chapter, SGRQ is a disease specific measurement 
mainly used in COPD. The questionnaire has 76 items which are divided into three 
components: 
1.  Symptom: concerned with the effect of respiratory symptoms, their frequency 
and severity. The symptom score is calculated from the summed weights for 
the positive responses (Questions 1-8). 
2.  Activity:  concerned  with  activities  that  cause  or  are  limited  by 
breathlessness. Activity score is calculated from the summed weights for the 
positive responses (Questions 11 and 15). 
3.  Impact:  covers  a  range  of  aspects  concerned  with  social  functioning  and 
psychological disturbances resulting from airways disease. The impact score 
is calculated from the summed weights for the positive responses (Questions 
9-10, 12-14 and 16-17). 
The total score is also calculated which summarises the impact of the disease on 
overall  health  status.  It  is  calculated  by  summing  all  positive  responses  in  the 
questionnaire,  and  scores  are  expressed  as  a  percentage  of  overall  impairment. 
(Appendix 6) 
The  questionnaire‘s  scores  are  expressed  in  %  for  all  the  components;  this 
percentage is calculated as follows: 
-  Symptom%: Symptoms score of each patient / 662.5 x 100 
-  Activity%: Activity score of each patient / 1209.1 x 100 Comparative Study on the QoL of COPD Patients 
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-  Impact%: Impact score of each patient/ 2117.8 x 100 
-  Total%: Total SGRQ score of each patient / 3989.4 x 100 
Each questionnaire response has a unique empirically derived 'weight'. The lowest 
possible weight is zero and the highest is 100. Where 100 represents poor health 
status and 0 indicates better health status. 
In multiple choice questions missing items were considered as ―No=0‖, and those 
with yes/no answer, the weight was subtracted from the total possible weight in each 
component.  
2.1.1.6  Extra Questions 
Some extra questions (see below) were asked to the patients in order to assess their 
awareness  of  their  condition  and  their  treatment.  The  results  will  be  compared 
between patients from the three countries: 
Question1: Do you know that you have COPD? 
Question2: Do you know your symptoms (cough, sputum and wheezing)?   
Question3: Do you know smoking is the primary cause of COPD? 
Question4: Do you know the most common causes of an exacerbation are infection 
of the tracheobronchial tree and air pollution? 
Question5: Do you expect simple, one-off treatment to cure the symptoms? 
Question6: Did you have influenza vaccination? 
Note: Influenza vaccinations are currently recommended in the care of people with 
COPD on a yearly basis. (Poole et al, 2010) 
Question7: Did you attend pulmonary rehabilitation? 
Question8: Do you take irregular inhaled corticosteroids? 
Note:  Some  patients  choose  to  take  irregular  inhaled  steroids;  both  regular  and 
irregular steroids reduce the risk of exacerbation. (Vollmer, 2007) 
 Comparative Study on the QoL of COPD Patients 
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2.2  Selection of Control Group 
The healthy group was recruited from the: 
-  Workers  and  passengers  of  the  Moroccan  National  Rail  Network  in 
Casablanca (Morocco) 
-  In  the  United  Arab  Emirates:  hospital  employees,  consultants,  and  some 
patients consulting other wards and not suffering from co-morbidities, severe 
illnesses such as severe visual impairments. 
-  Clients of Age Concern in the North East in the UK. 
Age range was matched in all the three centers studied; in other words very young or 
very old healthy subjects were not recruited. 
Participants aged 40 years old and above who agreed to take part in the study were 
included after being given a full explanation about the research and its purpose. 
The tests performed for the control group were similar to those used for patients. 
Subjects  were  asked  to  complete  the  English  version  (Appendix  3)  of  the 
questionnaire and it was administered by the same investigator (myself) throughout 
the data collection and it was translated directly to the patients into the appropriate 
dialect in Morocco and in the United Arab Emirates. Subjects did also perform the 
spirometry test using the hand-held spirometer and then their muscle strength was 
measured using the hand grip dynamometer. Other information was also collected 
including: age, gender, height, weight, and smoking history. 
Subjects  who  refused  to  take  part  in  the  study,  those  who  could  not  perform 
spirometry  and  with  known  respiratory  illness  were  excluded.  Data  was  collected Comparative Study on the QoL of COPD Patients 
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under supervision of a GP at the Moroccan National Rail Network therefore subjects 
with doubts of having COPD were excluded from the study.  
2.3  Statistical Analysis 
Data analysis was performed using the Statistical Package for the Social Sciences 
(SPSS)  Version  14.0.  Results  are  described  as  ‗significant‘  if  two-sided  p-values 
were less than or equal to 0.05, but this is purely a conventional value. Estimates of 
means are shown with 95% two-sided confidence intervals. 
2.3.1 Patients’ Data Analysis 
Chi-Square test is a statistical procedure for comparing proportions in two groups. 
In this study the Chi-Square test was used to compare the extra questions that were 
asked to the patients in two or more groups. It was also used to examine if there was 
a difference between countries for the two measures (gender and smoking status).  
ANOVA Post Hoc test was used to compare each centre to every other one to see 
if they are significantly different in terms of their total SGRQ scores. 
The  effects  of  various  study  variables  upon  the  QoL  scores  components  were 
assessed  using  linear  regression  (As  the  QoL  scores  were  measured  on  a 
continuous scale). Initially the separate effect of each variable upon the outcome 
was  examined  separately  in  a  series  of  univariate  analyses.  For  the  continuous 
explanatory variables, the relationship with the QoL outcome was examined to see if 
a non-linear (i.e. curved) relationship was more appropriate than a linear (straight 
line) one.  
The joint effect of the variables upon QoL in a multivariate analysis was assessed. 
This analysis has the advantage that the effect of each variable upon the  QoL is Comparative Study on the QoL of COPD Patients 
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adjusted for the other factors in the analysis. A backwards selection procedure was 
used to retain only the statistically significant variables. This involves removing the 
non-significant variables, one at a time, until all remaining variables were significant.  
The differences between the three countries were examined in terms of a number of 
parameters. All continuous variables were approximately normally distributed, and so 
analysis of variance (ANOVA) was used to compare between the three countries. 
The Chi-square test was used to compare the categorical variables (Gender and 
smoking status) between countries.  
The  differences  in  QoL  between  countries  were  examined  next.  Firstly  the 
differences between countries were examined without considering any other factors 
in the analysis. Subsequently, the same difference was examined, this time adjusting 
for factors found to be significant in the first part of the analysis. Smoking status was 
included  in  this  analysis,  as  this  factor  was  almost  significant  in  the  multivariate 
analysis. All the analysis was performed using linear regression.  
Additionally, the interaction between each of the explanatory variables and country 
was  examined.  A  significant  interaction  would  imply  that  the  difference  between 
country varied by that factor.  
The final set of analysis examined the effect of the three dyspnoea variables upon 
QoL. This analysis was performed in three stages. Firstly the effect of each variable 
upon QoL was examined separately. Then the variables were examined together in 
a multivariate analysis. Finally the multivariate analysis was extended to also include 
factors previously found to significantly influence QoL and centre.  Comparative Study on the QoL of COPD Patients 
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Before  the  multivariate  analysis,  the  collinearity  between  the  three  dyspnoea 
variables was examined. Collinearity between variables occurs when two or more 
variables are very similar to each other. In such situations this can influence the 
results  of  regression  analysis  and  produce  unusual  results.  Collinearity  was 
assessed  using  variance  inflation  factors  (VIFs),  with  values  of  over  10  used  to 
indicate collinearity. If this was present, then the solution is to only include one of the 
collinear variables in the regression analysis. 
2.3.2 Control Group Data Analysis 
The first set of analysis examined the differences between the countries in terms of a 
number  of  parameters.  Data  on  some  parameters  was  available  for  all  three 
countries,  whilst  other  information  was  only  available  for  the  UAE  and  Morocco. 
Where  information  was  available  for  3  countries,  the  comparisons  were  made 
between the 3 countries, and where it was available for only two, the comparisons 
were restricted to these two countries. All continuous variables were approximately 
normally distributed. Therefore, analysis of variance (ANOVA) was used to compare 
between the continuous measures between three countries, whilst the unpaired t-
test was used where data was only present for two countries. The Chi-square test 
was used to compare the categorical variables between countries. 
The effects of various study variables upon the QoL scores were examined. Due to 
missing data for some variables, this analysis was restricted to subjects from the 
UAE and Morocco only. As the QoL scores were measured on a continuous scale, 
the analysis was performed using linear regression. Initially the separate effect of 
each variable upon the outcome was examined separately in a series of univariate 
analyses. For the continuous explanatory variables, the relationship with the QoL Comparative Study on the QoL of COPD Patients 
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outcome was examined to see if a non-linear (i.e. curved) relationship was more 
appropriate than a linear (straight line) one.  
The second stage in the analysis process  was to examine the joint effect of the 
variables upon QoL in a multivariate analysis. This analysis has the advantage that 
the effect of each variable upon the outcome is adjusted for the other factors in the 
analysis. A backwards selection procedure was used to retain only the statistically 
significant variables. This involves removing the non-significant variables, one at a 
time, until all remaining variables were significant. 
The  differences  in  QoL  between  countries  were  examined  next.  Firstly  the 
differences between countries were examined without considering any other factors 
in the analysis. Subsequently, the same difference was examined, this time adjusting 
for  factors  that  could  potentially  confound  the  country  differences.  The  factors 
adjusted for were restricted to those where there was data for all three countries, 
namely age, BMI, gender and smoking status.   Comparative Study on the QoL of COPD Patients 
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Total  of  1800  subjects  were  included  in  this  study,  the  table  below  shows  the 
detailed number of subjects recruited from each centre. (Table 1) One of the first 
objectives was to compare the QoL between COPD patients and the control group, 
but after analysing the QoL of the control group we observed that in fact this group is 
not quite healthy therefore we decided to analyse both groups separately.  
Associations  between  QoL  and  the  physiological  measurements  will  also  be 
assessed, differences between the two genders from the United Kingdom will also 
be analysed as we were not able to recruit female COPD patients from the UAE and 
Morocco; we will come back to this point in the discussion chapter. 
Centre  United Arab Emirates  Morocco  United Kingdom 
Gender  Male  Male  Male  Female 
COPD Subjects  120  115  137  58 
Control Group  301  301  284  484 
Table 1: Number of COPD patients and control group included 
3.1  Analysis of COPD Patients Data 
ANOVA was used to compare the continuous variables between the three countries, 
and the results are summarised in the next table. (Table 2) The figures reported are 
the mean and standard deviation value for each country, and the p-values indicating 
the significance of the overall difference between the three countries. 
Variable  UAE 
Mean ±SD 
Morocco 
Mean ±SD 
UK 
Mean ±SD  p-value 
Age  60 ±15  62 ±10  71 ±9  <0.001 
BMI  25 ± 3.6  21 ±3.0  26 ±3.6  <0.001 
FEV1% Predicted  55 ±28  44 ±24  53 ±27  0.004 
FVC% Predicted  48 ±23  54 ±21  76 ±21  <0.001 
Grip score  58 ±19  57 ±19  51 ±18  <0.001 
FEV1: Forced Expiratory Volume in 1 second, FVC: Forced Vital Capacity, FEV1/FVC%: Forced Expiratory Ratio 
Table 2: Baseline characteristics for COPD patients Comparative Study on the QoL of COPD Patients 
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The results indicated that there was a highly significant difference in all variables 
between the three countries: 
-  Patients  from  the  UK  tended  to  be  older  than  patients  from  the  other  two 
countries,  with  a  mean  age  of  71,  compared  to  nearer  60  for  the  other 
countries.   
-  The BMI of Moroccan patients was the lowest, with similar values for the UAE 
and UK. The Patients from Morocco also had a lower FEV1% predicted than 
the other two countries. 
-  UK patients had the highest FVC% predicted, with a mean of 76 compared to 
54 for Morocco, and a mean of 48 for the UAE. Conversely, UK patients had a 
lower grip score than the other two countries. 
The  next  set  of  analysis  used  the  Chi-square  test  to  examine  if  there  was  a 
difference between countries for the two categorical measures (smoking status and 
gender. A summary of the analysis results is given in the next table. (Table 3) The 
figures reported are the number and percentage of responses in each category for 
each country. 
Variable  Category  UAE 
N (%) 
Morocco 
N (%) 
UK 
N (%)  P-value 
Smoking 
Status 
Non/Ex-Smoker  77 (64%)  76 (66%)  172 (88%) 
<0.001 
Smoker  43 (36%)  39 (34%)  23 (12%) 
Gender 
Male  120 (100%)  115 (100%)  137 (70%) 
<0.001 
Female  0 (0%)  0 (0%)  58 (30%) 
Table 3: Number and percentage of responses in gender and smoking status for each country 
 Comparative Study on the QoL of COPD Patients 
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The  results  suggested  that  both  smoking  status  and  gender  varied  between 
countries. Smoking was much higher in the UAE and Morocco where over 30% of 
patients smoked, than in the UK where the figure was only 12%.  The UAE and 
Moroccan  groups  consisted  of all  male patients,  whilst  30%  of  UK  patients  were 
females. 
3.1.1  Analysis of the Total Quality of Life of COPD Patients 
3.1.1.1  Factors Associated with Total SGRQ Scores 
Linear regression was used to examine the effect of various parameters upon the 
total SGRQ scores. Initially the separate effect of each variable upon this outcome 
was examined separately and the results are summarised in the next table. 
The  figures  reported  are  the  regression  coefficients  and  also  their  corresponding 
95% confidence intervals. For the continuous variables, the regression coefficients 
represent the change in the total SGRQ scores for a given increase in that variable 
(size of increase indicated in the table). For the categorical variables, the regression 
coefficients indicate the difference in QoL between each category and a baseline 
category. Also reported are the R-square values. These indicate the proportion of the 
total variation in QoL that is explained by each predictor. (Table 4) 
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Variable  Term /category  Coefficient (95% CI)  R
2  p-value 
Age 
(**) 
Linear term  -0.78 (-2.00, 0.45) 
0.16  <0.001 
Squared term  0.11 (0.02, 0.21) 
BMI 
(*)  -  -0.31 (-0.56, -0.06)  0.01  0.01 
FEV1% Predicted 
(**)  -  -0.31 (-0.38, -0.24)  0.15  <0.001 
FVC% Predicted 
(**) 
Linear term  -0.90 (-1.29, -0.51) 
0.17  <0.001 
Squared term  0.05 (0.01, 0.08) 
Grip score 
(**) 
Linear term  0.37 (-0.12, 0.86) 
0.28  <0.001 
Squared term  -0.08 (-0.13, -0.04) 
Smoking Status 
Non/Ex-Smoker  0 
0.09  <0.001 
Smoker  -1.49 (-1.94, -1.04) 
Gender 
Male  0 
0.00  0.84 
Female  -0.06 (-0.65, 0.53) 
  (*)  Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
  Table 4: Factors associated with the QoL in COPD patients 
The  results  of  the  univariate  analysis  indicated  that  age,  BMI,  FEV1%  predicted, 
FVC% predicted, Total Muscle Grip score and smoking status were all significantly 
associated with the total SGRQ scores. However, there was no significant difference 
between genders in terms of their QoL. 
The  analysis  indicated  that  there  was  a  significant  second  order  regression 
component shown in a non-linear effect of age upon QoL. This makes it difficult to 
interpret the regression coefficients, and so the results are best shown graphically. 
The graph below shows the fitted regression line between age and total QoL. (Figure 
3) Comparative Study on the QoL of COPD Patients 
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Figure 3: Regression line between age and QoL 
The graph suggests that for older subjects the QoL scores increases with age, in 
other terms older patients tend to have poor QoL. 
The results for BMI indicated that patients with a greater BMI had a better QoL. A 5-
unit increase in BMI was associated with the SGRQ total score decreasing by 0.3 
units. (Figure 4) A higher FEV1% predicted value indicated lower QoL scores. A 10-
unit increase in FEV1% predicted was associated with a decrease in SGRQ score of 
0.3 units. (Figure 5) Graphical representations of both of these two results are shown 
in the next graphs. 
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Figure 4: Regression line between BMI and QoL 
 
 
Figure 5: Regression line between FEV1% predicted and QoL 
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The  results  for  FVC%  predicted  indicated  that  there  was  a  non-linear  (i.e.  not  a 
straight  line)  relationship  with  QoL.  A  graphical  illustration  of  the  relationship  is 
shown in the next graph. (Figure 6) 
 
Figure 6: Relationship between FVC% predicted and QoL 
The  graph  suggests  that  there  was  a  decrease  in  SGRQ  scores  with  increased 
FVC% predicted up to around 80% or 90%, after which there was little relationship 
with QoL. 
There was also a non-linear relationship between TMG score and QoL. Again, with 
such  a  relationship  it  is  easier  to  interpret  the  results  graphically  than  from  the 
coefficients.  The fitted relationship between the two variables is shown in the next 
graph. (Figure 7) The graph suggests that there is little relationship between grip 
score  and  QoL  for  scores  below  40.  However,  for  scores  above  40  there  is  a 
decrease in the SGRQ scores with increase grip score therefore better QoL. 
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Figure 7: Relationship between Total Muscle Grip and QoL 
The results for smoking status indicated that non or ex-smokers (of which the vast 
majority were ex-smokers) had lower SGRQ scores than current smokers, meaning 
that non or ex-smokers had better QoL than current smokers. 
Afterwards  multivariate  analysis  was  performed  to  look  at  the  joint  effect  of  the 
factors upon the total SGRQ scores. A backwards selection procedure was used to 
retain only the statistically significant variables, and the final model is shown in the 
next table. (Table 5) 
Variable  Term / category  Coefficient (95% CI)  p-value  R² 
Age 
(**) 
Linear term  -1.41 (-2.49, -0.34) 
<0.001 
0.43 
Squared term  0.14 (0.06, 0.23) 
FVC% Predicted 
(**) 
Linear term  -0.74 (-1.07, -0.41) 
<0.001 
Squared term  0.04 (0.01, 0.06) 
Grip score 
(**) 
Linear term  0.66 (0.20, 1.11) 
<0.001 
Squared term  -0.09 (-0.13, -0.05) 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
  Table 5: Factors affecting the QoL (Multivariate analysis) 
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The results of the multivariate analysis indicated that age, FVC% predicted score 
and TMG score were all significantly associated with total QoL. After adjusting for 
these  three measures,  there  was  no  longer  a real evidence  of  an  effect of  BMI, 
FEV1% predicted and smoking status upon QoL (although the result for smoking 
status was very weakly significant p=0.049). 
The coefficients for age, FVC% and TMG score were all in the same direction as the 
univariate  analysis,  suggesting  similar  direction  of  effects  to  those  seen  in  this 
analysis. This suggests positive relationship between age and SGRQ scores, and a 
negative relationship between both FVC% predicted and TMG score with QoL score.  
This  final  model  had  an  R-square  value  of  0.43.  This  suggests  that  43%  of  all 
variation in QoL can be attributed to the combination of age, FVC% predicted and 
TMG score. This suggests that just over half the remaining variation is due to other 
sources. 
3.1.1.2  Difference in QoL between Countries 
When looking at the QoL of the patients included from each centre, we observed that 
the  UK  patients  had  lower  symptom  score  than  subjects  from  Morocco,  with  the 
poorest QoL seen in the UAE patients in terms of symptoms. In terms of activity 
scores, patients from the UAE had better QoL giving the low scores compared to the 
other centres, with no significant difference between Morocco and the UK. Patients 
from the UK had the best QoL in terms of impact scores over the UAE and Morocco. 
Overall, we observed that patients from the UAE had the poorest QoL, while the best 
QoL was recorded for patients from the UK. (Table 6) 
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Centre  United Arab Emirates  Morocco  United Kingdom 
Symptom  57±23  53±22  47±18 
Activity   67±25  81±24  82±21 
Impact  40±22  41±26  35±19 
Total Scores  63±25  55±22  51±17 
Table 6: Quality of Life of COPD patients in each centre 
 
To find out whether there were significant differences between the averages of the 
Total  SGRQ  scores  for  the  three  groups  of  patients,  the  one-way  analysis  of 
variance was used and the results were demonstrated in the following table.(Table 7) 
Source  Type III Sum of Squares  df  Mean Square  F  Sig. 
Intercept  1168104.84  1  1168104.84  2537.02  <0.001 
Centre  8706.99  2  4353.5  9.45  <0.001 
Dependent Variable: Total QoL percent, R square=0.049 (Adjusted R square=0.44) 
Table 7 : Univariate analysis of variance, tests of effects between-subjects 
 
The F-ratio value that was calculated from the analysis of variance of total SGRQ 
scores factor values for the three groups of patients was 9.455 and less than 1% 
significance level; this indicates the existence of significant differences among the 
averages of the Total SGRQ scores for COPD patients in the three regions. In other 
words,  the  averages  of  the  Total  SGRQ  scores  for  COPD  patients  at  the  three 
regions are not at the same intensity. 
The ANOVA Post Hoc test was used to test whether several means are equal across 
one variable. The table of post hoc analysis using Tukey test (using centre only) lists 
the three centres in the first column, and then compares each centre to every other 
centre to see if they are significantly different. It lists the mean differences between 
the total scores.  Comparative Study on the QoL of COPD Patients 
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The  differences  in  QoL  between  countries  were  examined  next.  Firstly  the 
differences between countries were examined without considering any other factors 
in the analysis. Subsequently, the same difference was examined, this time adjusting 
for factors found to be significant in the first part of the analysis. Smoking status was 
included  in  this  analysis,  as  this  factor  was  almost  significant  in  the  multivariate 
analysis. All the analysis was performed using linear regression. 
Here we see that the UAE (Centre 1) has a mean total SGRQ score 8 points higher 
than Morocco (Centre 2) with p=0.013 and more than 10 points higher than the UK 
(Centre  3)  with  p<0.001,  meaning  that  the  UAE  has  the  worst  QoL  of  the  three 
centres. Morocco has higher SGRQ scores than the UK but not at significant level 
(p=0.4). (Table 8) 
Centre  Centre  Mean 
Difference 
Std. 
Error  p-value 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
1 
2  8.03  2.81  .013  1.41  14.64 
3  11.54  2.69  .000  5.19  17.88 
2 
1  -8.03  2.81  .013  -14.64  -1.41 
3  3.50  2.71  .400  -2.87  9.89 
3 
1  -11.54  2.69  .000  -17.88  -5.19 
2  -3.50  2.71  .400  -9.89  2.87 
Dependent variable: Total QoL percent 
Table 8: Post Hoc Tests (Tukey HSD) 
 
The results above show that there is: 
-   Statistical  significant  differences  between  the  total  SGRQ  scores  for  COPD 
patients in the regions of the UAE and Morocco, it can be said that with 95% 
confidence level that the average of total SGRQ scores for COPD patients in the 
UAE is higher than patients from Morocco. In other words patients from the UAE 
have poorer QoL than Moroccan patients. Comparative Study on the QoL of COPD Patients 
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-  Statistical  significant  differences  at  (1%)  significance  level  between  the  total 
SGRQ scores for COPD patients from the UAE and the UK, Patients from the UK 
had better QoL than patients from the UAE. 
-  No statistical significant differences between the total SGRQ scores for COPD 
patients from Morocco and the UK. 
Another way to analyse if there are differences between the three countries was 
done  twice;  firstly  unadjusted  and  then  adjusted  for  factors  associated  with  total 
QoL.  A  summary  of  the  results  is  given  in  the  next  table.  The  figures  are  the 
regression coefficients, which represent the difference in QoL between each country 
and the baseline category (in this case the UAE). The first p-value reported is the 
significance of the overall difference between countries. The subsequent p-values 
indicated the specific differences between pairs of countries. These latter set of p-
values were given a Bonferroni adjustment to allow for multiple comparisons.(Table 
9) 
Country  Unadjusted  Adjusted 
  Coefficient (95% CI)  p-value  Coefficient (95% 
CI) 
p-value 
UAE  0 
<0.001 
0 
<0.001  Morocco  -0.9 (-1.4, -0.3)  -0.8 (-1.2, -0.4) 
UK  -1.1 (-1.6, -0.6)  -1.4 (-1.9, -1.0) 
UAE vs. Morocco 
 
0.006 
 
<0.001 
UAE vs. UK  <0.001  <0.001 
Morocco vs. UK  1.00  0.009 
Table 9: Differences between pairs of countries before and after adjusting for the other factors 
The results indicated that there was an overall significant difference between three 
countries  when  no  other  factors  were  considered  (the  unadjusted  results).  The 
highest  scores  were  for  the  UAE,  which  were  significantly  higher  than  those  in 
Morocco and the UK. On average, there was a difference of around 1 unit on the 
scale  between  countries.  However,  there  was  no  significant  difference  between Comparative Study on the QoL of COPD Patients 
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Morocco and the UK. In other words the UAE patients have the poorest QoL than 
those from the UK and Morocco. 
When the significant risk factors (BMI, age, TMG, FEV1% predicted, smoking) were 
taken into account, there was still a significant overall difference between the three 
countries. Again scores in the UAE were the highest, significantly more than both of 
the other two countries. However, after adjustment, scores were now significantly 
lower in the UK than they were in Morocco. The difference in total SGRQ scores 
between the UAE and the UK was 1.4 units. 
Subsequently the interaction between country and each of the other variables was 
examined.  The  results  suggested  no  significant  interaction  between  country  and 
TMG score (p=0.35). This suggests that differences between countries do not vary 
depending on either age or TMG score. 
However, there was found to be a significant interaction between country and FVC% 
predicted  (p=0.03).  This  suggests  that  the  difference  between  countries  varies 
depending of the FVC% predicted values. As a result of this, the effect of FVC% 
predicted upon QoL was quantified for each of the three countries. The results are 
summarised below. (Table 10) 
Country  Term / category  Coefficient (95% CI)  P-value 
UAE  Linear term  -0.04 (-0.19, 0.12)  0.002 
Squared term  0.05 (0.01, 0.08) 
Morocco  Linear term  -0.29 (-0.44, -0.14)  <0.001 
Squared term  0.05 (0.01, 0.08) 
UK  Linear term  -0.20 (-0.32, -0.08)  0.004 
Squared term  0.05 (0.01, 0.08) 
Table 10: Effect of FVC% predicted upon QoL on each country Comparative Study on the QoL of COPD Patients 
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The results show that although there is a significant interaction with country, there 
was  still  a  significant  effect  of  FVC%  predicted  upon  QoL  for  each  of  the  three 
countries. 
Due to the non-linear relationship between variables, it is easier to show the results 
graphically. A graphical illustration of the nature of the interaction is shown in the 
next graph. This shows the relationship between FVC% predicted and total QoL for 
each of the three countries. (Figure 8) 
 
Figure 8: Relationship between FVC% predicted and total QoL for each of the three countries 
 
The nature of the interaction suggests that for patients with low FVC% predicted 
values,  the  total  SGRQ  scores  are  lowest  in  the  UAE  and  highest  in  Morocco. 
Conversely  for  patients  with  high  FVC%  predicted  scores,  values  are  lowest  in 
Morocco, but highest in the UAE. 
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The following  graphs  represent  the effect of  FVC% predicted on  the  total SGRQ 
scores for each country and representing individual regression points. Figures 9-11 
show the relationship between FVC% predicted and total SGRQ scores in the UAE, 
Morocco and the UK respectively. 
 
Figure 9: Effect of FVC% predicted on the total SGRQ scores in the UAE 
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Figure 10: Effect of FVC% predicted on the total SGRQ scores in Morocco 
 
 
Figure 11: Effect of FVC% predicted on the total SGRQ scores in the UK 
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3.1.1.3    Effect of Dyspnoea on the Total QoL Scores  
Dyspnoea, which is defined as an uncomfortable sensation of breathing is the main 
cause of disability in COPD patients.  Several studies confirm that dyspnoea affects 
the QoL of COPD patients. 
The next set of analysis examined the effect of the three dyspnoea variables from 
the BDI upon QoL. This was done using linear regression in three stages, and the 
results are summarised in the next table. (Table 11) Noting that in the multivariate 
analysis  including  the  three  dyspnoea  variables:  magnitude  of  task,  functional 
impairment  and  magnitude  of  effort,  a  strong  evidence  of  collinearity  was  found 
between the magnitude of effort and the magnitude of task. This suggests that these 
two variables are almost identical to each other; in fact they have a correlation of 
0.99, with VIF of 12.7 (greater than 10), and the tolerance of 0.079 (below 0.1). 
These results suggest that the two variables are near perfect linear combinations of 
one  another;  therefore  it  is  not  possible  to  include  both  variables  in  the  same 
analysis, and so it was chosen to include only the magnitude of effort. (Figure 12) 
 
Figure 12: Collinearity between magnitude of task and magnitude of effort Comparative Study on the QoL of COPD Patients 
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The figures reported are the regression coefficients and their corresponding 95% 
confidence intervals. The scales for all variables are that higher values represent a 
lower grade. So the regression coefficients represent the change in total QoL for a 
one-grade decrease in each variable. (Table 11) 
Analysis  Variable  Coefficient (95% 
CI) 
P-value 
Univariate 
Functional impairment  1.23 (1.11, 1.35)  <0.001 
Magnitude of task  1.17 (1.05, 1.28)  <0.001 
Magnitude of effort  1.17 (1.05, 1.29)  <0.001 
Multivariate  Functional impairment  0.77 (0.45, 1.08)  <0.001 
Magnitude of task  0.49 (0.19, 0.79)  0.002 
Multivariate + adjusted  Functional impairment  0.50 (0.24, 0.76)  <0.001 
Magnitude of task  0.58 (0.34, 0.83)  <0.001 
Table 11: Relationship between dyspnoea and total QoL 
The  univariate  results  suggested  that  all  three  factors  were  associated  with  total 
SGRQ scores. A one-grade decrease in any of the variables was associated with an 
increased total SGRQ score of just over one-unit. 
The relationship between function impairment and the total SGRQ score is illustrated 
in  the  next  graph,  which  shows  that  COPD  patients  with  advanced  dyspnoea 
(functional impairment) have poor QoL. (Figure 13) Comparative Study on the QoL of COPD Patients 
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Figure 13: Association between total SGRQ scores and functional impairment 
 
When both functional impairment and magnitude of task were included in the same 
regression  model  in  a  multivariate  analysis,  both  were  still  statistically  significant 
although  the  effects  of  each  factor  were  smaller.  Similarly  both  factors  were  still 
significant after adjusting for age, FVC% predicted and TMG score. 
3.1.1.4 QoL and Gender Differences in COPD Patients 
Because  no  female  COPD  patients  were  recruited  in  the  UAE  or  Morocco,  the 
gender  differences  will  be  analysed  comparing  the  UK  COPD  patients  only:  137 
male patients and 58 female patients. The table below represents the patients‘ main 
characteristics. (Table 12) 
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Centre  United Kingdom 
Subjects  Male (n=137)  Female (n=58) 
Age (yrs)  71±9.2  73±9.7 
BMI  26±3.5  25±4.5 
FEV1% predicted  53±26.7  60±26.1 
FVC% predicted  76±20.9  74±20.4 
Total Muscle Grip  51±17.6  36±10.8 
Table 12: UK patients’ characteristics 
In order to assess the effect of gender on the QoL of COPD patients a T-test was 
used. This test is used to verify whether there is significant difference between the 
means of two groups (male v female). 
The table below represents the means of the QoL components for the two genders. 
(Table 13) 
     Gender  N  Mean  Std. Error Mean 
Symptom score 
Male  137  47±18.4  1.5 
Female  58  51±18.8  2.4 
Impact score 
Male  137  35±18.5  1.6 
Female  58  38±16.8  2.2 
Activity score 
Male  137  82±20.6  1.7 
Female  58  86±15.7  2 
Total score 
Male  137  51±16.9  1.4 
Female  58  55±14.7  1.9 
Table 13: QoL of COPD patients from the UK 
 
The results indicate that there is no significant difference between the mean total 
SGRQ scores for males and females. There is no significant difference between the 
mean symptom, impact and activity scores for males and females (0.09, 0.32 and 
0.11 respectively). (Table 14) 
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Scores 
Levene's test 
for equality of 
variances 
t-test for equality of means 
F  Sig.  df  p-value 
Mean 
difference 
Std. error 
difference 
95% confidence 
interval of the 
difference              Lower  Upper 
Total   0.45  0.50  193  0.14  -3.70  2.55  -8.74  1.32 
Symptom   0.11  0.74  193  0.09  -4.81  2.90  -10.54  .918 
Impact   1.04  0.30  193  0.32  -2.76  2.82  -8.33  2.80 
Activity   2.74  0.09  193  0.11  -4.75  3.02  -10.72  1.21 
Table 14: Effect of gender on the QoL of COPD patients from the UK 
3.1.2 Analysis of the Symptom SGRQ Scores of COPD Patients  
This section details how the three different countries varied in terms of the symptoms 
component  of  the  QoL  score.  In  this  section  only  male  patients  were  included 
because  gender  did  not  have  any  effect  as  noted  in  the  previous  section.  The 
methods used for the analysis was equivalent to those described in the first section 
of the results.  
3.1.2.1    Factors Associated with the Symptom Scores 
Linear regression was used to examine the effect of various parameters upon the 
symptom scores. Initially effect of each variable upon this outcome was examined 
one at a time, and the results are  summarised in the next table. (Table 15) The 
figures reported are the regression coefficients, and also their corresponding 95% 
confidence  intervals.  For  the  continuous  variables,  the  regression  coefficients 
represent the change in the symptom scores for a given increase in that variable 
(size of increase indicated in the table). For the categorical variables, the regression 
coefficients indicate the difference in QoL in terms of symptom scores between each Comparative Study on the QoL of COPD Patients 
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category and a baseline category. Also reported are the R-square values. These 
indicate  the  proportion  of  the  total  variation  in  symptom  SGRQ  score  that  is 
explained by each predictor. (Table 15) 
Variable  Term / category  Coefficient (95% CI)  R
2  P-value 
Age 
(**)  Linear term  0.75 (0.58, 0.91)  0.16  <0.001 
Squared term  0.17 (0.07, 0.26) 
BMI 
(*)  -  -0.32 (-0.57, -0.07)  0.01  0.01 
FEV1% Predicted 
(**)  -  -0.28 (-0.35, -0.20)  0.12  <0.001 
FVC% Predicted 
(**)  Linear term  -0.30 (-0.38, -0.22)  0.16  <0.001 
Squared term  0.05 (0.02, 0.08) 
Total Muscle Grip
(**)  Linear term  -0.48 (-0.57, -0.38)  0.21  <0.001 
Squared term  -0.06 (-0.10, -0.01) 
Smoking Status  Non/Ex-Smoker  0  0.06  <0.001 
Smoker  -1.22 (-1.67, -0.76) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
 
Table 15: Effect of each variable upon the Quality of Life 
 
Our results showed a very similar picture to those observed for the total QoL. The 
univariate analysis indicated that age, BMI, FEV1% predicted, FVC% predicted, grip 
score  and  smoking  status  were  all  significantly  associated  with  the  symptom 
component of QoL score.  
The  analysis  indicated  that  there  was  a  non-linear  effect  of  age  upon  the  QoL 
symptom component. This makes it difficult to interpret the regression coefficients, 
and so the results are best shown graphically. The graph below shows the fitted 
regression line between age and symptom SGRQ score. (Figure 14) Comparative Study on the QoL of COPD Patients 
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Figure 14: Association between age and symptom scores 
The  graph  suggests  that  the  symptom SGRQ  scores  increase with  age;  in  other 
words the older the patient is the poorest the QoL symptom is. 
The results for BMI indicated that patients with a high BMI had a poor QoL (high 
symptom scores). A 5-unit increase in BMI was associated with the SGRQ symptom 
score decreasing by 0.3 units. A higher FEV1% predicted value was also associated 
with a lower SGRQ symptom score. A 10-unit increase in  FEV1% predicted was 
associated with a decrease in the symptom score of 0.3 units.  
The  results  for  FVC%  predicted  indicated  that  there  was  a  non-linear  (i.e.  not  a 
straight line) relationship with the QoL symptom measure. A graphical illustration of 
the relationship is shown in the next graph. (Figure 15) 
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Figure 15: Effect of FVC% predicted on symptom scores 
The  graph  suggest  that  there  was  a  decrease  in  SGRQ  symptom  scores  with 
increased FVC% predicted up to around 80% or 90%, after which there was little 
relationship with QoL. 
There was also a non-linear relationship between TMG score and QoL. Again, with 
such  a  relationship  it  is  easier  to  interpret  the  results  graphically  than  from  the 
coefficients.  The fitted relationship between the two variables is shown in the next 
graph. The graph suggests that there is little relationship between TMG and QoL for 
scores below 40. However, for scores above 40 there is a decrease in the SGRQ 
symptom score with an increase in grip score. (Figure 16) 
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Figure 16: Association between Total Muscle Grip and symptom scores 
The results for smoking status indicated that non or ex-smokers had  higher QoL 
scores  in  terms  of  symptom  scores  than  current  smokers.  Current  smokers  had 
scores that were, on average, 1.2 units lower than non/ex-smokers. 
A multivariate analysis was performed to look at the joint effect of the factors upon 
the QoL symptom score. A backwards selection procedure was used to retain only 
the statistically significant variables and the final model is shown in the next table. 
(Table 16) 
Variable  Term / 
category 
Coefficient (95% CI)  P-value 
Age 
(**)  Linear term  0.55 (0.38, 0.73)  <0.001 
Squared term  0.18 (0.10, 0.27) 
FVC% Predicted 
(**)  Linear term  -0.27 (-0.34, -0.21)  <0.001 
Squared term  0.04 (0.01, 0.07) 
Total Muscle Grip 
(**)  Linear term  -0.23 (-0.34, -0.12)  <0.001 
Squared term  -0.07 (-0.11, -0.03) 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
  Table 16: Joint effect of the significant variables on the symptoms scores 
0
2
0
4
0
6
0
8
0
1
0
0
Q
u
a
l
i
t
y
 
o
f
 
L
i
f
e
 
-
 
S
y
m
p
t
o
m
s
 
(
%
)
20 40 60 80 100
Grip Score
Grip score range: <25=4%, 25-50=37%, 50-75=43%, 75-100=16%, 100+=1%Comparative Study on the QoL of COPD Patients 
  Page 83 
 
The results of the multivariate analysis indicated that age, FVC% predicted score 
and TMG were all significantly associated with the symptoms component of QoL. 
After  adjusting  for  these  three  measures,  there  was  no  longer  found  to  be  real 
evidence of an effect of BMI, FEV1% predicted and smoking status upon symptom 
scores. 
The coefficients for age, FVC% and TMG were all in the same direction and a similar 
magnitude as the univariate analysis, suggesting similar direction of effects to those 
seen in this analysis. This suggests positive relationship between age and symptom 
score, and a negative relationship between both FVC% predicted and TMG and the 
QoL symptom score.  
This  final  model  had  an  R-square  value  of  0.38.  This  suggests  that  38%  of  all 
variation in QoL symptoms score can be attributed to the combination of age, FVC% 
predicted and TMG. This suggests that the remaining 62% of variation is due to 
other sources. 
3.1.2.2    Difference in Symptoms Scores between Countries 
The next  set  of  analyses  compared  the  QoL  symptoms  score  between  the  three 
countries.  Initially  this  was  done  twice,  firstly  unadjusted,  and  then  adjusted  for 
factors associated with symptoms scores. A summary of the results is given in the 
next table. The figures are the regression coefficients, which represent the difference 
in QoL between each country and the baseline category (in this case UAE). The first 
p-value reported is the significance of the overall difference between countries. The 
subsequent p-values indicated the specific differences between pairs of countries. 
These latter set of p-values were given a Bonferroni adjustment to allow for multiple 
comparisons. (Table 17) Comparative Study on the QoL of COPD Patients 
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Country  Unadjusted  Adjusted 
Coefficient 
(95% CI) 
P-value  Coefficient (95% 
CI) 
P-value 
UAE  0 
<0.001 
0 
<0.001  Morocco  -0.6 (-1.1, -0.1)  -0.4 (-1.2, -0.4) 
UK  -1.0 (-1.4, -0.5)  -1.2 (-1.9, -1.0) 
UAE vs. Morocco    0.08    0.20 
UAE vs. UK    <0.001    <0.001 
Morocco vs. UK    0.44    0.003 
Table 17: Comparison of the symptoms scores between the three countries 
The results indicated that there was an overall significant difference between the 
three countries when no other factors were considered (the unadjusted results). The 
highest scores were for the UAE, which were significantly higher than those in the 
UK. On average, there was a difference of around 1 unit in the symptoms score 
between the UK and the UAE. However, there was no significant difference between 
Morocco and the UK. 
When the significant risk factors were taken into account, there was still a significant 
overall difference between the three countries. Again scores in the UAE were the 
highest, although there was no significant difference with the scores from Morocco. 
Patients  from  the  UK  had  the  lowest  scores,  and  after  adjusting  for  the  other 
variables, symptom scores from the UK were now significantly lower than they were 
in both Morocco and the UAE. The difference in the QoL symptom scores between 
the UAE and the UK was 1.2 units. 
Subsequently the interaction between country and each of the other variables was 
examined. The results suggested no significant interaction between country and age 
(p=0.12), between FVC% predicted and country (p=0.48), or between country and 
TMG  (p=0.55).  This  suggests  that  differences  between  countries  do  not  vary 
depending on age, FVC% or TMG. Comparative Study on the QoL of COPD Patients 
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3.1.2.3    Effect of Dyspnoea on the Symptom Scores 
The next set of analysis examined the effect of the three dyspnoea variables from 
the BDI upon the QoL symptoms component. This was done using linear regression 
in three stages, and the results are summarised in the next table. 
As indicated previously, there was strong collinearity between the magnitude of effort 
and the magnitude of task, suggesting that only one of the two variables can be 
included in the multivariate analysis. 
The figures reported are the regression coefficients and their corresponding 95% 
confidence  intervals.  The  scales  for  all  variables  are  such  that  higher  values 
represent a lower grade. So the regression coefficients represent the change in QoL 
for a one-grade decrease in each variable. (Table 18) 
Analysis  Variable  Coefficient (95% CI)  p-value 
Univariate 
Functional impairment  1.00 (0.86, 1.15)  <0.001 
Magnitude of task  0.93 (0.79, 1.06)  <0.001 
Magnitude of effort  0.93 (0.78, 1.07)  <0.001 
Multivariate  Functional impairment  0.79 (0.43, 1.16)  <0.001 
Magnitude of task  0.22 (-0.13, 0.57)  0.21 
Multivariate + adjusted  Functional impairment  0.45 (0.12, 0.78)  0.008 
Magnitude of task  0.27 (-0.04, 0.58)  0.09 
Table 18: Association between Dyspnoea and symptom scores in COPD patients 
The univariate results suggested that all three factors were associated with symptom 
QoL. A one-grade decrease in any of the variables was associated with an increased 
QoL symptom score of around one-unit. 
When both functional impairment and magnitude of task were included in the same 
regression  model  in  a  multivariate  analysis,  only  functional  impairment  was Comparative Study on the QoL of COPD Patients 
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statistically  significant.  After  adjusting  for  this  variable,  there  was  no  longer  a 
significant effect of magnitude of the task upon the QoL symptom scores.  
3.1.3 Analysis of Activity SGRQ Scores of COPD Patients 
In this section we will study how the three countries varied in terms of the activity 
component of the QoL. This part will only analyse and compare male COPD patients 
as gender effect appeared to be non significant as noted in the previous section. 
This will be analysed using similar tests used in the previous sections. 
3.1.3.1    Factors Associated with Activity Scores 
Linear regression analysis was used to examine the effect of various parameters 
upon the activity SGRQ scores. Initially the separate effect of each variable upon this 
outcome was examined separately and the results are summarised in the next table. 
The figures reported are the regression coefficients, and also their corresponding 
95% confidence intervals. For the continuous variables, the regression coefficients 
represent the change in the activity score for a given increase in that variable (size of 
increase  indicated  in  the  table).  For  the  categorical  variables,  the  regression 
coefficients indicate the difference in QoL between each category and a baseline 
category.  (Table  19)  Also  reported  are  the  R-square  values.  These  indicate  the 
proportion of the total variation in QoL activity component that is explained by each 
predictor. (Table 19) 
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Variable  Term / category  Coefficient (95% CI)  R
2  p-value 
Age 
(**)  -  0.97 (0.82, 1.13)  0.27  <0.001 
BMI 
(*)  -  -0.39 (-0.66, -0.12)  0.02  0.004 
FEV1% predicted 
(**)  -  -0.29 (-0.37, -0.21)  0.12  <0.001 
  FVC% predicted 
(**)  -  -0.11 (-0.20, -0.02)  0.01  0.02 
Grip score 
(**)  Linear term  -0.59 (-0.69, -0.49)  0.31  <0.001 
Squared term  -0.10 (-0.15, -0.06) 
Smoking status  Non/Ex-Smoker  0  0.18  <0.001 
Smoker  -2.21 (-2.67, -1.74)  0.02 
 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
  Table 19: Univariate analyses of the effect of the variables on the activity scores 
 
The univariate analysis indicated that all the variables examined were significantly 
associated with the activity component of QoL score.  
The results for age suggested that there was a significant positive relationship with 
activity  score.  A10  year  increase  in  age  was  associated  with  the  activity  score 
increasing by almost one-unit.  
The  results  for  BMI  indicated  that  patients  with  a  greater  BMI  had  a  lower  QoL 
activity score, meaning better QoL in terms of activity. A 5-unit increase in BMI was 
associated with the QoL activity scores decreasing by 0.4 units.  
Higher FEV1% and FVC% predicted values were also associated with better QoL. A 
10-unit  increase  in  FEV1%  predicted  was  associated  with  a  decrease  in  activity 
scores of 0.3 units, whilst a 10-unit increase in FVC% predicted was associated with 
a decrease in activity score of 0.1units.  
There was a non-linear relationship between TMG and QoL activity score. With such 
a relationship it is easier to interpret the results graphically than from the coefficients.  
The fitted relationship between the two variables is shown in the next graph. The Comparative Study on the QoL of COPD Patients 
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graph suggests that there is little relationship between TMG and activity score for 
TMG scores below 40. However, for grip scores above 40 there is a decrease in the 
QoL activity score with an increase in grip score, so the higher the TMG the better 
the QoL. (Figure 17) 
 
Figure 17: Relationship between Total Muscle Grip and activity scores 
The results for smoking status indicated that current smokers had better QoL than 
non or ex-smokers. Current smokers had scores that were, on average, 2.2 units 
lower than non/ex-smokers. 
Then, a multivariate analysis was performed to look at the joint effect of the factors 
upon the QoL activity scores. A backwards selection procedure was used to retain 
only the statistically significant variables and the final model is shown in the next 
table. (Table 20) 
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Variable  Term / category  Coefficient (95% CI)  p-value 
Age 
(**)  -  0.55 (0.38, 0.73)  <0.001 
BMI 
(*)  -  -0.25 (-0.47, -0.04)  0.02 
FEV1% Predicted 
(**)  -  -0.16 (-0.23, -0.09)  <0.001 
Grip score 
(**) 
Linear term  -0.27 (-0.38, -0.15) 
<0.001 
Squared term  -0.05 (-0.09, 0.00) 
Smoking Status 
Non/Ex-Smoker  0 
<0.001 
Smoker  -0.86 (-1.30, -0.41) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
  Table 20: Joint effect of the factors on the activity scores (multivariate analysis) 
 
The results of the multivariate analysis indicated that age, BMI, FEV1% predicted 
score, Total Muscle Grip and smoking status were all significantly associated with 
the activity component of QoL. After adjusting for these three measures, there was 
no longer evidence of an effect of FVC% predicted upon the activity SGRQ score. 
The results again suggested that older patients had poor QoL activity component, 
whilst  those  with  a  higher  BMI  and  FEV1%  predicted  values  had  lower  scores 
therefore  better  QoL  in  terms  of  activity.  The  shape  of  the  relationship  for  TMG 
scores was similar to that observed in the univariate analysis. Again smokers had 
lower activity scores than non/ex-smokers. 
This  final  model  had  an  R-square  value  of  0.44.  This  suggests  that  44%  of  all 
variation in QoL activity scores can be attributed to the combination of age, BMI, 
FEV1% predicted, TMG and smoking status. This suggests that the remaining 56% 
of variation is due to other sources. Comparative Study on the QoL of COPD Patients 
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3.1.3.2     Differences in Activity Scores between Countries 
The  next  set  of  analysis  compared  the  QoL  activity  score  between  the  three 
countries.  Initially  this  was  done  twice,  firstly  unadjusted,  and  then  adjusted  for 
factors associated with QoL. A summary of the results is given in the next table. The 
figures  are  the  regression  coefficients,  which  represent  the  difference  in  QoL 
between each country and the baseline category (in this case UAE). The first p-value 
reported  is  the  significance  of  the  overall  difference  between  countries.  The 
subsequent p-values indicated the specific differences between pairs of countries. 
These latter set of p-values were given a Bonferroni adjustment to allow for multiple 
comparisons. (Table 21) 
Country  Unadjusted  Adjusted 
Coefficient 
(95% CI) 
p-value  Coefficient 
(95% CI) 
p-value 
UAE  0 
<0.001 
0 
0.002  Morocco  1.6 (1.0, 2.1)  0.9 (0.4, 1.4) 
UK  1.7 (1.1, 2.2)  0.4 (0.0, 0.9) 
UAE vs. Morocco    <0.001    <0.001 
UAE vs. UK    <0.001    0.20 
Morocco vs. UK    1.00    0.11 
Table 21: Differences between the three centres 
The results indicated that there was an overall significant difference between the 
three countries in their activity score when no other factors were considered (the 
unadjusted results). The lowest scores were for the UAE, which were significantly 
lower than those in both Morocco and the UK. On average, there was a difference of 
around 1.6 units in the activity score between the UAE and the other two countries. 
However, there was no significant difference between Morocco and the UK. 
When the significant risk factors were taken into account, there was still a significant 
overall difference between the three countries. Again scores in the UAE were the Comparative Study on the QoL of COPD Patients 
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lowest, although there was now no significant difference with the scores from the UK. 
Patients  from  Morocco  had  the  highest  scores,  and  after  adjusting  for  the  other 
variables, these were significantly higher than in the UAE. The difference in the QoL 
activity scores between the UAE and Morocco was 0.9 units. 
Subsequently the interaction between country and each of the other variables was 
examined. The results suggested no significant interaction between country and BMI 
(p=0.42),  between  FEV1%  predicted  and  country  (p=0.40),  between  country  and 
TMG  score  (p=0.41),  or  between  country  and  smoking  status  (p=0.47).  This 
suggests that differences in activity scores between countries do not vary depending 
on any of BMI, FEV1% predicted, TMG score or smoking status. 
However, there was found to be a significant interaction between country and age 
(p=0.01). This suggests that the difference between countries varies depending on 
patient age. As a result of this, the effect of age upon activity score was quantified for 
each of the three countries. The results are summarised below. (Table 22) 
Country  Coefficient (95% CI)  p-value 
UAE  0.34 (0.07, 0.60)  0.01 
Morocco  0.25 (-0.08, 0.59)  0.14 
UK  0.81 (0.53, 1.08)  <0.001 
Table 22: Interaction between country and age 
The results indicated that there was significant effect of age upon activity scores in 
both the UAE and UK, although the strongest effect was seen in the UK. There was 
no significant effect of age upon activity score in Morocco. Comparative Study on the QoL of COPD Patients 
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3.1.3.3    Effect of Dyspnoea on Activity SGRQ Scores 
The next set of analysis examined the effect of the three dyspnoea variables upon 
the QoL activity component. This was done using linear regression in three stages, 
and the results are summarised in the next table. 
As indicated previously, there was strong collinearity between the magnitude of effort 
and magnitude of task, suggesting that only one of the two variables can be included 
in the multivariate analyses. 
The figures reported are the regression coefficients and their corresponding 95% 
confidence intervals. The scales for all variables are that higher values represent a 
lower  grade.  So  the  regression  coefficients  represent  the  change  in  the  activity 
SGRQ score for a one-grade decrease in each variable. (Table 23) 
Analysis  Variable  Coefficient (95% CI)  p-value 
Univariate 
Functional impairment  1.39 (1.26, 1.52)  <0.001 
Magnitude of task  1.34 (1.22, 1.46)  <0.001 
Magnitude of effort  1.34 (1.21, 1.46)  <0.001 
Multivariate 
Functional impairment  0.72 (0.40, 1.03)  <0.001 
Magnitude of task  0.70 (0.40, 1.01)  <0.001 
Multivariate + adjusted 
Functional impairment  0.52 (0.22, 0.84)  0.001 
Magnitude of task  0.53 (0.24, 0.82)  <0.001 
Table 23: Dyspnoea effect on activity scores in COPD patients 
 
The univariate analysis results suggested that all three factors were associated with 
the  activity  SGRQ  scores.  A  one-grade  decrease  in  any  of  the  variables  was 
associated with an increased QoL activity score of around 1.3 units. 
When both functional impairment and magnitude of task were included in the same 
regression  model  in  a  multivariate  analysis,  both  were  found  to  be  statistically Comparative Study on the QoL of COPD Patients 
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significant. This was also the case after adjusting for the other significant risk factors 
(e.g. age, grip score etc.). 
3.1.4 Analysis of the Impact QoL Scores of COPD Patients 
In this section we will analyse how the three countries studied varied in terms of the 
impact  component  of  QoL  using  similar  methods  as  used  to  analyse  the  other 
components of the  QoL.  Only  males  were included  in  the analysis of  the  impact 
scores, because there was no significant gender difference in terms of the impact 
SGRQ scores. 
3.1.4.1    Factors Associated with QoL 
Linear regression was used to examine the effect of various parameters upon the 
QoL impact SGRQ scores. Initially the separate effect of each variable upon this 
outcome was examined separately, and the results are summarised in the next table. 
The figures reported are the regression coefficients, and also their corresponding 
95% confidence intervals. For the continuous variables, the regression coefficients 
represent the change in the impact score for a given increase in that variable (size of 
increase  indicated  in  the  table).  For  the  categorical  variables,  the  regression 
coefficients indicate the difference in QoL between each category and a baseline 
category.  (Table  24)  Also  reported  are  the  R-square  values.  These  indicate  the 
proportion of the total variation in QoLe activity component that is explained by each 
predictor. (Table 24) 
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Variable  Term / 
category  Coefficient (95% CI)  R
2  p-value 
Age 
(**) 
Linear term  0.74 (0.57, 0.91) 
0.15  <0.001  Squared term  0.14 (0.04, 0.24) 
BMI 
(*)  Linear term  -0.59 (-0.87, -0.32)  0.04  <0.001  Squared term  0.19 (0.01, 0.37) 
FEV1% Predicted 
(**)  -  -0.36 (-0.42, -0.29)  0.19  <0.001 
FVC% Predicted 
(**) 
Linear term  -0.29 (-0.20, -0.02) 
0.15  <0.001  Squared term  0.05 (0.02, 0.09) 
Grip score 
(**)  Linear term  -0.54 (-0.64, -0.45)  0.26  <0.001 
Squared term  -0.06 (-0.11, -0.02) 
Smoking Status  Non/Ex-Smoker  0  0.08  <0.001 
Smoker  -1.40 (-1.87, -0.93) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 24: Separate effect of variable on the impact scores 
The  univariate  analysis  indicated  that  all  variables  examined  were  significantly 
associated with the impact component of QoL score, with the exception of gender 
where there were no differences between males and females. 
The results for age suggested that there was a non-linear relationship with impact 
score.  Therefore,  this  relationship  is best  shown  graphically,  and  the  relationship 
between  the  two  variables  is  shown  in  the  next  graph.  (Figure  18)  The  graph 
suggests that there is an increase in the impact SGRQ scores with increased age. Comparative Study on the QoL of COPD Patients 
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Figure 18: Effect of age on the impact scores of COPD patients 
The results for BMI also suggested a non-linear relationship between the variables, 
and  this  relationship  is  shown  in  the  next  graph.  QoL  scores  decreased  with 
increasing BMI up to a BMI of around 30 after which the QoL remained fairly stable, 
in other words the higher the BMI the better the QoL. (Figure 19) 
The analysis for FEV1% predicted indicated that higher values were associated with 
lower QoL impact scores (Patients with high FEV1% predicted have better QoL). A 
10-unit  increase  in  FEV1%  predicted  was  associated  with  a  decrease  in  impact 
score of 0.4 units. 
There was a significant effect of FVC% predicted upon the impact component of the 
QoL, and a graphical representation of the relationship between the measures is 
given in the figure 20. 
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Figure 19: Effect of BMI on impact scores of COPD patients 
 
 
Figure 20: Association between FVC% predicted and impact scores of COPD patients 
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The  graph  suggests  a  general  decrease  in  impact  scores  with  increased  FVC% 
predicted, although this relationship tails off for larger FVC% predicted values. 
There was also a non-linear relationship between TMG score and QoL impact score. 
The fitted relationship between the two variables is shown in the next graph. The 
graph suggests that there is little relationship between grip score and impact score 
for grip scores below 40. However, for TMG scores above 40 there is a decrease in 
the QoL impact score (better QoL) with an increase in TMG score. (Figure 21) 
 
 
Figure 21: Effect of TMG on the impact scores of COPD patients 
 
The results for smoking status indicated that non- or ex-smokers had poorer QoL 
compared to current smokers. Current smokers had scores that were, on average, 
1.4 units lower than non/ex-smokers. 
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A multivariate analysis was performed to look at the joint effect of the factors upon 
the QoL impact score. A backwards selection procedure was used to retain only the 
statistically  significant  variables,  and  the  final  model  is  shown  in  the  next  table. 
(Table 25) 
Variable  Term / category  Coefficient (95% 
CI)  P-value 
Age 
(**) 
Linear term  0.48 (0.31, 0.66) 
<0.001 
Squared term  0.19 (0.10, 0.28) 
BMI 
(*)  -  -0.26 (-0.47, -0.04)  0.02 
FEV1% Predicted 
(**)  -  -0.14 (-0.22, -0.06)  0.001 
FVC% Predicted 
(**) 
Linear term  -0.15 (-0.24, -0.07) 
<0.001 
Squared term  0.03 (0.01, 0.06) 
Total Muscle Grip 
(**) 
Linear term  -0.29 (-0.38, -0.15) 
<0.001 
Squared term  -0.06 (-0.10, -0.01) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 25: Joint effect of the physiologic measurement on the impact scores 
The results of the multivariate analysis indicated that age, BMI, FEV1% predicted 
score,  FVC%  predicted  and  grip  score  were  all  significantly  associated  with  the 
impact component of QoL. After adjusting for these three measures, there was no 
longer found to be evidence of an effect of smoking status upon the impact score. 
After adjusting for the effects of the other variables, there was now a more linear 
effect of BMI, with increasing BMI associated with a decreased impact score. 
The results for the other variables were of a similar nature to those obtained in the 
univariate analysis. That is an increase in impact score with increasing age, but a 
decrease in impact scores with increasing FEV1% predicted, FVC% predicted and 
TMG score. Comparative Study on the QoL of COPD Patients 
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This  final  model  had  an  R-square  value  of  0.42.  This  suggests  that  42%  of  all 
variation in QoL impact scores can be attributed to the combination of age, BMI, 
FEV1%  predicted,  FVC%  predicted  and  TMG  score.  This  suggests  that  the 
remaining 58% of variation is due to other sources. 
3.1.4.2    Difference in Impact SGRQ Scores between Countries 
The  next  set  of  analysis  compared  the  QoL  impact  score  between  the  three 
countries.  Initially  this  was  done  twice,  firstly  unadjusted,  and  then  adjusted  for 
factors associated with the QoL. A summary of the results is given in the next table.  
The figures are the regression coefficients, which represent the difference in QoL 
between each country and the baseline category (in this case UAE). The first p-value 
reported  is  the  significance  of  the  overall  difference  between  countries.  The 
subsequent p-values indicated the specific differences between pairs of countries. 
These latter set of p-values were given a Bonferroni adjustment to allow for multiple 
comparisons. (Table 26) 
Country 
Unadjusted  Adjusted 
Coefficient (95% 
CI) 
p-value  Coefficient (95% 
CI) 
p-value 
UAE  0 
0.13 
0 
0.001  Morocco  0.2 (1.0, 0.7)  -0.1 (0.6, 0.4) 
UK  -0.3 (-0.8, 0.2)  -0.9 (-1.5, -0.4) 
UAE vs. Morocco    1.00    1.00 
UAE vs. UK    0.56    0.003 
Morocco vs. UK    0.16    0.006 
Table 26: Differences between the studied countries in their impact scores 
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The  results  indicated  that  there  was  no  significant  difference  between  the  three 
countries  in  their  impact  score  when  no  other  factors  were  considered  (the 
unadjusted results).  
However, when the significant risk factors were adjusted for, there was found to be a 
significant overall difference between the three countries. The results suggested that 
results from the UK were the lowest, and significantly lower than those from both the 
UAE and Morocco. The difference in the QoL activity scores between UAE and the 
UK was 0.9 units. There was no difference in impact SGRQ scores between the UAE 
and Morocco. 
Subsequently the interaction between country and each of the other variables was 
examined.  The  results  suggested  no  strong  evidence  of  a  significant  interaction 
between  country  and  age  (p=0.05),  between  BMI  and  country  (p=0.09).  This 
suggests that differences in impact scores between countries do not strongly vary 
depending on age or BMI. 
However, there was found to be a significant interaction between country and FEV1 
(p<0.001), between country and FVC (p<0.001) and also between country and TMG 
score  (p=0.007).  This  suggests  that  the  difference  between  countries  varies 
depending on each of these 3 variables. As a result of this, the effect of these 3 
variables upon the impact score was quantified for each of the three countries. The 
results are summarised below. (Table 27) 
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Variable  Country  Term  Coefficient (95% CI)  p-value 
FEV1% predicted 
UAE  -  0.02 (-0.13, 0.17)  0.78 
Morocco  -  -0.34 (-0.51, -0.18)  <0.001 
UK  -  -0.24 (-0.34, -0.14)  <0.001 
FVC% predicted 
UAE  Linear term  0.19 (0.01, 0.37)  0.03 
Squared term  0.05 (0.01, 0.09) 
Morocco 
Linear term  -0.24 (-0.41, -0.07) 
<0.001 
Squared term  0.05 (0.01, 0.09) 
UK 
Linear term  -0.07 (-0.21, 0.07) 
0.04 
Squared term  0.05 (0.01, 0.09) 
Grip Score 
UAE 
Linear term  -0.18 (-0.37, 0.01) 
0.007 
Squared term  -0.04 (-0.08, 0.00) 
Morocco 
Linear term  -0.53 (-0.71, -0.35) 
<0.001 
Squared term  -0.04 (-0.08, 0.00) 
UK 
Linear term  -0.27 (-.049, -0.04) 
<0.001 
Squared term  -0.04 (-0.08, 0.00) 
Table 27: Difference in the effect of the three variables between the three countries 
The results for FEV1% predicted indicated that there was significant effect of this 
measure  upon  impact  scores  in  both  Morocco  and  the  UK.  For  both  of  these 
countries higher FEV1% predicted values were associated with a decrease in impact 
score.  There  was  no  significant  effect  of  age  upon  activity  score  in  the  UAE.  A 
graphical illustration of the nature of the interaction is shown in the next graph. This 
shows the relationship between FEV1% predicted and QoL impact scores for each of 
the three countries. (Figure 22) 
The  next  graphs  represent  the  effect  of  FEV1%  predicted  on  the  SGRQ  impact 
scores of COPD patients in each country; the graphs also illustrate the individual 
regression points where figures 23-25 represent the relationship between FEV1% 
predicted and the impact scores in the UAE, Morocco and the UK respectively.  
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Figure 22: Relationship between FEV1% predicted and impact scores for the three 
countries 
 
 
Figure 23: Effect of FEV1% predicted on the impact scores in the UAE 
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Figure 24: Effect of FEV1% predicted on the impact scores in Morocco 
 
 
Figure 25: Effect of FEV1% predicted on impact scores in the UK 
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The results for FVC% predicted suggested there was a very  strong effect of this 
measure for Moroccan patients, but significant results for the other two countries 
also. Due to the non-linear relationships the results are best viewed graphically, and 
these are shown in the next graph. (Figure26) 
 
Figure 26: Relationship between FVC% predicted and QoL impact scores 
The graph shows that in Morocco higher FVC% predicted values are associated with 
lower impact scores therefore better QoL. The picture is less consistent for the UAE 
and UK, where it appears that those with the highest and lowest FVC% predicted 
values have the highest impact SGRQ scores. 
The  next  graphs  represent  the  effect  of  FEV1%  predicted  on  the  SGRQ  impact 
scores of COPD patients in each country; the graphs also illustrate the individual 
regression points where figures 27, 28 and 29 represent the relationship between 
FVC% predicted and impact scores in the UAE, Morocco and the UK respectively. 
(Figure 27-29)  
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Figure 27: Relationship between FVC% predicted and impact scores in the UAE 
 
Figure 28: Relationship between FVC% predicted and impact scores in Morocco 
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Figure 29: Relationship between FVC% predicted and impact scores in the UK 
 
There was also a non-linear relationship between TMG score and impact scores, so 
again the results are best viewed graphically, and the relationships for each of the 
three countries is given in the next graph. Although the interaction was similar, there 
was a broadly similar picture for each of the three countries. There was generally a 
better QoL with increased TMG score, although the effects were less strong for lower 
TMG scores. The effect of TMG scores was highly significant for each of the three 
countries. (Figure 30) 
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Figure 30: Relationship between TMG and QoL impact scores 
3.1.4.3    Effect of Dyspnoea on Impact SGRQ Scores 
The next set of analysis examined the effect of the three dyspnoea variables from 
the BDI upon the impact SGRQ scores. This was done using linear regression in 
three stages, and the results are summarised in the next table. (Table 28) 
As indicated in the first report, there was strong collinearity between the magnitude 
of effort and magnitude of task, suggesting that only one of the two variables can be 
included in the multivariate analyses. 
The figures reported are the regression coefficients and their corresponding 95% 
confidence intervals. The scales for all variables are that higher values represent a 
lower grade. So the regression coefficients represent the change in the impact score 
for a one-grade decrease in each variable. 
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Analysis  Variable  Coefficient (95% CI)  p-value 
Univariate 
Functional impairment  1.28 (1.14, 1.40)  <0.001 
Magnitude of task  1.22 (1.10, 1.34)  <0.001 
Magnitude of effort  1.22 (1.10, 1.34)  <0.001 
Multivariate 
Functional impairment  0.73 (0.40, 1.05)  <0.001 
Magnitude of task  0.57 (0.26, 0.88)  <0.001 
Multivariate + adjusted 
Functional impairment  0.44 (0.14, 0.75)  0.005 
Magnitude of task  0.59 (0.30, 0.88)  <0.001 
Table 28: Effect of dyspnoea on the Quality of Life impact scores 
The univariate results suggested that all three factors were associated with QoL. A 
one-grade decrease in any of the variables was associated with an increased QoL 
impact score of around 1.2 units. 
When both functional impairment and magnitude of task were included in the same 
regression  model  in  a  multivariate  analysis,  both  were  found  to  be  statistically 
significant. This was also the case after adjusting for the other significant risk factors 
(e.g. age, TMG score etc.). 
3.2  Analysis of the Control Group 
In this section of our study, we measured the QoL of control subjects from the UK, 
the  UAE  and  Morocco.  The  first  set  of  data  analysis  examined  the  differences 
between the countries in terms of a number of variables. Data on some variables 
was available for all three countries, whilst other information was only available for 
the  UAE  and  Morocco.  Where  information  was  available  for  three  countries,  the 
comparisons were made between the three countries, and where it was available for 
only  two,  the  comparisons  were  restricted  to  these  two  countries.  All  continuous 
variables were approximately normally distributed. Therefore, analysis of variance Comparative Study on the QoL of COPD Patients 
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(ANOVA) was used to compare between the continuous measures between three 
countries, whilst the unpaired t-test was used where data was only present for two 
countries.  The  Chi-square  test  was  used  to  compare  the  categorical  variables 
between countries. 
The next set of analysis examined the effects of various study variables upon QoL 
scores. Due to missing data for some variables, these analyses were restricted to 
subjects from the UAE and Morocco only. As the QoL scores were measured on a 
continuous scale, the analysis was performed using linear regression. Initially the 
separate effect of each variable upon the outcome was examined separately in a 
series  of  univariate  analysis.  For  the  continuous  explanatory  variables,  the 
relationship with the QoL outcome was examined to see if a non-linear (i.e. curved) 
relationship was more appropriate than a linear (straight line) one. 
The  next  stage  in  the  analysis  process  was  to  examine  the  joint  effect  of  the 
variables upon QoL in a multivariate analysis. This analysis has the advantage that 
the effect of each variable upon the outcome is adjusted for the other factors in the 
analysis. A backwards selection procedure was used to retain only the statistically 
significant variables. This involves removing the non-significant variables, one at a 
time, until all remaining variables were significant. 
The  differences  in  QoL  between  countries  were  examined  next.  Firstly  the 
differences between countries were examined without considering any other factors 
in the analysis. Subsequently, the same difference was examined, this time adjusting 
for  factors  that  could  potentially  confound  the  country  differences.  The  factors 
adjusted for were restricted to those where there was data for all three countries, 
namely age, BMI, gender and smoking status. Comparative Study on the QoL of COPD Patients 
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3.2.1 Analysis of the Total SGRQ Scores of the Control Group 
3.2.1.1    Control Group Characteristics 
The first set of analysis compared various factors between countries.  
Firstly  the  continuous  variables  were  compared.    ANOVA  was  used  to  compare 
between  countries  where  data  was  available  for  all  three  countries,  whilst  the 
unpaired t-test was used where data from the UK was unavailable. The results are 
summarised in the next table. (Table 29) The figures reported are the mean and 
standard  deviation  value  for  each  country,  and  the  p-values  indicating  the 
significance of the overall difference between countries. 
Variable  UAE 
Mean (SD) 
Morocco 
Mean (SD) 
UK 
Mean (SD)  p-value 
Age  52 (6)  46 (5)  76 (8)  <0.001 
BMI  27.1 (3.8)  25.4 (4.1)  24.5 (4.7)  <0.001 
FEV1% Predicted   82 (17)  71 (19)  -  <0.001 
FVC% Predicted  69 (14)  65 (15)  -  0.001 
Grip score  97 (8)  86 (14)  -  <0.001 
Table 29: Control group characteristics 
The results indicated that there was a highly significant difference in all variables 
between the three countries. 
Centre  United Arab Emirates  Morocco  United Kingdom 
Symptom  6.67±13.58  3.01±8.47  45.63±24.87 
Activity  8.71±14.03  16.3±17.63  34.96±15.08 
Impact  2.07±3.71  0  6.83±3.89 
Total Scores  4.85±8.03  5.44±5.86  21.8±9.57 
Table 30: Quality of Life of the control Group Comparative Study on the QoL of COPD Patients 
  Page 111 
 
The above table represents the descriptive analysis for the QoL of the control group. 
The  table  clearly  shows  a  difference  in  the  QoL  between  the  three  countries, 
especially the UK having the highest symptoms, impact, activity and total scores. 
 The  next  set  of  analysis  used  the  Chi-square  test  to  examine  if  there  was  a 
difference between countries for the two categorical measures. A summary of the 
analysis results is given in the next table. The figures reported are the number and 
percentage of responses in each category for each country. (Table 31) 
Variable  Category  UAE 
N (%) 
Morocco 
N (%) 
UK 
N (%)  p-value 
Smoking 
Status 
Non/Ex-Smoker  285 (95%)  217 (72%)  630 (88%) 
<0.001 
Smoker  16 (5%)  84 (28%)  18 (18%) 
Gender 
Male  301 (100%)  301 (100%)  284 (37%) 
<0.001 
Female  0 (0%)  0 (0%)  484 (63%) 
Table 31: Gender and smoking differences between the countries 
The  results  suggested  that  both  smoking  status  and  gender  varied  between 
countries. Smoking was by far the lowest in the UAE where only 5% of the groups 
were  current  smokers.  Conversely  smoking  was  much  higher  in  Morocco,  where 
over  30%  of  the  subjects  currently  smoked.  The  UAE  and  Moroccan  groups 
consisted of all male patients, whilst 63% of UK subjects were female. 
3.2.1.2   Factors Associated with the Total SGRQ Scores 
The next set of analysis concerned the total SGRQ scores. The first objective was to 
examine  the  effect  of  various  parameters  upon  the  total  SGRQ  scores.  Due  to 
missing data for some variables, the analysis was performed on subjects from the 
UAE and Morocco only.  Comparative Study on the QoL of COPD Patients 
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All analysis was performed using linear regression. Initially the separate effect of 
each  variable  upon  this  outcome  was  examined  separately,  and  the  results  are 
summarised in the next table. (Table 32) 
The figures reported are the regression coefficients, and also their corresponding 
95% confidence intervals. For the continuous variables, the regression coefficients 
represent the change in the total QoL for a given increase in that variable (size of 
increase  indicated  in  the  table).  For  the  categorical  variables,  the  regression 
coefficients indicate the difference in QoL between each category and a baseline 
category. Also reported are the R-square values. These indicate the proportion of the 
total variation in QoL that is explained by each predictor. 
Variable  Category  Coefficient (95% CI)  R
2  p-value 
Age 
(**)  -  0.09 (-0.03, 0.22)  0.003  0.15 
BMI 
(*)  -  0.05 (-0.05, 0.15)  0.002  0.33 
FEV1% Predicted 
(**)  -  -0.09 (-0.13, -0.05)  0.03  <0.001 
FVC% Predicted 
(**)  -  -0.07 (-0.12, -0.01)  0.009  0.02 
Total Muscle Grip 
(**)  -  -0.03 (-0.08, 0.03)  0.002  0.31 
Smoking Status 
Non/Ex-Smoker  0     
Smoker  0.58 (0.37, 0.78)  0.05  <0.001 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 32: Univariate analysis of Effect of physiological measurements on the QoL 
The  results  of  the  univariate  analysis  indicated  that  FEV1%  predicted,  FVC% 
predicted  and  smoking  status  were  all  significantly  associated  with  the  total  QoL 
score. However, there was no significant effect of age, BMI or TMG score upon total 
QoL. Comparative Study on the QoL of COPD Patients 
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A higher FEV1% predicted and FVC% predicted value indicated lower QoL scores. A 
10-unit increase in FEV1% predicted was associated with a decrease in QoL score 
of  0.09  unit,  whilst  a  10-unit  increase  in  FVC%  predicted  resulted  in  0.03  unit 
decrease.  
Unlike  the  COPD  patients,  the  results  for  smoking  status  indicated  that  current 
smokers had higher QoL scores than non/ex-smokers meaning that current smokers 
have  lower  QoL  than  ex-smokers.  Current  smokers  had  scores  that  were,  on 
average, 0.6 units higher than non/ex-smokers. 
Secondly,  a  multivariate  analysis was  performed to  look  at  the  joint  effect  of  the 
factors upon  the  total  QoL  score.  A  backwards  selection  procedure  was  used  to 
retain only the statistically significant variables, and the final model is shown in the 
next table. (Table 33) 
Variable  Category  Coefficient (95% CI)  P-value 
Age 
(**)  -  0.23 (0.10, 0.35)  0.001 
BMI 
(*)  -  0.15 (0.05, 0.24)  0.003 
FEV1% Predicted 
(**)  -  -0.20 (-0.29, -0.12)  <0.001 
FVC% Predicted 
(**)  -  0.14 (0.02, 0.25)  0.02 
Smoking Status 
Non/Ex-Smoker  0 
<0.001 
Smoker  0.57 (0.36, 0.79) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 33: Joint effect of the factors upon the QoL (Multivariate analysis) 
The results of the multivariate analysis indicated that age, BMI, FEV1% predicted, 
FVC% predicted score and smoking status were all significantly associated with total 
QoL. Comparative Study on the QoL of COPD Patients 
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Neither age nor BMI was significant in the univariate analysis, but after adjusting for 
the other variables, older subjects and those with higher BMI values had higher total 
SGRQ scores. 
As in the univariate analyses, smokers had higher scores, whilst subjects with higher 
FEV1% predicted scores had lower scores therefore better QoL.  
This  final  model  had  an  R-square  value  of  0.11.  This  suggests  that  11%  of  all 
variation in QoL can be attributed to the variables in this model. This suggests that 
around 90% of the remaining variation is due to other sources. In the patient data, 
the  R-square  value  was  0.43  suggesting  that  the  QoL  of  patients  is  much  more 
determined by the measured factors than the QoL of the control group. 
3.2.1.3    Differences in Total SGRQ Scores of Control Group 
The  next  set  of  analysis  compared  the  total  SGRQ  score  between  the  three 
countries. The analysis was performed twice, firstly unadjusted, and then adjusted 
for potentially confounding factors. Adjustments in the second analysis were made 
for age, BMI, gender and smoking status. 
A summary of the results is given in the next table. (Table 34) The figures are the 
regression coefficients, which represent the difference in QoL between each country 
and  the  baseline  category  (in  this  case  UAE).  The  first  p-value  reported  is  the 
significance of the overall difference between countries. The subsequent p-values 
indicated the specific differences between pairs of countries. These latter set of p-
values were given a Bonferroni adjustment to allow for multiple comparisons. 
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Country  Unadjusted  Adjusted 
  Coefficient (95% 
CI) 
p-value  Coefficient (95% 
CI) 
p-value 
UAE  0 
<0.001 
0 
<0.001  Morocco  0.33 (0.17, 0.49)  0.33 (0.16, 0.50) 
UK  1.90 (1.77, 2.03)  1.64 (1.40, 1.90) 
UAE vs. Morocco    <0.006    <0.001 
UAE vs. UK    <0.001    <0.001 
Morocco vs. UK    <0.001    <0.001 
Table 34: Comparison of the QoL between the three countries for control group 
The results indicated that there was an overall significant differences between three 
countries when no other factors were considered (the unadjusted results), and also 
after adjusting for potentially confounding factors. 
Both  analyses  indicated  that  the  highest  scores  were  for  the  UK,  which  were 
significantly higher than those in Morocco and the UAE. On average, QoL scores 
were 1.9 units higher in the UK than in the UAE, and 1.6 units higher after adjusting 
for confounding factors. 
The scores were lowest in the UAE, significantly lower than in Morocco. Morocco 
had scores that were, on average, 0.3 units higher than in the UAE. 
3.2.2 Analysis of Symptom SGRQ Scores for the Control Group 
3.2.2.1    Factors Associated with Symptom SGRQ Scores  
The next set of analysis concerned the symptoms component of the QoL scores. 
The  effect  of  various  parameters  upon  the  symptoms  scores  for  subjects  from 
Morocco and the UAE will also be analysed.  All analysis was performed using linear 
regression.  Initially  the  separate  effect  of  each  variable  upon  this  outcome  was 
examined separately, and the results are summarised in the next table. (Table 35) Comparative Study on the QoL of COPD Patients 
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Variable  Category / 
Term  Coefficient (95% CI)  R
2  P-value 
Age 
(**)  -  0.39 (0.23, 0.55)  0.04  <0.001 
BMI 
(*)  -  0.17 (0.05, 0.29)  0.01  0.006 
FEV1%  Predicted 
(**)  -  -0.05 (-0.11, 0.00)  0.007  0.04 
FVC% Predicted 
(**)  -  -0.09 (-0.16, -0.02)  0.01  0.01 
Grip score 
(**) 
Linear term  -0.45 (-0.62, -0.27) 
0.07  <0.001 
Squared term  0.05 (0.02, 0.08) 
Smoking Status 
Non/Ex-Smoker  0 
0.005  0.08 
Smoker  0.23 (-0.03, 0.50) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 35: Association physiological measurements and symptoms score (Univariate analysis) 
 
The  results  of  the  univariate  analyses  indicated  some  evidence  that  all  factors 
investigated were associated with the symptoms component of QoL. However, the 
results for smoking status were not quite statistically significant (p=0.08).   
Both age and BMI were positively associated with symptoms score. In other words 
older subjects and those with a greater BMI had higher scores. A 10-year increase in 
age  was  associated  with  symptoms  scores  increasing  by  0.4  units,  whilst  a  BMI 
increase of 5-units was associated with scores increasing by 0.17 units.  
Conversely, higher values of both FEV1% predicted and FVC% predicted value were 
associated with lower QoL symptom scores. A 10-unit increase in FEV1% predicted 
was associated with a decrease in symptom scores of 0.05 units, whilst a 10-unit 
increase in FVC% predicted resulted in 0.09 unit decrease.  Comparative Study on the QoL of COPD Patients 
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The  results  suggested  that  there  was  a  non-linear  (i.e.  a  curved)  relationship 
between total Muscle Grip score and symptoms score. Therefore, this relationship is 
best viewed graphically, and this relationship is shown below. (Figure 31) 
The graph shows a decrease in QoL with increased TMG score, up to a score of 
around  80,  after  which  there  was  little  relationship  with  symptoms  score  for 
increased QoL. 
 
 
Figure 31: Relationship between TMG and symptom scores 
 
A multivariate analysis was performed to look at the joint effect of the factors upon 
the  QoL  score.  A  backwards  selection  procedure  was  used  to  retain  only  the 
statistically  significant  variables,  and  the  final  model  is  shown  in  the  next  table. 
(Table 36) 
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Variable  Category / Term  Coefficient (95% CI)  P-value 
Age 
(**)  -  0.26 (0.09, 0.43)  0.003 
BMI 
(*)  -  0.22 (0.10, 0.34)  <0.001 
FVC% Predicted 
(**)  -  -0.14 (-0.20, -0.07)  <0.001 
Grip score 
(**) 
Linear term  -0.42 (-0.60, -0.25) 
<0.001 
Squared term  0.05 (0.02, 0.08) 
Smoking Status 
Non/Ex-Smoker  0 
<0.001 
Smoker  0.58 (0.32, 0.84) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 36: Multivariate analysis of the factors associated with the symptom scores 
 
The  results  of  the  multivariate  analysis  indicated  that  age,  BMI,  FVC%  predicted 
score,  TMG  and  smoking  status  were  all  significantly  associated  with  the  QoL 
symptoms component. After adjusting for these variables, there was no longer found 
to be any significant effect of FEV1% predicted. 
As in the univariate analysis, older subjects and those with higher BMI values had 
higher QoL scores, whilst subjects with higher FVC% predicted values had lower 
symptoms scores. The coefficients for TMG score were also similar to the univariate 
analysis, suggesting a similar effect of this variable. 
There  was  no  strong  evidence  of  an  effect  of  smoking  status  in  the  univariate 
analysis. However, after adjusting for the other variables, this factor was now found 
to be highly significant. Current smokers had symptoms scores that were almost 0.6 
unit higher than non or ex-smokers. 
This  final  model  had  an  R-square  value  of  0.14.  This  suggests  that  14%  of  all 
variation in QoL can be attributed to the variables in this model. This is fairly similar Comparative Study on the QoL of COPD Patients 
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to that obtained from the control group for the total QoL. Again, it is much lower than 
the equivalent figure for the patient group. 
3.2.2.2    Difference in Symptom SGRQ Scores  
The next set of analysis compared the QoL symptom SGRQ scores between the 
three  countries.  The  analysis  was  performed  twice,  firstly  unadjusted,  and  then 
adjusted  for  potentially  confounding  factors.  Adjustments  in  the  second  analysis 
were made for age, BMI, gender and smoking status. 
A summary of the results is given in the next table. (Table 37) The figures are the 
regression coefficients, which represent the difference in QoL between each country 
and  the  baseline  category  (in  this  case  UAE).  The  first  p-value  reported  is  the 
significance of the overall difference between countries. The subsequent p-values 
indicated the specific differences between pairs of countries. These latter set of p-
values were given a Bonferroni adjustment to allow for multiple comparisons. 
Country  Unadjusted  Adjusted 
  Coefficient (95% 
CI)  p-value  Coefficient (95% 
CI)  p-value 
UAE  0 
<0.001 
0 
<0.001  Morocco  -0.43 (0.76, -0.10)  -0.54 (-0.88, -0.19) 
UK  3.79 (3.51, 4.06)  3.67 (3.17, 4.18) 
UAE vs. Morocco    0.03    0.009 
UAE vs. UK    <0.001    <0.001 
Morocco vs. UK    <0.001    <0.001 
Table 37: Differences in symptom scores between the three countries 
The results indicated that there was an overall significant differences between three 
countries when no other factors were considered (the unadjusted results), and also 
after adjusting for potentially confounding factors.  Comparative Study on the QoL of COPD Patients 
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Both  analyses  indicated  that  the  highest  scores  were  for  the  UK,  which  were 
significantly  higher  than  those  in  Morocco  and  the  UAE.  On  average,  symptom 
scores were over 3.5 units higher in the UK than in the UAE. 
There were also significant differences in QoL symptom scores between Morocco 
and  the  UAE.  Both  sets  of  analyses  suggested  lower  scores  in  Morocco.  In  the 
adjusted analyses subjects from Morocco had scores that were 0.5 units lower than 
those in the UAE. 
3.2.3 Analysis of the Activity SGRQ Scores for the Control Group 
3.2.3.1    Factors Associated with Activity SGRQ Scores 
The next set of analyses concerned the activity component of the SGRQ scores. The 
first objective was to examine the effect of various parameters upon the activity QoL 
scores. Due to missing data for some variables, the analyses were performed on 
subjects from the UAE and Morocco only.  
All analyses were performed using linear regression. Initially the separate effect of 
each  variable  upon  this  outcome  was  examined  separately,  and  the  results  are 
summarised in the next table. (Table 38) The figures reported are the regression 
coefficients,  and  also  their  corresponding  95%  confidence  intervals.  For  the 
continuous variables, the regression coefficients represent the change in the QoL for 
a given increase in that variable (size of increase indicated in the table). For the 
categorical  variables,  the  regression  coefficients  indicate  the  difference  in  QoL 
between  each  category  and  a  baseline  category.Also  reported  are  the  R-square 
values. These indicate the proportion of the total variation in QoL that is explained by 
each predictor. Comparative Study on the QoL of COPD Patients 
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Variable  Category  Coefficient (95% 
CI)  R
2  P-value 
Age 
(**)  -  0.11 (-0.13, 0.35)  0.001  0.38 
BMI 
(*)  -  0.03 (-0.15, 0.22)  0.001  0.72 
FEV1% Predicted 
(**)  -  -0.19 (-0.27, -0.12)  0.04  <0.001 
FVC% Predicted 
(**)  -  -0.14 (-0.23, -0.03)  0.01  0.01 
Grip score 
(**)  -  0.01 (-0.08, 0.11)  0.001  0.81 
Smoking Status 
Non/Ex-Smoker  0 
0.05  <0.001 
Smoker  1.12 (0.73, 1.51) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 38: Univariate analysis of factors associated with activity scores 
The  results  of  the  univariate  analyses  indicated  that  FEV1%  predicted,  FVC% 
predicted and smoking status were all significantly associated with the QoL activity 
scores. However, there was no significant effect of age, BMI or TMG score upon 
QoL. 
A higher FEV1% predicted and FVC% predicted value indicated lower QoL scores. A 
10-unit  increase  in  FEV1%  predicted  was  associated  with  a  decrease  in  activity 
scores of 0.19 units, whilst a 10-unit increase in FVC% predicted resulted in 0.14 unit 
decrease.  
The  results for smoking  status  indicated  that  current  smokers had  higher activity 
scores than non/ex-smokers. Current smokers had scores that were, on average, 1.1 
units higher than non/ex-smokers. 
A multivariate analysis was performed to look at the joint effect of the factors upon 
the QoL activity scores. A backwards selection procedure was used to retain only the 
statistically  significant  variables,  and  the  final  model  is  shown  in  the  next  table. 
(Table 39) Comparative Study on the QoL of COPD Patients 
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Variable  Category  Coefficient (95% CI)  P-value 
Age 
(**)  -  0.37 (0.13, 0.61)  0.002 
BMI 
(*)  -  0.23 (0.05, 0.41)  0.01 
FEV1% Predicted 
(**)  -  -0.41 (-0.58, -0.25)  <0.001 
FVC% Predicted 
(**)  -  0.29 (0.08, 0.50)  0.008 
Smoking Status 
Non/Ex-Smoker  0 
<0.001 
Smoker  1.06 (0.66, 1.46) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 39: Multivariate analysis of factors associated with the activity scores 
The results of the multivariate analysis indicated that age, BMI, FEV1% predicted, 
FVC% predicted score and smoking status were all significantly associated with QoL 
activity scores. 
Neither age nor BMI was significant in the univariate analyses, but after adjusting for 
the  other  variables,  older  subjects  and  those  with  higher  BMI  values  had  higher 
activity scores meaning lower QoL. 
As in the univariate analysis, smokers had lower QoL, whilst subjects with higher 
FEV1% predicted scores had better QoL. 
This  final  model  had  an  R-square  value  of  0.11.  This  suggests  that  11%  of  all 
variation  in  activity  component  of  QoL  can  be  attributed  to  the  variables  in  this 
model. This suggests  that  almost 90%  of the  remaining  variation  is due  to  other 
sources.  
3.2.3.2    Differences  in  Activity  SGRQ  Scores  between  the  Control 
Groups 
The  next  set  of  analysis  compared  the  QoL  activity  scores  between  the  three 
countries.  The analysis was performed twice, firstly unadjusted, and then adjusted Comparative Study on the QoL of COPD Patients 
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for potentially confounding factors. Adjustments in the second analysis were made 
for age, BMI, gender and smoking status. 
A summary of the results is given in the next table. (Table 40) The figures are the 
regression  coefficients,  which  represent  the  difference  in  activity  between  each 
country and the baseline category (in this case UAE). The first p-value reported is 
the  significance  of  the  overall  difference  between  countries.  The  subsequent  p-
values indicated the specific differences between pairs of countries. These latter set 
of p-values were given a Bonferroni adjustment to allow for multiple comparisons. 
Country  Unadjusted  Adjusted 
  Coefficient (95% 
CI)  p-value  Coefficient (95% 
CI)  p-value 
UAE  0 
<0.001 
0 
<0.001  Morocco  0.80 (0.49, 1.11)  0.79 (0.46, 1.12) 
UK  2.81 (2.55, 3.07)  2.52 (2.04, 2.99) 
UAE vs. Morocco    <0.001    <0.001 
UAE vs. UK    <0.001    <0.001 
Morocco vs. UK    <0.001    <0.001 
Table 40: Difference in activity scores between the three centres 
The results indicated that there was an overall significant differences between three 
countries when no other factors were considered (the unadjusted results), and also 
after adjusting for potentially confounding factors.  
Both  analyses  indicated  that  the  highest  scores  were  for  the  UK,  which  were 
significantly higher than those in Morocco and the UAE. On average, QoL scores 
were 2.8 units higher in the UK than in the UAE, and 2.5 units higher after adjusting 
for confounding factors. The scores were lowest in the UAE, significantly lower than 
in Morocco. Morocco had scores that were, on average, 0.8 units higher than in the 
UAE. Comparative Study on the QoL of COPD Patients 
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3.2.4 Analysis of the Impact SGRQ Scores for the Control Group 
3.2.4.1    Factors Associated with Impact SGRQ Scores 
The next set of analysis concerned the impact component of the QoL scores. All 
analyses were performed using linear regression. Initially the separate effect of each 
variable  upon  this  outcome  was  examined  separately,  and  the  results  are 
summarised in the next table. (Table 41) 
 
Variable  Category / 
Term  Coefficient (95% CI)  R
2  p-value 
Age 
(**)  -  0.21 (0.15, 0.26)  0.09  <0.001 
BMI 
(*)  -  0.09 (0.05, 0.13)  0.03  <0.001 
FEV1% Predicted 
(**)  -  -0.02 (-0.03, 0.00)  0.005  0.07 
FVC% Predicted 
(**)  -  -0.04 (-0.06, -0.02)  0.02  0.001 
Total Muscle Grip 
(**) 
Linear term  -0.28 (-0.33, -0.22) 
0.21  <0.001 
Squared term  0.03 (0.02, 0.04) 
Smoking Status 
Non/Ex-Smoker  0 
0.02  0.001 
Smoker  -0.15 (-0.24, -0.06) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 41: Univariate analysis of factors' effect on impact scores 
The  results  of  the  univariate  analyses  indicated  some  evidence  that  all  factors 
investigated  were  associated  with  the  impact  component  of  QoL.  However,  the 
results for FEV1% predicted were not quite statistically significant (p=0.07). 
Both age and BMI were positively associated with impact score. In other words older 
subjects and those with a greater BMI had higher scores. A 10-year increase in age 
was associated with impact scores increasing by 0.2 units, whilst a BMI increase of 
5-units was associated with scores increasing by 0.09 units. 
 Comparative Study on the QoL of COPD Patients 
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Conversely, higher values of both FEV1% predicted and FVC% predicted value were 
associated with lower QoL impact scores. A 10-unit increase in FEV1% predicted 
was  associated  with  a  decrease  in  impact  scores  of  0.02  units,  whilst  a  10-unit 
increase in FVC% predicted resulted in 0.04 unit decrease.  
The  results  suggested  that  there  was  a  non-linear  (i.e.  a  curved)  relationship 
between total grip score and symptoms score. Therefore, this relationship is best 
viewed graphically, and this relationship is shown below. (Figure 32) 
 
Figure 32: Relationship between Muscle Grip and impact SGRQ scores of control group 
 
The graph shows a decrease in impact scores with increased TMG score, up to a 
score of around 80, after which there was little relationship with impact score for 
increased QoL. 
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The results for smoking status suggested that current smokers had lower impact 
scores. These were, on average, 0.15 units lower than non or ex-smokers. 
A multivariate analysis was performed to look at the joint effect of the factors upon 
the QoL impact score. A backwards selection procedure was used to retain only the 
statistically  significant  variables,  and  the  final  model  is  shown  in  the  next  table. 
(Table 42) 
Variable  Category / 
Term  Coefficient (95% CI)  P-value 
Age 
(**)  -  0.11 (0.06, 0.17)  <0.001 
BMI 
(*)  -  0.09 (0.05, 0.12)  <0.001 
FVC% Predicted 
(**)  -  -0.06 (-0.08, -0.04)  <0.001 
Grip score 
(**) 
Linear term  -0.25 (-0.30, -0.19) 
<0.001  Squared term  0.03 (0.02, 0.04) 
(*) Coefficients reported for a 5-unit increase in explanatory variable 
(**) Coefficients reported for a 10-unit increase in explanatory variable 
Table 42: Multivariate analysis of factors associated with impact scores 
The  results  of  the  multivariate  analysis  indicated  that  age,  BMI,  FVC%  predicted 
score  and  TMG  score  were  all  significantly  associated  with  the  QoL  impact 
component. After adjusting for these variables, there was no longer found to be any 
significant effect of FEV1% predicted or smoking status. 
As in the univariate analysis, older subjects and those with higher BMI values had 
higher QoL scores, whilst subjects with higher FVC% predicted values had lower 
activity  SGRQ  scores.  The  coefficients  for  TMG  score  were  also  similar  to  the 
univariate analysis, suggesting a similar effect of this variable. 
This  final  model  had  an  R-square  value  of  0.30.  This  suggests  that  30%  of  all 
variation in QoL impact scores can be attributed to the variables in this model.  Comparative Study on the QoL of COPD Patients 
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3.2.4.2    Differences in Impact SGRQ Scores between the Countries 
The  next  set  of  analyses  compared  the  QoL  impact  scores  between  the  three 
countries. The analysis was performed twice, firstly unadjusted, and then adjusted 
for potentially confounding factors. Adjustments in the second analysis were made 
for age, BMI, gender and smoking status. 
A summary of the results is given in the next table. (Table 43) The figures are the 
regression  coefficients,  which  represent  the  difference  in  impact  scores  between 
each country and the baseline category (in this case UAE). The first p-value reported 
is the significance of the overall difference between countries. The subsequent p-
values indicated the specific differences between pairs of countries. These latter set 
of p-values were given a Bonferroni adjustment to allow for multiple comparisons. 
Country  Unadjusted  Adjusted 
  Coefficient (95% 
CI)  p-value  Coefficient (95% 
CI)  p-value 
UAE  0 
<0.001 
0 
<0.001  Morocco  -0.33 (0.40, -0.26)  -0.33 (-0.88, -0.19) 
UK  0.44 (0.38, 0.50)  0.42 (0.32, 0.52) 
UAE vs. Morocco 
 
<0.001    <0.001 
UAE vs. UK  <0.001    <0.001 
Morocco vs. UK  <0.001    <0.001 
Table 43: Differences in impact scores between the three countries 
The results indicated that there was an overall significant differences between three 
countries when no other factors were considered (the unadjusted results), and also 
after adjusting for potentially confounding factors. Comparative Study on the QoL of COPD Patients 
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Both  analyses  indicated  that  the  highest  scores  were  for  the  UK,  which  were 
significantly higher than those in Morocco and the UAE. On average, impact scores 
were 0.4 units higher in the UK than in the UAE. 
There were also significant differences in QoL impact scores between Morocco and 
the UAE. Both sets of analyses suggested lower scores in Morocco. In both sets of 
analyses subjects from Morocco had scores that were 0.3 units lower than those in 
the UAE.   Comparative Study on the QoL of COPD Patients 
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The main goal of our study was to compare between the QoL of COPD patients in 
three different regions, and investigate the causative factors behind any differences 
that might be found. Due to the aetiological diversity and natural complexity of the 
COPD, it is vital for any researcher to maintain an eye on the whole picture while 
looking at the tiny details at the same time to end up with a sound judgment. 
We  would  like  to  highlight  few  points  regarding  our  study  in  general  before  we 
discuss our findings and provide an assessment for our data analysis results and the 
related factors in contrast to similar studies and our own observations. 
4.1 COPD Patients 
This study is believed to be the first study to compare the QoL of a group of COPD 
patients from three different regions: the United Kingdom, Morocco and the United 
Arab Emirates, using St Georges‘ Respiratory Questionnaire, muscle strength and 
lung function measurements as QoL dimensions. For the United Arab Emirates in 
particular,  it  is  also  believed  to  be  the  first  study  looking  into  the  Quality  of  Life 
aspects of COPD patients. 
Determining the extent of impact of measurable QoL dimensions on the overall QoL 
of COPD patients, while assessing people who live in different parts of the world with 
entirely  different  life  styles,  along  with  adjusting  the  data  analysis  for  different 
demographic, socio-economical and disease factors were major tasks to carry out. 
Nevertheless, the desire to obtain the most possible information out of the huge data 
we  have  collected  was  greater  than  any  obstacle.  As  mentioned  in  the  previous 
chapter, we had to analyse the data using several statistical methods in order to 
achieve the most significant results. Comparative Study on the QoL of COPD Patients 
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Impact of Studied Factors 
Baring  in  mind  that  we  are  comparing  between  patients  from  three  different 
countries, for that we had to follow a standardised systematic approach to minimise 
any  possible  bias  and  thoroughly  examine  all  possible  interactions  between  the 
various factors with QoL dimensions. We studied the different relationships between 
the several factors related to the QoL and assessed their degree of dependency, 
under high confidence levels, to come out with many interesting significant results. 
Afterward,  we  assessed  the  combined  effect  of  those  factors  that  proved  to  be 
significantly related to the QoL, using a multivariate analysis, to achieve yet more 
significant outcomes. 
The interest in the QoL of COPD patients has increased recently because patients 
are more concerned about their symptoms, their physical function, their emotional 
status and their adaptation to the disease. The management of COPD should be 
aimed at improving patients‘ Quality of Life, not only by relieving their symptoms, but 
also by enhancing their functionality and helping them to lead happier lives. 
The present study was specifically set out to analyse the vulnerable QoLof stable 
COPD  patients,  as  well  as  the  QoL  of  control  groups  in  the  three  countries  by 
comparison. We also assessed the relationship between their QoL and BMI, muscle 
strength, lung function and dyspnoea in order to point out more specific factors that 
influence the QoL of stable COPD patients. 
Generally,  in  terms  of  differences  between  countries,  the  analysis  of  our  results 
indicated that there were significant differences in all variables between the three 
countries,  such  as  their  age,  BMI,  FEV1%  predicted,  FVC%  predicted,  smoking 
status averages and gender. Comparative Study on the QoL of COPD Patients 
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The  differences  in  general  public  culture,  education,  socio-economical  status  and 
health awareness are crucial points that should be taken in consideration all the way 
long,  since  they  play  important  roles  in  explaining  the  reason  behind  many 
discrepancies  and  differences  between  variables  among  the  three  countries.  For 
example, smoking was much higher in the UAE and Morocco where over 30% of 
patients smoked than in the UK where the figure was only 12%; this reflects the 
weak  awareness  regarding  the  general  health  and  the  bad  effects  of  smoking  in 
those countries. 
Another  example  of  the  main  variations,  which  was  due  to  cultural  and  socio-
economical differences in our study countries, is that all our recruited patients from 
the UAE and Morocco were males, whilst 30% of UK patients were females. 
Although there was no significant difference between genders in terms of their QoL, 
which  might  be  due  to  the  small  number  of  females  recruited  in  this  study.  Our 
results confirmed the well supported statements that there is a significant association 
between the total QoL and the age, BMI, FEV1% predicted, FVC% predicted, TMG 
score and smoking status of any individual. These results were observed when each 
factor was assessed one at a time.  
A part of our data analysis was exploring any combined effect of some variables on 
the overall QoL, which was done by carrying out a multivariate analysis. However, In 
order to achieve a significant outcome, we applied a reversed selection procedure to 
retain only the statistically significant variables. 
The results of the multivariate analysis indicated that age, FVC% predicted score 
and TMG score were all significantly contributing to the overall QoL. After adjusting 
for these three measures, there was no real evidence of an effect of BMI, FEV1% Comparative Study on the QoL of COPD Patients 
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predicted and smoking status upon QoL. About half of all variations in QoL can be 
attributed to the combination of age, FVC% predicted and TMG score. 
Age and Quality of Life 
Some studies confirmed that QoL of COPD patients is affected by age. Stahl et al 
found that the COPD patients‘ QoL deteriorates with disease severity and age (Stahl 
et  al,  2005),  while  another  research  by  Engstrom  and  Ketelaars  carried  out  two 
different studies to find out that there is no relationship between the QoL and age. 
(Engstrom  et  al,  2001,  Ketelaars  et  al,  1997)  Furthermore,  in  another  study 
performed on 136 COPD patients from Greece to assess the impact of age on their 
QOL,  the  findings  showed  that  younger  patients  had  worse  QoL.  (Dimitropoulos, 
2009) 
In this current study, our results confirm the relationship between the age and the 
overall QoL in patients with COPD, with a decline in the QoL being associated with 
an  older  age  in  all  the  three  centres  studied,  which  agrees  with  many  previous 
studies. (Martin et al 2008, Peruzza et al 2003, de Torres et al 2006 and Carrasco 
Garrido  et  al 2006). This finding  is  supported  by  the  wide  range  of  patients  age 
included in this study; however, elderly patients might experience poor QoL due to 
other  reasons  beside  the  COPD,  especially  in  Morocco  and  the  UAE  where  the 
general public health is hindered. Another interesting finding, in this regard, was the 
significant relationship between age and country, which can be explained by the fact 
that people age at different levels in different countries. 
We have noticed that patients from the UK are much older than those from Morocco 
and the UAE. We have accounted for this age difference for the analysis by adjusting 
the comparative statistics for age. In general, a number of factors could explain this Comparative Study on the QoL of COPD Patients 
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age differences including the general population census data where the percentage 
of population over 65 years old is higher in the UK than the other countries. This 
percentage  is  15%  in  the  UK  (www.statistics.gov.uk),  5%  in  Morocco 
(http://commons.wikimedia.org) and less than 1% in Dubai (www.statisticsdubai.ae). 
One more specific reason that few elderly patients (over 60 years old) can be found 
in Dubai government hospitals, is that these hospitals are mostly frequented by low 
income  people,  being  mainly  foreign  residents  or  immigrant  workers.  They  are 
generally below 60  years of age and when they reach an older age, they  would 
usually go back home. In fact, according to the census conducted by the Statistics 
Centre of Dubai, the population of the Emirate was about 1.4 million as of 2006 with 
approximately 71% of the Emirate's total population being foreigners mostly from 
India, Pakistan, Bangladeshi and Arab countries. With regards to Morocco, it is also 
the  experience  of  the  author  to  note  a  general  attitude  of  the  elderly  people  in 
Morocco towards illness is to stay home resisting consultation of medical care and 
would usually resort to traditional remedies or just cope with the disease. 
Gender and Quality of Life 
In order to look at the extent of the effect of gender on the QoL of COPD patients, we 
used T test which indicated that there is no significant difference between the mean 
symptom, impact and activity SGRQ scores for males and females.  
In contrast, when assessing the gender differences in the QoL of a group of COPD 
patients, Katsutra and colleagues found that gender differences have an effect on 
the  QoL  with  females  having  significantly  worse  QoL  then  males  except  in  the 
symptom score. (Katsutra et al, 2007) De Torres et al compared gender differences 
in 53 men and women and reported that females had worse QoL, lower BMI, and Comparative Study on the QoL of COPD Patients 
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higher degree of dyspnoea than COPD males. (De Torres et al, 2006) Di Marco et al 
also reported a poor symptom related QoL in female patients compared with men. 
(Di Marco et al, 2006) In a previous study performed by De Torres and co-workers, it 
was reported that SGRQ scores in all domains were higher in female patients than 
men. The authors also observed that when they classified the patients by severity of 
obstruction  into  FEV1%  greater  and  lower  than  50%,  only  women  with  mild  to 
moderate disease had higher scores in all domains of the SGRQ than the men. This 
is therefore suggesting that COPD females develop symptoms influencing the SGRQ 
at a younger age and with less degree of obstruction than men. (De Torres et al, 
2005) Data suggests that women may actually be at greater risk of smoking-induced 
lung function impairment, more severe dyspnoea, and poorer health status for the 
same level of tobacco exposure than men. (Han et al, 2007) It is also suggested that 
the impairment in women‘s QoL can be due to their high prevalence of disability and 
chronic conditions. (Orfila et al, 2006) Other reports found that females have worse 
QoL than males. (Martinez et al 2007, Katsura et al 2007, Tashkin et al 1992, de 
Torres et al 2002 and Oga et al 2002) 
In  contrast,  another  study  by  Skumlien  et  al  found  no  gender  differences  in 
pulmonary
 function (% of predicted) and SGRQ. Activity scores were only different 
for men  and  women for items  concerning  home management  where  women
  had 
changed their functional performance the
 most, particularly for the heaviest chores. 
No  gender  differences  were  noticed  in  dyspnoea  scores.  (Skumlien  et  al,  2006) 
Similar  findings  were  suggested  by  Stahl  et  al;  their  study  suggested  that  no 
significant differences were noticed in QoL with regards to gender, smoking status or 
socio-economic group. (Stahl et al, 2005) Comparative Study on the QoL of COPD Patients 
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A recent study of gender differences in five commonly used measures of QoL, from 
four  nationally  representative  studies  in  the  USA,  indicated  that  US  women  on 
average  have  slightly  lower self-reported  QoL  than men. The  QoL  gap  is largely 
explained  by  sociodemographic  and  socioeconomic  status  (SES)  differentials 
between  men  and  women.  All  five  measures  of  QoL  showed  similar  gender 
differences prior to sociodemographic and SES adjustments and relatively similar 
patterns  with  adjustment.  Income  and  marital  status  contributed  the  most  to 
explaining  gender  differences  in  QoL  across  measures.  (Cherepanov  et  al,  May 
2010) 
Our findings are in agreement with the results of previous studies, suggesting that 
there was no difference in QoL between women and men. In our case these results 
are focusing on UK patients only as it was the only centre where we were able to 
perform  the  analysis  by  gender.  Generally,  women  tend  to  be  more  sensitive  to 
changes  in  their  QoL  (Juniper  et  al,  1992),  therefore  more  attention  should  be 
devoted to assess the gender differences in the COPD patients and to study the 
effect of gender on the clinical manifestations of COPD. 
Unfortunately, the comparison between COPD in men and women from the Middle 
East and North Africa was not possible due to the limited number of female patients 
seen during the data collection (only two and therefore excluded from the study). We 
believe that this is due to the small number of female smokers from both countries. 
In fact, according to the country profiles published by the World Health Organisation 
(WHO), the prevalence of smoking among females is 2% in Morocco, while no data 
is  published  for  the  United  Arab  Emirates  concerning  the  smoking  prevalence 
.(www.who.int/en/)  Another  reason  from  my  experience,  having  lived  in  both 
countries, is the social and cultural pressure in these countries where women seen Comparative Study on the QoL of COPD Patients 
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smoking  are  discredited  leading  them  to  deny  smoking,  so  COPD  is  poorly 
diagnosed in women in these countries. 
BMI and Quality of Life 
Looking at the BMI influences, it is known that malnutrition increases dyspnoea and 
exercise intolerance in COPD patients and hence the drop off in their QoL. Hesselink 
et al suggest that QoL is associated with body weight. (Hesselink et al, 2006) Salepci 
et  al  also  reported  that  QoL  is  predicted  by  BMI  in  a  group  of  COPD  patients. 
(Salepci et al, 2007) Katsutra and colleagues found that patients with low BMI had 
poor QoL which was assessed by SGRQ and SF-36. (Katsutra et al, 2005) Our study 
did not find a significant relationship between the BMI and the total QoL scores when 
the effect of the other factors is taken into account (age, TMG, etc). However, it 
showed a significant relationship between BMI and impact QoL scores, with COPD 
patients  with  low  BMI  tending  to  have  poor  impact  QoL.  As  mentioned  in  the 
introduction chapter, the reasons behind the weight loss in COPD patients is poorly 
understood, although we found that there is an effect of BMI on the impact scores, 
further  studies  are  still  needed  to  study  this  relationship  and  to  confirm  those 
findings. 
The  relationship  between  activity  scores  and  BMI  appears  to  differ  between  the 
countries. The  social and financial  status  of  patients from  Morocco  and the  UAE 
could be influencing factors on their BMI and might not be specifically linked to the 
COPD  condition.  The  data  was  collected  from  patients  visiting  government  and 
public hospitals in Morocco and the UAE, who are mostly considered being of the 
low income society class; their social and financial status affect their nutrition (some Comparative Study on the QoL of COPD Patients 
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people cannot afford three meals a day or a balanced diet) and subsequently their 
BMI. 
Muscle Strength and Quality of Life 
Regarding muscle grip, some studies suggested that COPD patients have muscle 
dysfunction which limits their exercise capacity and their QoL like the one done by 
Agusti et al in 2003. (Agusti et al, 2003) In 2004, Coronell et al reported as well that 
COPD  patients  have  impaired  peripheral  muscle  function  when  compared  to  a 
healthy control group, suggesting that there might be other factors contributing to this 
impairment, including malnutrition, exposure to corticosteroids, tissue hypoxia, heart 
disease  history,  tobacco  use,  systemic  inflammation  and  hormone  alteration. 
(Coronell et al, 2004) Janaudis-Ferreira et al showed in 2006 that there are gender 
related differences regarding muscle strength in COPD patients with female patients 
seemed to experience decrease in thigh muscle function when compared to male 
patients. (Janaudis-Ferreira, 2006) A study carried out by Giampaoli et al on elderly 
men  aged  between  71  and  91  years  old  suggested  that  poor  hand  strength  as 
measured by hand-grip is a predictor of disability in older people. (Giampaoli et al, 
1999) 
Our  analysed  data  confirmed  and  supported  the  findings  of  previous  studies 
concerning the relationship between the QoL of COPD patients and their muscle 
strength.  We  found  a  significant  relationship  between  all  the  components  of  the 
SGRQ and the TMG of the subjects studied, where COPD patients with poor muscle 
strength were having poor QoL. We also noted that the UK patients had lower TMG 
than patients from the UAE and Morocco, but this can be due to the age range as 
patients from the UK were much older than the other groups or the fact that in the Comparative Study on the QoL of COPD Patients 
  Page 139 
 
UAE or Morocco even older people would still remain in activity with some heavy 
duties because of the economical conditions and absence of pension support. We 
believe  that  exercise  training  will  improve  the  muscle  function  in  COPD  patients 
which  will  improve  their  exercise  capacity  as  well  as  their  QoL.  In  fact  a  study 
performed by McKeough and colleagues has shown an increase in the quadriceps 
muscle  mass  and  strength  following  twice  weekly  training  in  COPD  patients. 
(McKeougha et al, 2006) 
Smoking and Quality of Life 
Some studies have investigated the relationship between the smoking status and the 
QoL  of  COPD  patients.  Stahl  et  al  reported  that  smoking  status  did  not  affect 
patients‘ QoL. (Stahl et al, 2005) Prigatano et al carried out a study and found that 
current smoking patients have lower QoL than ex-smokers. (Prigatano et al, 1984) 
Spencer and colleagues used the SGRQ and SF-36 to assess if smoking had an 
influence on the health status and its rate of deterioration, their results found that 
smokers had worse QoL than ex-smokers with no effect of smoking on the rate of 
deterioration in the QoL. Although current smokers had worse QoL than ex-smokers, 
it was not sure if smoking cessation was the cause for the better QoL.  (Spencer et 
al, 2001)  Another study found that smoking affected the QoL by causing COPD 
exacerbations although it did not directly cause QoL deterioration. (Havlucu et al 
2005) But Mulder et al found that ex-smokers had poorer QoL than current smokers 
(Mulder  et  al,  2001)  and  in  another  study  by  Wijnhoven,  current  smoking  was 
associated with better QoL compared to ex-smokers. (Wijnhoven et al, 2001) The 
explanation given was that subjects who do not quit smoking might be those with a 
less severe stage of disease. Wilson and colleagues compared the QoL of COPD 
between  ex-smokers,  light,  moderate  and  heavy  smokers  and  found  that  heavy Comparative Study on the QoL of COPD Patients 
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smokers had significantly better QoL than the other groups. (Wilson et al, 1999) A 
different study by Wilson et al performed on heavy smokers reported that there is a 
relationship of smoking with impaired QoL and this is more marked in females than 
in males. (Wilson et al, 2004) Tillmann and colleague suggest that these differences 
in the QoL between current and ex-smokers are relatively small and are explained by 
variation in age, housing and economic status. (Tillmann and Silcock, 1997) 
Our results support those of Mulder and Wijnhoven, although none of them used the 
SGRQ to assess patients‘ QoL, where we found that ex-smokers had worse QoL 
than  current  smokers,  and  this  was  observed  in  all  the  three  centres  (the  UK, 
Morocco and the UAE).  This can be explained by the various factors that determine 
the extent of harm smoking can cause on health. Such factors might include the 
intensity  of  smoking,  time  since  quitting  smoking,  the  age  at  which  the  smoker 
quitted the habit, as well as the patients‘ life style. We couldn‘t calculate the pack 
years, due to the lack of some information about the intensity of smoking and how 
many cigarettes did the subjects smoke.  A possible reason behind current smokers 
having worse QoL than ex-smokers might be that patients quitting smoking even in a 
very short period of time were considered as ex-smokers.  
Lung Function and Quality of Life 
Some studies found a weak or no relationship between pulmonary function and the 
QoL measurements. (Wijnhoven et al, 2001)
 However Ferrer et al suggested that 
both lung function and QoL should be used to determine patients with COPD. (Ferrer 
et al, 1997) Stahl et al also found a strong relationship between FEV1% predicted 
and the QoL in COPD patients, (Stahl et al, 2005) while other studies reported that 
there  is a  weak  relationship between pulmonary  function  (FEV1)  and  the  QoL  in Comparative Study on the QoL of COPD Patients 
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COPD patients. (Ferrer et al 1996, Jones et al 1992, Jones et al 1989) Another study 
conducted by McGlone and colleagues found that there is a significant relationship 
between physical activity, disease severity which was assessed by spirometry and 
QoL of COPD patients. (McGlone et al, 2006) 
According  to  our  findings  there  was  a  significant  relationship  between  FEV1% 
predicted and FVC% predicted and the QoL of COPD patients when used in the 
univariate analysis but when the effect of other variables was taken into account 
there  appear  to  be  no  effect  of  the  FEV1%  predicted  but  the  effect  of  FVC% 
predicted  remained  significant,  with  low  pulmonary  function  associated  with  an 
impairment in the QoL. However it was suggested in a number of studies that an 
improvement in COPD patients‘ QoL does not always mean an improvement in their 
lung function. 
Our  results  also  showed  a  non  linear  relationship  between  FVC%  predicted  and 
SGRQ scores, which could be explained by a possible infection or deterioration of 
the  condition.  Although  exacerbations  were  excluded  from  the  study,  but  some 
patients came for a follow-up and/or some mild cough and cold like symptoms.   
Differences in QoL between the Countries 
Through the comparative study of the variables impacting the QoL of COPD patients 
in three different countries, our main hypothesis is that the COPD patients in the UK 
would have better QoL than the patients in the other countries. That assumption was 
based on the economical and social development situation of the countries and the 
more advanced health care system in the UK compared to the other countries. This 
study is believed to be the first one comparing the QoL of COPD patients between 
the UK, Morocco and the UAE. In terms of total SGRQ scores, the UK had better Comparative Study on the QoL of COPD Patients 
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QoL than Morocco and the UAE which validates our hypothesis. However due to the 
absence of previous studies comparing between the three countries in this field (our 
simply, to our knowledge, the absence of studies on the QoL of COPD patients in the 
UAE for example), we could not contrast our findings with any published literature. 
When comparing all SGRQ domains (symptom, activity, impact and total scores), we 
found that patients in the UK had the lowest symptom scores followed by patients in 
Morocco then by patients in the UAE and the lowest symptom scores are the better 
the QoL is. A similar trend is seen with the impact scores with the UK patients having 
the lowest impact scores but followed by UAE patients then by Moroccan patients. 
However, the highest activity scores were seen in Moroccan and the UK patients 
(with similar scores) and the lowest scores were observed in patients from the UAE. 
So  when  looking  at  these  aspects  individually,  no  immediate  conclusion  can  be 
reached  but  considering  the  total  scores,  a  significant  difference  between  the 
countries was observed (even after considering various contributing factors such as 
age, gender, pulmonary function, dyspnoea, BMI and TMG), leading to the validation 
of our hypothesis that the UK patients would have better QoL. 
A further analysis to confirm the differences in QoL between the three countries was 
done; firstly unadjusted and then adjusted for factors associated with total QoL. The 
outcome figures were the regression coefficients, which represented the difference 
in  QoL  between  each  country  and  the  UAE  as  a  baseline  category.  The  first 
significance  level reported  was  the  significance of  the  overall  difference  between 
countries.  The  subsequent  significance  levels,  which  were  given  a  Bonferroni 
adjustment  to  allow  for  multiple  comparisons,  indicated  the  specific  differences 
between pairs of countries. Comparative Study on the QoL of COPD Patients 
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The  unadjusted  results  indicated  that  there  was  an  overall  significant  difference 
between the three countries when no other factors were considered. The poorest 
Quality of Life was for the UAE patients with SGRQ score significantly higher than 
those  in  Morocco  and  the  UK.  Moreover,  there  was  still  a  significant  overall 
difference between the three countries when the significant factors were taken into 
account. However, there was no significant difference between Morocco and the UK. 
Subsequently the interaction between country and each of the other variables was 
examined.  The  results  suggested  that  QoL  differences  between  countries  do  not 
vary depending on either age range or TMG score. However, the interaction between 
country and FVC% predicted turned out to be significant, which implies that the QoL 
difference  between  countries  varies  depending  on  the  FVC%  predicted  values. 
Consequently, we quantified the effect of FVC% predicted upon the patients‘ QoL for 
each of the three countries to end up with a confirmation on the dependency of the 
QoL on FVC% predicted in the three countries with a significant level. The nature of 
the interaction suggests that for patients with low FVC% predicted values, the QoL 
scores are lowest in UAE and highest in Morocco. Conversely for patients with high 
FVC% predicted scores, the QoL scores are lowest in Morocco but highest in the 
UAE. The reasons behind this trend cannot be easily explained but we suspect that 
maybe  this is due  to the  effect of  the  other factors such as  age,  smoking  habit, 
muscle strength or BMI. Further investigation is needed to study the differences in 
the effect of lung function on the QoL between the countries. 
One of the main reasons that a patient would seek a medical care is shortness of 
breath (dyspnoea) and it is an important predictor of QoL, therefore the management 
of COPD should be aimed at reducing the shortness of breath in these patients and Comparative Study on the QoL of COPD Patients 
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measurement  of  dyspnoea  reveals  the  practical  effects  of  the  treatment  on  the 
patient‘s daily life. (Mahler et al 1995) 
The correlation between dyspnoea and QoL in COPD was also indicated in other 
studies supportive of our hypothesis that COPD patients with low QoL would have 
severe shortness of breath. (Karapolat et al 2008; Miravitlles et al 2007; Rector et al 
2006; Hu et al 2005; Gonzalez et al 2005) A study by Mannino has shown that the 
increase in the disease severity is accompanied by an increase in dyspnoea in these 
patients. (Mannino et al, 2002) A study carried out by Mahler in 1992 to examine the 
relationship  between  dyspnoea,  QoL  and  pulmonary  function  in  COPD  patients 
found that dyspnoea ratings influence
 and predict general health status to a greater 
extent than do physiologic
 measurements. (Mahler et al, 1992) In 1995 Mahler and 
colleagues reported that the severity of dyspnoea but not the respiratory function 
was a significant predictor of various components of QoL. (Mahler et al, 1995) 
Our  results  show  that  the  total  QoL  scores  were  significantly  correlated  with 
dyspnoea (assessed by BDI): the higher the SGRQ scores (meaning a poor QoL) 
were, the worse was the dyspnoea in stable COPD patients from the UAE, Morocco 
and the UK. When both functional impairment and magnitude of task were included 
in the same regression model in a multivariate analysis, both were still statistically 
significant, although the effects of each factor were smaller. With these results, it can 
be assumed that dyspnoea symptoms will probably cause restrictions in the daily 
activities of patients.  
In this study we found a strong collinearity between two components of the BDI: 
magnitude  of  task  and  magnitude  of  effort.  This  leads  to  a  question  about  the 
purpose of including the two components in the BDI if they are nearly identical. This Comparative Study on the QoL of COPD Patients 
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seems to be a unique pattern found in our data since none of the articles reviewed 
fortify this collinearity. There are two possible explanations that can be given to this 
pattern: (1) a possible data entry mistake might have occurred when transferring the 
collected figures to the SPSS software, but this is unlikely since care was taking 
during this process and a cross check was performed after entering the data in the 
system; (2) another explanation is that some patients might have given the same 
answer to both questions because they are not making the distinction between ―task‖ 
and ―effort‖ as the meaning was not explicit enough for them or simply not willing to 
go  into  the  details and  probably  taking  the  pessimistic approach,  thus  answering 
negatively to both questions. 
Patients’ Awareness 
From the extra questions that we asked the COPD patients, we could see a big 
difference  in  disease  awareness  between  patients  from  the  UK  and  those  from 
Morocco and the UAE. For example when patients from the UAE and Morocco were 
asked if they knew that they had COPD, most of them were not fully aware of their 
condition as such and their answer was that they had Asthma. From the author‘s 
point  of  view,  this  can  be  explained  by  the  lack  of  communication  between  the 
consultants and the patients especially in the hospitals visited. As mentioned earlier 
the  data  collection  was  from  government  hospitals  and  it  was  observed  that  the 
consultants were too busy to take time to explain or educate the patients about their 
condition.  It  would  also  seem  that  the  system  is  more  focused  on  medication 
treatment than counselling (or continuous treatment). Another reason behind this is 
maybe that most of the subjects were illiterate, limiting their capability to understand 
their conditions and asthma is a word generally understood and linked to respiratory Comparative Study on the QoL of COPD Patients 
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problems whereas anything where pulmonary disease is mentioned would be linked 
to tuberculosis (TB). 
When the patients were asked if they expected one-off treatment, those from the UK 
who answered ―No‖ understood and were told that there is almost no cure for COPD 
and that the medication would only help to stabilise their condition. While those from 
the UAE or Morocco who were asked the same question answered with the general 
saying ―God knows‖ but the answer was considered as a ―No‖. 
Patients  were  asked  if  they  are  aware  that  the  most  common  causes  of  an 
exacerbation are infections of the trachea and bronchial tree and air pollution. We 
observed that most of the UK patients were aware of that and would do the influenza 
vaccination to prevent them from any infection. The other groups of patients who 
were aware of that fact could not do much about it especially for those who get 
exposed to pollution either at work and could not change their job or where they live 
(popular areas), bearing in mind that the data was collected from two large cities in 
Morocco  which  are  very  polluted.  Very  few  patients  from  Morocco  had  influenza 
vaccination and those who did were the few ones entitled for medical insurance and 
therefore  they  would  pay  very  little  for  the  flu  shot  (the  normal  cost  of  the  flu 
vaccination is about 100 MAD= £7, which the majority of the patients would not be 
able to afford). Concerning patients from the UAE, only patients who knew about the 
flu vaccination and that it might prevent them from exacerbations would have it. 
During  the  questioning  of  the  patients  from  Morocco  or  the  UAE  about  their 
treatment, we noted that patients did not seem to take their medication properly. The 
main reason behind that is that they are unable to afford their treatment as very few 
people  are  supported  by  health  insurance  and  it  is  still  seen  as  expensive  to Comparative Study on the QoL of COPD Patients 
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subscribe to one. The consultants were asked about the protocol of managing COPD 
and  according  to  them,  they  should  theoretically  follow  the  GOLD  guidelines  but 
unfortunately  in  the  real life  they  are  prescribing  the medication  according to the 
patients‘ situation (for example some patients would only afford to take salbutamol 
temporarily for 2 to 3 months then stop it). 
Overall COPD patients from the UK were more aware of their condition and following 
their treatment (with a system that is supporting this) than patients from Morocco or 
the UAE. The impact of the socio-economical and cultural background of each region 
may affect the management of COPD and health related issues in general. 
4.2 Control Group 
The second phase of our study was to analyse the measured and collected data 
about the control group subjects from the UK, the UAE and Morocco, by examining 
the  differences  between  the  countries  parameters.  As  mentioned  earlier,  data on 
some  parameters  was  available  for  all  three  countries  allowing  us  to  do  a 
comparison on the total QoL; however, other information (such as lung function and 
muscle strength measures) was only available for the UAE and Morocco. For these 
two countries, we were able to examine the effects of various variables upon QoL 
scores and as we did with the patients‘ data, a series of univariate analysis have 
been carried out independently to examine the individual effect of each variable upon 
the overall QoL outcome. 
When we compared between the control group from the three countries, our results 
showed differences in their QoL, where the UK subjects had poorer QoL compared 
to  the  control  groups  from  the  UAE  and  Morocco.  This  might  be  due  to  the 
comparatively older age the UK subjects had that indicates lower QoL commonly. In Comparative Study on the QoL of COPD Patients 
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fact, the control group in the UK were clients of the Age Concern organisation whose 
aim is to provide leisure space for older people and improve their social life. Noting 
that  the  English  Longitudinal  Study  of  Ageing  (ELSA)  which  collects  a  range  of 
measures of well-being including CASP-19, used to measure the Quality of Life of 
older adults, suggested that the overall QoL increases between the age groups of 
55-59  and  60-64  but  then  decreases  with  age.  In  other  words,  CASP-19  scores 
decrease from state pension age onwards with the fastest decline occurring after the 
age of 70. (English Longitudinal Study of Ageing, Wave 3, 2005/06) Another reason 
which could be behind the relatively low QoL of the UK control group subjects is the 
possibility  of  co-existing  medical  conditions  apart  from  respiratory  illness,  as  we 
excluded subjects who suffered from any respiratory disease. 
Given  these  discrepancies  in  our UK  control  group  data  and  since  we  could  not 
generalise our control group scores to represent healthy individuals from the UK, we 
could not compare the Quality of Life between COPD patients and control group 
from the UK but we recommend further studies to be carried out in this field. 
When  we  studied  the  difference  in  smoking  status  between  the  countries,  the 
number of current smokers among the UAE control group subjects was considerably 
less than their counterparts in the UK and Morocco. 
4.3 Limitation of the Study 
A number of limitations of this study should be mentioned. 
The data sample used for comparison between the countries consisted of males only 
due to the small number of COPD females found in Morocco and in the United Arab 
Emirates, as we have discussed earlier, with one reason being the low prevalence of 
smoking women in the population or the socio-cultural denial of this. Because our Comparative Study on the QoL of COPD Patients 
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study included predominantly men, the generalisation of the results to women with 
COPD may be uncertain. 
As  the  sample  in  Morocco  and  the  UAE  was  from  public  hospitals  with  subjects 
predominantly from the middle to lower socioeconomic scale, the results may not 
generalise to other populations (for example affluent patients of a private hospital or 
rural populations). For the United Arab Emirates in particular, only few UAE nationals 
were recruited which is due to the large number of expatriates living in the UAE and 
also the fact that most of local people would prefer to go to private hospitals/clinics. 
This sample is certainly not representative of the local people from the UAE neither it 
is  representative  of  the  entire  expatriate  population  which  is  from  different 
backgrounds and different aspirations. 
The  English  version  of  the  St  George‘s  Respiratory  Questionnaire  was  used 
throughout the study even for non-English speakers. We paid attention to explaining 
all the items to the patients in their own language (mix of Arabic, French or Moroccan 
dialect).  Although  the  questionnaire  was  administered  by  the  same  investigator 
(myself) and translated into the appropriate language directly to the patient, it was 
observed that some of the questions do not directly apply to subjects from the UAE 
or Morocco (e.g. if housework is limited because of chest trouble) as males from 
these  centres  rarely  perform  any  of  the  housework  activities  stated  in  the 
questionnaire given the cultural and the social organisation of life. 
Moreover,  we  suspect  that  some  respondents  might  have  overstated  (or 
understated) their  answers.  This is  in  fact a  general  disadvantage  of  any  survey 
related to personal or controversial topics where participants might not always say 
the truth. Comparative Study on the QoL of COPD Patients 
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Another possible limitation is about lung function measurement since as stated in the 
methodology chapter for the COPD patients from the UK we had to use the hospital 
readings  for  spirometry.  Besides,  some  patients  might  have  used  bronchodilator 
(Salbutamol)  some minutes before  measuring  lung  function  which  may  affect the 
results in some way. 
The fact that we could not obtain lung function measurements and the muscle grip 
readings from the UK control group is also a limitation because the full comparison 
between the  three  groups  was  not  possible.  Besides,  the  control groups  were  of 
different profiles: clients of the Age Concern organisation in the UK, workers of the 
National Rail Network in Morocco and staff/ visitors of the hospitals in the UAE, so 
the results may not be extrapolable to the general healthy population. 
4.4 Conclusion 
To  our knowledge  this study  is the first  approach  to  compare  the  QoL of  COPD 
patients  between  three  different  regions: The  United  Kingdom  (Europe),  Morocco 
(North  Africa)  and  the  United  Arab  Emirates  (Middle  East).  Using  St  George‘s 
Respiratory Questionnaire and lung function measurements, as well as a hand grip 
dynamometer to measure the total muscle strength, this study also assessed and 
tested any possible differences in the QoL between the studied countries after taking 
into consideration the effect of other variables such as age, BMI, dyspnoea, smoking 
history and gender differences (but the latter factor only within the UK patients). 
After careful studying  and  analysing  of  the  collected  data,  we  found  out  that  the 
COPD patients in the UK had the lowest total SGRQ scores (meaning better QoL) 
than Morocco and the UAE. This finding supports our hypothesis that the COPD 
patients in the UK would have better QoL than the patients in the other countries. Comparative Study on the QoL of COPD Patients 
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The available literature studying the relationship between age, gender differences, 
lung  function,  BMI,  dyspnoea  and  the  QoL  came  out  with  variable  results  from 
confirming such relationship to discarding it. Our study also assessed the association 
between  those  parameters  and  the  QoL  in  COPD  patients.  As  a  result,  TMG, 
dyspnoea, age and FVC% predicted were found to be good predictors of the QoL 
and significantly associated with the QoL. 
The results show that there is no significant gender difference in terms of total QoL 
and no significant difference between males and females within the UK for the effect 
of lung function, TMG, BMI and dyspnoea. 
BMI had no effect on the QoL in our study, except for the activity and impact SGRQ 
scores. 
Muscle  strength  is  a  good  predictor  of  QoL  in  COPD  patients  according  to  our 
results.  Due  to  the  shortness  of  breath  during  exercise,  COPD  patients  become 
inactive, stop exercising and their day-to-day activities are limited. Further studies 
are needed to confirm our findings and to assess the effect of the handgrip strength 
on the QoL as well as morphologic studies on the handgrip muscle since most of the 
existing studies are mainly performed on the quadriceps muscle. 
Dyspnoea is one of the most powerful predictors of QoL in COPD. Its importance 
was  expected  and  supported  by  all  previous  studies.  Because  the  Baseline 
Dyspnoea  Index  (BDI) is  a  descriptive  tool to  measure  activities  modified  due  to 
shortness of breath, we suggest that BDI should be used in health care settings to 
measure qualitative assessment of dyspnoea in patients with COPD. Comparative Study on the QoL of COPD Patients 
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This study reported that current smokers have better QoL than ex-smokers and this 
statement  was  supported  by  many  other  studies  which  were  discussed  in  the 
previous chapters. However, we do not believe that keeping a smoking habit would 
be an indication for a better QoL, since smoking influence on the QoL is affected by 
many other factors such as the intensity of smoking, time since quitting smoking, the 
age at which the smoker quitted the habit, as well as the patients‘ life style. We 
suggest  designing  more  public  health  smoking  cessation  programs  which  will 
consider the varying characteristics of different segments of the smoking population. 
These programs should mainly target the population in Morocco or in the United 
Arab Emirates due to the lack of these programs in those countries. 
Age  should  be  taken  into  consideration  when  managing  COPD  patients,  elderly 
patients usually have lower QoL than younger patients which could be due to other 
reasons than their COPD condition (for example most of their daily activities become 
limited). 
Supported by an additional specific questionnaire, our study suggests that there is a 
real  need  to  develop  treatment  strategies  taking  into  account  individual  goals, 
requirements,  cultural  background  and  socio-economical  status  of  the  COPD 
patients. 
On  a  Personal level,  this study  and  experience  allowed  me  to fulfil  a  number of 
objectives I had set myself through the PhD program: 
1.  I  previously  completed  an  MSc  in  Clinical  Pharmacy  and  Medicines 
Management, and working on the QoL aspects is a continuation of my interest 
in the Clinical Pharmacy topics. Furthermore the QoL aspects are valid to be 
considered in any condition or disease. Comparative Study on the QoL of COPD Patients 
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2.  This  study  allowed  me  to  familiarise  myself  with  COPD  and  respiratory 
conditions  that  caught  my  interest  since  a  younger  age  as  some  family 
members suffered from acute asthma affecting their day-to-day life. 
3.  This study allowed me to work with clinics from the three different countries I 
have  lived  in  and  to  travel  between  these  countries  to  get  to  know  some 
aspects of the medical care in each and be exposed to it in real life. This is 
obviously a valuable experience, thank you to the patients and the medical 
staff from the clinics. 
4.  Improve my statistical and analytical skills and put them into use in a concrete 
research project. 
In the future I plan to invest some time in academic life, in parallel to some voluntary 
work through associations and local health organisations. 
From  the  academic  and  research  point  of  view,  as  mentioned  in  this  discussion 
chapter, I believe that there are a number of topics that need further investigation. 
We  mentioned  for  example  that  our  study  is  not  representative  of  the  whole 
population of the UAE or Morocco given life style and the level of living differences 
across  the  population.  Ideally  I  would  like  to  work  with  students  from  the  UK, 
Moroccan or the UAE universities to study the QoL of COPD patients in rural areas 
in  Morocco  versus  patients  living  in  cities  (actually  the  majority  of  Moroccan 
population  is  living  in  rural  areas  and  remote  from  any  ongoing  medical  care). 
Equally  in  the  UAE  it  is  worth  looking  into  the  QoL  of  South  Asian  immigrants 
(Pakistan, India, etc) who are residents in the Middle East and those living in their 
country and study if country of origin, area of residence and ethnicity are factors 
influencing the QoL of COPD patients. Comparative Study on the QoL of COPD Patients 
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There are also some general topics such as the effect of smoking that need further 
research as we found different perspectives from previous studies about the QoL of 
smokers versus ex-smokers. As mentioned earlier, such research should include a 
number of factors such as age since quitting smoking or intensity of smoking. 
I  would  like  to  work  with  health  care  professional  to  design  more  public  health 
smoking cessation programs especially in Morocco and the United Arab Emirates 
due to their lack of these programs. 
From a social and community point of view, I would like to approach the Moroccan 
Society  of  Respiratory  Diseases  (SMMR)  (I  met  with  the  representatives  of  the 
association  in  the  last  ERS  congress  I  attended  and  noted  that  there  are 
opportunities  to  help  the  association  to  be  more  productive)  and  the  ministry  of 
health  or  the  local  office  of  WHO  to  design  campaigns  or  programs  in  order  to 
increase the awareness of patients and ultimately improve their QoL. Being exposed 
to  the  UK  system and  the  UK  patients  through  this study,  I  felt  that  there  are a 
number of inspirations we could take from the UK system and the management of 
COPD and try to promote the same with the patients in the UAE and Morocco. One 
concrete example is the smoking cessation programs. Another possible action would 
also be to approach consultants and the hospitals to encourage their staff to use 
SGRQ to get to know more about the QoL of the patients instead of just focusing on 
medication treatment. We noted for example that spirometry is not systematically 
performed on patients from Morocco and the UAE as we have seen in the UK, and 
we would encourage the consultants to perform such measures alongside the use of 
SGRQ mentioned earlier. Comparative Study on the QoL of COPD Patients 
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Future research should apply the knowledge that has been gained from this work in 
the assessment of the Quality of Life of COPD patients. Comparative Study on the QoL of COPD Patients 
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Appendix 1: Patient Information Sheet 
 
 
Chronic Lung Disease study 
Patient information sheet 
 
We would like to invite you to take part in this study, which investigates 
the effects of social support and stress on the wellbeing of patients with 
chronic  obstructive  lung  disease.  We  would  like  you  to  read  the 
information sheet and give us you permission to access your medical 
records, if this is appropriate 
 
What is the purpose of the study? 
 
We are investigating how support from families and friends help people 
with chronic lung disease to cope with their condition. 
 
What will happen if I agree to take part in the study? 
 
An investigator will ask you to fill some questionnaires and will help you 
to  do  this.  The  questionnaire  will  record  information  about  your 
symptoms, how you feel about yourself, how you cope with your illness, 
and who helps you. This will take just few minutes to complete. 
 
The investigator will get a copy of your lung function results from your 
medical records, and the questionnaires will be analysed. 
 
Is the study voluntary? 
 
Yes. If you do not want to take part in the study this will not affect your 
current or future treatment in anyway. 
 
Will the information obtained in the study be confidential? 
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Yes  the  information  gather  will  be  treated  with  strict  medical 
confidentiality. No one else will be given the results in any form that can 
identify a particular person.  
Any written reports of the study will ensure that each person who takes 
part remains anonymous. 
 
Will there be any risks or side effects associated with the study? 
 
The study involves an interview only. Your medical investigations and 
treatment will not be changed in any way. 
 
How long will the study last? 
 
It will take only few minutes to fill in the questionnaire. 
 
Will anyone else be told about my participation in the study? 
 
A note will be made in your medical records, which are confidential. No 
one else will be told that you have taken part in the study 
 
Will anyone else have access to my medical records? 
 
Your lung function results will be copied and used in the study. The rest 
of your medical records will remain entirely confidential. 
 
Who should I contact if I require further information about the study? 
 
Dr  M  Shamssain.  University  of  Sunderland,  who  is  co-ordinating  the 
study. Dr Shmassain‘s address is: 
 
Dr M Shamssain 
School of Health, Natural and Social Sciences 
University of Sunderland 
Darwing Building, Chester road 
Sunderland, SR1 3SD 
 
Tel 0191 5153784 or 5152525 
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Appendix 2: Patients Record Form 
 
Investigator: Imane Ben Bihi  Centre code: ------  Inclusion Date  : ----/----/---- 
Patient Record 
Patient Information 
Patient‘s ID 
------------ 
Date Of Birth 
-----/-----/---- 
Male        
Female     
Height (M) 
------------- 
Weight (Kg) 
----------- 
Patient History 
Smoking classification:           Smoker              Never smoker            Ex Smoker       
If smoker or ex-smoker, how many cigarettes/day?   --------------------------------------- 
Drug History                  Previous or current treatment for COPD?        Yes                        No 
  
If yes, what is the medication used? 
 
 
 
Medical History                                                   Overall, no significant history     
   Hypertension 
   Cardiac Failure 
   Heart disease 
   Stroke 
   High cholesterol 
   Ulcers 
   Hepatitis 
   Diabetes 
   Thyroid disorder 
   Kidney disorder 
   Visual abnormalities 
   Allergies 
   Tuberculosis 
   Breast disease (cancer) 
   Breast disease (benign) 
   Arthritis 
   Tuberculosis 
   Liver disease 
   Bleeding/clotting disorder 
   Others: ---------------------------- 
Medical Examination 
Lung Function 
Test    1
st Reading  2
nd Reading  3
rd Reading  Average 
  PEF  ---------------  ---------------  ---------------  --------------- 
FVC  ---------------  ---------------  ---------------  --------------- 
FEV1  ---------------  ---------------  ---------------  --------------- 
FVC/FEV1  ---------------  ---------------  ---------------  --------------- 
Muscle Strength    1
st Reading  2
nd Reading  3
rd Reading  Average 
  Right   ---------------  ---------------  ---------------  --------------- 
Left  ---------------  ---------------  ---------------  --------------- 
Right + Left  ---------------  ---------------  ---------------  --------------- Comparative Study on the QoL of COPD Patients 
  Page 180 
 
Appendix 3: St Georges’ Respiratory Questionnaire 
(English) 
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Appendix 4: St Georges’ Respiratory Questionnaire 
(Arabic) 
 Comparative Study on the QoL of COPD Patients 
  Page 187 
 
 Comparative Study on the QoL of COPD Patients 
  Page 188 
 
 Comparative Study on the QoL of COPD Patients 
  Page 189 
 
 Comparative Study on the QoL of COPD Patients 
  Page 190 
 
 Comparative Study on the QoL of COPD Patients 
  Page 191 
 
 Comparative Study on the QoL of COPD Patients 
  Page 192 
 
Appendix 5: SGRQ Item Weights 
 
PART I 
QUESTIONS ABOUT HOW MUCH CHEST TROUBLE YOU HAVE HAD OVER THE 
LAST YEAR 
PLEASE TICK IN ONE BOX FOR EACH QUESTION. 
  Most days 
a week 
Several 
days a 
week 
A few 
days a 
month 
Only with 
chest 
infections 
not at 
all 
1)  Over  the  last  year,  I  have 
coughed 
80.6  63.2  29.3  28.1  0 
2)  Over  the  last  year,  I  have 
brought up phlegm (sputum) 
76.8  60.0  34.0  30.2  0 
3)  Over the last year, I have had 
shortness of breath 
87.2  71.4  43.7  35.7  0 
4)  Over the last year, I have had 
attacks of wheezing 
86.2  71.0  45.6  36.4  0 
 
5) During the last year, how many severe or very 
unpleasant attacks of chest trouble have you had : 
more than 3 attacks..................... 86.7 
3 attacks...................................... 73.5 
2 attacks...................................... 60.3 
1 attack........................................ 44.2 
no attacks.......................................... 0 
6) How long did the worst attack of chest trouble last:  
(Go to Question 7 if you had no severe attacks)  
a weak or more….....…………… 89.7 
3 or more days………......……… 73.5 
1 or 2 days.................................... 58.8 
less than a day….......................... 41.9 
7) Over the last year, in an average week, how many good days 
(with little chest trouble) have you had: 
no good days................................. 93.3 
1 or 2 good days…........................ 76.6 
3 or 4 good days............................ 61.5 
nearly every day is good.….…….. 15.4 
every day is good................................ 0 
8) If you have a wheeze, is it worse in the morning: 
no……………………….…………... 0 
yes.................................................. 62.0 
 
 
 
 
 
 Comparative Study on the QoL of COPD Patients 
  Page 193 
 
PART 2 
SECTION 1: 
HOW WOULD YOU DESCRIBE YOUR CHEST CONDITION? (PLEASE TICK IN ONE 
BOX ONLY) 
the most important problem I have.........................................   83.2 
causes me quite a lot a problems............................................... 82.5 
causes me a few problems......................................................... 34.6 
causes no problem.......................................................................... 0 
IF YOU HAVE EVER HAD PAID EMPLOYMENT, PLEASE TICK ONE OF THESE:  
my chest trouble made me stop work............................................................ 88.9 
my chest trouble interferes with my work or made me change my work..... 77.6 
I my chest trouble does not affect my work....................................................... 0 
 
SECTION 2: QUESTIONS ABOUT WHAT ACTIVITIES USUALLY MAKE YOU FEEL 
BREATHLESS THESE DAYS. 
FOR EACH ITEM, PLEASE TICK EITHER TRUE OR FALSE AS IT APPLIES TO YOU. 
a. Sitting or lying still............................................ 90.6 
b. Getting washed or dressed................................  82.8 
c. Walking around the home.................................. 80.2 
d. Walking outside on the level….......................... 81.4 
e. Walking up a flight of stairs............................... 76.1 
f. Walking hills....................................................... 75.1 
g. Playing sports or games...................................... 72.1 
 
SECTION  3:  SOME  MORE  QUESTIONS  ABOUT  YOUR  COUGH  AND 
BREATHLESSNESS THESE DAYS. 
FOR EACH ITEM, PLEASE TICK EITHER TRUE OR FALSE AS IT APPLIES TO YOU. 
a.  My cough hurts................................................ 81.1 
b. My cough makes me tired................................ 79.1 
c.  I am breathless when I talk............................... 84.5 
d. I am breathless when I bend over.……............ 76.8 
e.  My cough or breathing disturbs my sleep…..   87.9 
f.  I get exhausted easily....................................... 84.0 
 
 SECTION  4:  QUESTIONS  ABOUT  OTHER  EFFECT  S  THAT  YOUR  CHEST 
TROUBLE MAY HAVE ON YOU THESE DAYS. 
FOR EACH ITEM, PLEASE TICK EITHER TRUE OR FALSE AS I'I` APPLIES TO YOU. 
a. My cough or breathing is embarrassing in public….…………......................74.1 
b.  My  chest  trouble  is  a  nuisance  to  my  family,  friends  or 
neighbours..............79.1 
c. I get afraid or panic when I cannot get my breath.......................................... 87.7 
d. I feel that I am not in control of my chest problem………………………… 90.1 
e. I do not expect my chest to get any better...................................................... 82.3 
f. I have become frail or an invalid because of my chest…............................... 89.9 
g. Exercise is not safe for me.............................................................................. 75.7 
h. Everything seems too much of an effort……………..................................... 84.5 
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SECTION 5: QUESTIONS ABOUT YOUR MEDICATION. IF YOU ARE RECEIVING 
NO MEDICATION GO STRAIGHT TO SECTION 6. 
TO  COMPLETE  THIS  SECTION  PLEASE  TICK  EITHER  TRUE  OR  FALSE  AS  IT 
APPLIES TO YOU. 
a. My medication does not help me very much.............. 88.2 
b. I get embarrassed using my medication in public….. 53.9 
c. I have unpleasant side effects from my medication.... 81.1 
d. My medication interferes with my life a lot............... 70.3 
 
SECTION 6: THESE ARE QUESTIONS ABOUT HOW YOUR ACTIVITIES MIGHT BE 
AFFECTED BY YOUR BREATHING. FOR EACH QUESTION, PLEASE TRUE IF ONE 
OR  MORE  PARTS  APPLIES  TO  YOU  BECAUSE  OF  YOUR  BREATHING. 
OTHERWISE TICK FALSE. 
a.  I take a long tune to get washed or dressed..................................................................... 74.2 
b. I cannot take a bath or shower, or I take a long time……………......................…........ 81.0 
c.  I walk slower than other people, or I stop for rests……..…………............................... 71.7 
d. Jobs such as housework take a long time, or l have to stop for rests............................... 70.6 
e.  If I walk up one flight of stairs, I have to go slowly or stop............................................ 71.6 
f.  If I hurry or walk fast. I have to stop or slow down........................................................ 72.3 
g. My breathing makes it difficult to do things like walk up hills; carrying things up stairs, 
light  gardening  such  as  weeding,  dance,  play  bowls  or  play 
golf……............................................. 74.5 
h. My breathing makes it difficult to do things such as carry heavy loads, dig the garden or 
shovel snow, jog or walk at 5 miles per hour, play tennis or swim...................................... 71.4 
i.  My breathing makes it difficult to do things such as very heavy manual work, run, cycle, 
swim fast or play competitive sports.................................................................................... 63.5 
 
SECTION  7:  WE  WOULD  LIKE  TO  KNOW  HOW  YOUR  CHEST  TROUBLE 
USUALLY AFFECTS YOUR DAILY LIFE. 
PLEASE  TICK  EITHER  TRUE  OR  FALSE  AS  IT  APPLIES  TO  YOU  BECAUSE  OF 
YOUR CHEST TROUBLE.   
(REMEMBERTHAT  TRUE  ONLY  APPLIES  TO  YOU  IF  YOU  CAN  NOT  DO 
SOMETHING BECAUSE OF YOUR BREATHING) 
a. I cannot play sports or games............................... 64.8 
b. I cannot go out for entertainment or recreation......... 79.8 
c. I cannot go out of the house to do the shopping........ 81.0 
d. I cannot do housework............................................... 79.1 
e. I cannot move far from my bed or chair.................... 94.0 
SECTION  8:  HERE  IS  A  LIST  OF  OTHER  ACTIVITIES  THAT  YOUR  CHEST 
TROUBLE MAY PREVENT YOU DOING. (YOU DO NOT HAVE TO TICK THESE; 
THEY ARE JUST TO REMIND YOU OF WAYS IN WHICH YOUR BREATHLESSNESS 
MAY AFFECT YOU): 
GOING FOR WALKS OR WALKING TI-IE DOG 
DOING THINGS AT HOME OR IN THE GARDEN 
SEXUAL INTERCOURSE 
GOING OUT TO CHURCH, OR PLACE OF ENTERTAINMIQIT 
GOING OUT IN BAD WEATHER OR INTO SMOKY ROOMS 
VISITING FAMILY OR FRIENDS OR PLAYING WITH CHILDREN Comparative Study on the QoL of COPD Patients 
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PLEASE  WRITE  IN  ANY  OTHER  IMPORTANT  ACTIVITIES  THAT  YOUR  CHEST 
TROUBLE MAY STOP YOU DOING; 
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
SECTION 9: NOW, WOULD YOU TICK IN THE BOX (ONE ONLY) WHICH YOU 
THINK BEST DESCRIBES HOW YOUR CHEST AFFECTS YOU: 
It does not stop me doing anything I would like to do………..... 0 
It stops me doing one or two things I would like to do.......... 42.0 
It stops me doing most of the things I would like to do......... 84.2 
It stops me doing everything I would like to do..................... 96.7 
THANK  YOU  FOR  FILLING  IN  TI-IIS  QUESTTONNAIRE.  BEFORE  YOU  FINISH 
WOULD YOU CHECK TO SEE THAT YOU HAVE ANSWERED ALL TIE QUESTIONS. Comparative Study on the QoL of COPD Patients 
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SYMPTOMS COMPONENT 
This  consists  of  all  the  questions  in  Part  1.  The  weights  for  Questions  1-8  are 
summed.  It  will  be  noted  that  the  questionnaire  requests  a  single  response  to 
Questions  1-7.  If  multiple  responses  are  given  to  a  question  then  averaging  the 
weights for the positive responses for that question is acceptable. We feel that is a 
better  approach  than  losing  an  entire  data  set  and  have  used  this  technique  in 
calculating the results used in our validation studies. (Clearly a better approach is to 
prevent such multiple responses occurring, but it is difficult to prevent occasional 
accidents). 
ACTIVITY COMPONENT 
This is calculated from the summed weighs for the positive responses to Section 2 
and Section 6 in Part 2 of the questionnaire. 
IMPACTS COMPONENT 
This  is  calculated  from  Sections  1;  3;  4;  5;  7.  Again  it  will  be  noted  from  the 
questionnaire that a single response is required for the two parts of Section l and the 
last  part  of  Section  7.  In  the  case  of  multiple  responses  we  have  adopted  the 
approach of meaning the weights for any multiple responses to these parts.   
TOTAL SCORE   
The  Total  score  is  calculated  by  summing  the  all  positive  responses  in  the 
questionnaire and expressing the result as a percentage of the weights for all items 
in the questionnaire (as shown on previous page). 
HANDLING MISSED ITEMS 
It is better not to miss items and any missing items are the fault of the experimenter, 
not the patient. We have examined the effect of missing items and recommend the 
following methods: 
Part 1 
Missed items are treated as if the answer was in the negative. 
Part 2   
The following approach may be used. Items in Sections 2, 3,4,5,6, and first part of 
section 7 all require a response of either ‗True‘ or ‗False‘. If neither box is ticked, the 
item  should  be  coded  as  ‗missing‘.  If  this  approach  is  to  be  used,  the  scoring 
program should be written so that when an item is coded as ‗missing‘, the weight for 
that  item  is  subtracted  from  the  total  possible  weight  for  that  component  of  the 
questionnaire (i.e. either the Impacts or the Activity component) and from the Total 
weight.   
We have very carefully tested this method of handling missing data and found that it 
is reliable for up to 10 missed items in Part 2 of the questionnaire. 
CALCULATION METHOD FOR THE SGRQ 
SUMMARY 
Three component scores are calculated: Symptoms; Activity; Impacts. 
One Total score is also calculated. 
PRINCIPLE OF CALCULATION 
Each questionnaire response has a unique empirically derived 'weight'. The lowest 
possible weight is zero and the highest is 100. 
Each component of the questionnaire is scored separately in two steps: 
i. The Weights for all items with a positive response are summed. 
ii. The score is calculated by dividing the summed weights by the maximum possible 
weight for that component and expressing the result as a percentage: Comparative Study on the QoL of COPD Patients 
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Score = 100 x Summed weights from positive items in that component 
Sum of weights for all items in that component 
The Total score is calculated in similar way: 
Score = 100 x Summed weights from positive items in the questionnaire 
Sum of weights for all items in the questionnaire 
 
Sum of maximum possible weights for each component and Total: 
Symptoms   662.5 
Activity   1209.1 
Impacts   21 17.8 
Total     3989.4 
(Note: these are the maximum possible weights that could be obtained for the worst 
possible state of the patient). 
 
 
EXAMPLE OF CALCLULATION 
(FOR CHECKING COMPUTER PROGRAM) 
Questionnaire Part 1 
Positive responses to: 
Question 1: I have coughed several days a week 
Question 2: I have brought up sputum a few days a month 
Question 7: In the last year in an average week nearly every day was a good day  
Questionnaire Part 2 
Positive responses to: 
Section 1: A few problems. 
Section 2: Walking up hills. 
      Playing sport or games. 
Section 3: My cough hurts. 
      My cough or breathing disturbs my sleep. 
Section 4: My cough or breathing is embarrassing in public. 
Section 5: I have unpleasant side effects from my medication. 
Section 6: My breathing makes it difficult to .... swim 
Section 6: My breathing makes it difficult to .... play competitive sports 
Section 7: I cannot play sports or games 
Section 7: It stops me doing one or two things I would like to do. 
Calculated scores: 
Symptoms: 
(Sum of weights=112.6) 
Score= 17.0 
Activity: 
(Sum of weights= 282.1) 
Score= 23.3 t 
Impacts:   
(Sum of weights= 465.6) 
Score =22.0 
Total: 
(Sum of weights =860.3) 
Score =21.6 Comparative Study on the QoL of COPD Patients 
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Appendix 6: Base Line Dyspnoea Index 
 
Baseline Dyspnoea Index 
Functional Impairment 
 
______ Grade 4:  No Impairment. Able to carry out usual activities and occupation 
without shortness of breath. 
______ Grade 3:   Slight Impairment. Distinct impairment in at least one activity but no 
activities completely abandoned. Reduction, in activity at work or in 
usual activities, that seems slight or not clearly caused by shortness of 
breath. 
______ Grade 2:   Moderate Impairment. Patient has changed jobs and/or has abandoned 
at least one usual activity due to shortness of breath. 
______ Grade 1:   Severe Impairment. Patient unable to work or has given up most or all 
usual activities due to shortness of breath. 
______ Grade 0:   Very Severe Impairment. Unable to work and has given up most or all 
usual activities due to shortness of breath. 
__________ W:   Amount Uncertain. Patient is impaired due to shortness of breath, but 
amount cannot be specified. Details are not sufficient to allow 
impairment to be categoried. 
__________ X:   Unknown. Information unavailable regarding impairment. 
__________ Y:   Impaired for Reasons Other than Shortness of breath. For example, 
musculoskeletal problem or chest pain. 
 
Usual activities refer to requirements of daily living, maintenance or upkeep of residence, 
yard work, gardening, shopping, etc. 
 
Magnitude of Task 
______ Grade 4:   Extraordinary.  Becomes  short  of  breath  only  with  extraordinary 
activity such as carrying very heavy loads on the level, lighter loads 
uphill, or running. No shortness of breath with ordinary tasks. 
______ Grade 3:   Major. Becomes short of breath only with such major activities as 
walking up a steep hill, climbing more than three flights of stairs, or 
carrying a moderate load on the level. 
______ Grade 2:   Moderate.  Becomes short of breath  with  moderate or average tasks 
such as walking up a gradual hill, climbing fewer than three flights of 
stairs, or carrying a light load on the level. 
______ Grade 1:   Light. Becomes short of breath with light activities such as walking on 
the level, washing, or standing. 
______ Grade 0:   No Task. Becomes short of breath at rest, while sitting, or lying down. 
__________  W:   Amount Uncertain. Patient's ability to perform tasks is impaired due to 
shortness of breath, but amount cannot be specified. Details are not 
sufficient to allow impairment to be categorised. 
___________ X:   Unknown. Information unavailable regarding limitation of magnitude 
of task. 
___________ Y:   Impairment for Reasons Other than Shortness of Breath. For example, 
musculoskeletal problem or chest pain. Comparative Study on the QoL of COPD Patients 
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Magnitude of Effort 
______ Grade 4:   Extraordinary. Becomes short of breath only with the greatest 
imaginable effort. No shortness of breath with ordinary effort. 
______ Grade 3:   Major. Becomes short of breath with effort distinctly submaximal, but 
of major proportion. Tasks performed without pause unless the task 
requires extraordinary effort that may be performed with pauses. 
______ Grade 2:   Moderate. Becomes short of breath with moderate effort. Tasks 
performed  with  occasional  pauses  and  requiring  longer  to  complete 
than the average person. 
______ Grade 1:   Light. Becomes short of breath with little effort. Tasks performed with 
little effort or more difficult tasks performed with frequent pauses and 
requiring 50-100% longer to complete than the average person might 
require. 
______ Grade 0:   No effort. Becomes short of breath at rest, while sitting, or lying down. 
__________ W:   Amount Uncertain. Patient's exertional ability is impaired due to 
shortness of breath, but amount cannot be specified. Details are not 
sufficient to allow impairment to be categorized. 
__________ X:   Unknown. Information unavailable regarding limitation of effort. 
__________ Y:   Impaired for Reasons Other than Shortness of Breath. For example, 
musculoskeletal problem or chest pain. Comparative Study on the QoL of COPD Patients 
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Appendix 7: Poster 1 Presented at the ERS Congress (Copenhagen 2005) 
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Appendix 8: Poster 2 Presented at the ERS Congress (Copenhagen 2005) 
 Comparative Study on the QoL of COPD Patients 
  Page 202 
 
Appendix 9: Poster Presented at the ERS Congress (Munich 2006) 
 